<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01234</drugbank-id>
  <drugbank-id>APRD00674</drugbank-id>
  <name>Dexamethasone</name>
  <description>Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724,A188724]&#13;
&#13;
Dexamethasone was granted FDA approval on 30 October 1958.[L10695]</description>
  <cas-number>50-02-2</cas-number>
  <unii>7S5I7G3JQL</unii>
  <average-mass>392.4611</average-mass>
  <monoisotopic-mass>392.199902243</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A187268</ref-id>
        <pubmed-id>9408089</pubmed-id>
        <citation>Tomlinson ES, Maggs JL, Park BK, Back DJ: Dexamethasone metabolism in vitro: species differences. J Steroid Biochem Mol Biol. 1997 Jul;62(4):345-52. doi: 10.1016/s0960-0760(97)00038-1.</citation>
      </article>
      <article>
        <ref-id>A188405</ref-id>
        <pubmed-id>24347992</pubmed-id>
        <citation>Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, Russo E: Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. doi: 10.4103/0976-500X.120975.</citation>
      </article>
      <article>
        <ref-id>A187463</ref-id>
        <pubmed-id>30285357</pubmed-id>
        <citation>Yasir M, Sonthalia S: Corticosteroid Adverse Effects .</citation>
      </article>
      <article>
        <ref-id>A187436</ref-id>
        <pubmed-id>15634032</pubmed-id>
        <citation>Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.</citation>
      </article>
      <article>
        <ref-id>A188718</ref-id>
        <pubmed-id>3709651</pubmed-id>
        <citation>Loew D, Schuster O, Graul EH: Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol. 1986;30(2):225-30. doi: 10.1007/bf00614309.</citation>
      </article>
      <article>
        <ref-id>A188721</ref-id>
        <pubmed-id>24400953</pubmed-id>
        <citation>Spoorenberg SM, Deneer VH, Grutters JC, Pulles AE, Voorn GP, Rijkers GT, Bos WJ, van de Garde EM: Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol. 2014 Jul;78(1):78-83. doi: 10.1111/bcp.12295.</citation>
      </article>
      <article>
        <ref-id>A10059</ref-id>
        <pubmed-id>9141556</pubmed-id>
        <citation>Diederich S, Hanke B, Oelkers W, Bahr V: Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11beta-reduction. J Clin Endocrinol Metab. 1997 May;82(5):1598-602.</citation>
      </article>
      <article>
        <ref-id>A188556</ref-id>
        <pubmed-id>9618784</pubmed-id>
        <citation>Diederich S, Hanke B, Burkhardt P, Muller M, Schoneshofer M, Bahr V, Oelkers W: Metabolism of synthetic corticosteroids by 11 beta-hydroxysteroid-dehydrogenases in man. Steroids. 1998 May-Jun;63(5-6):271-7. doi: 10.1016/s0039-128x(98)00039-7.</citation>
      </article>
      <article>
        <ref-id>A188724</ref-id>
        <pubmed-id>13560344</pubmed-id>
        <citation>BUNIM JJ, BLACK RL, LUTWAK L, PETERSON RE, WHEDON GD: Studies on dexamethasone, a new synthetic steroid, in rheurheumatoid arthritis: a preliminary report; adrenal cortical, metabolic and early clinical effects. Arthritis Rheum. 1958 Aug;1(4):313-31. doi: 10.1002/art.1780010404.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L10695</ref-id>
        <title>FDA Approved Drug Products: Decadron Dexamethasone Oral Tablet (Discontinued)</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=011664</url>
      </link>
      <link>
        <ref-id>L10698</ref-id>
        <title>FDA Approved Drug Products: Ciprodex Dexamethasone and Ciprofloxacin Otic Suspension</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021537s017lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10701</ref-id>
        <title>FDA Approved Drug Products: Dexamethasone Injection</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/40572s002lbledt.pdf</url>
      </link>
      <link>
        <ref-id>L10704</ref-id>
        <title>FDA Approved Drug Products: Dextenza Dexamethasone Ophthalmic Insert</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208742s001lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10707</ref-id>
        <title>FDA Approved Drug Products: Dexycu Dexamethasone Intraocular Suspension</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208912s000lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10710</ref-id>
        <title>FDA Approved Drug Products: Hemady Dexamethasone Oral Tablets</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10713</ref-id>
        <title>FDA Approved Drug Products: Maxidex Dexamethasone Ophthalmic Suspension</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/013422s045lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10716</ref-id>
        <title>FDA Approved Drug Products: Maxitrol Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Suspension</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050023s036lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10719</ref-id>
        <title>FDA Approved Drug Products: Ozurdex Dexamethasone Intravitreal Implant</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022315s012lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10722</ref-id>
        <title>FDA Approved Drug Products: Maxitrol Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Ointment</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050065s064lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10725</ref-id>
        <title>FDA Approved Drug Products: Tobradex Tobramycin and Dexamethasone Ophthlamic Suspension</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050818s001lbl.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation.&#13;
Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.</synthesis-reference>
  <indication>Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]</indication>
  <pharmacodynamics>Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Dexamethasone's duration of action varies depending on the route.[L10698,L10701,L10704,L10707,L10710,L10713,L10716,L10719,L10722,L10725] Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]</pharmacodynamics>
  <mechanism-of-action>The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]&#13;
&#13;
Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]&#13;
&#13;
Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]</mechanism-of-action>
  <toxicity>The oral LD&lt;sub&gt;50&lt;/sub&gt; in female mice was 6.5g/kg and 794mg/kg via the intravenous route.[L10701]&#13;
&#13;
Overdoses are not expected with otic formulations.[L10698] Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.[A188405] Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.[A188405]</toxicity>
  <metabolism>Dexamethasone is 6-hydroxylated by CYP3A4 to 6α- and 6β-hydroxydexamethasone.[A187268] Dexamethasone is reversibly metabolized to 11-dehydrodexamethasone by corticosteroid 11-beta-dehydrogenase isozyme 2 and can also be converted back to dexamethasone by Corticosteroid 11-beta-dehydrogenase isozyme 1.[A10059,A188556]</metabolism>
  <absorption>Absorption via the intramuscular route is slower than via the intravenous route.[L10701] A 3mg intramuscular dose reaches a C&lt;sub&gt;max&lt;/sub&gt; of 34.6±6.0ng/mL with a T&lt;sub&gt;max&lt;/sub&gt; of 2.0±1.2h and an AUC of 113±38ng\*h/mL.[A188718] A 1.5mg oral dose reaches a C&lt;sub&gt;max&lt;/sub&gt; of 13.9±6.8ng/mL with a T&lt;sub&gt;max&lt;/sub&gt; of 2.0±0.5h and an AUC of 331±50ng\*h/mL.[A188718] Oral dexamethasone is approximately 70-78% bioavailable in healthy subjects.[A188721]</absorption>
  <half-life>The mean terminal half life of a 20mg oral tablet is 4 hours.[L10710] A 1.5mg oral dose of dexamethasone has a half life of 6.6±4.3h, while a 3mg intramuscular dose has a half life of 4.2±1.2h.[A188718]</half-life>
  <protein-binding>Dexamethasone is approximately 77% protein bound in plasma.[L10710] The majority of protein binding is with serum albumin.[A188559] Dexamethasone does not significantly bind to corticosteroid binding protein.[A188559]</protein-binding>
  <route-of-elimination>Corticosteroids are generally eliminated predominantly in the urine.[A187436] However, dexamethasone is &lt;10% elminated in urine.[L10710]</route-of-elimination>
  <volume-of-distribution>A 1.5mg oral dose of dexamethasone has a volume of distribution of 51.0L, while a 3mg intramuscular dose has a volume of distribution of 96.0L.[A188718]</volume-of-distribution>
  <clearance>A 20mg oral tablet has a clearance of 15.7L/h.[L10710] A 1.5mg oral dose of dexamethasone has a clearance of 15.6±4.9L/h while a 3.0mg intramuscular dose has a clearance of 9.9±1.4L/h.[A188718]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.</description>
    <direct-parent>21-hydroxysteroids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Steroids and steroid derivatives</class>
    <subclass>Hydroxysteroids</subclass>
    <alternative-parent>11-beta-hydroxysteroids</alternative-parent>
    <alternative-parent>17-hydroxysteroids</alternative-parent>
    <alternative-parent>20-oxosteroids</alternative-parent>
    <alternative-parent>3-oxo delta-1,4-steroids</alternative-parent>
    <alternative-parent>Alkyl fluorides</alternative-parent>
    <alternative-parent>Alpha-hydroxy ketones</alternative-parent>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Cyclic ketones</alternative-parent>
    <alternative-parent>Delta-1,4-steroids</alternative-parent>
    <alternative-parent>Fluorohydrins</alternative-parent>
    <alternative-parent>Gluco/mineralocorticoids, progestogins and derivatives</alternative-parent>
    <alternative-parent>Halogenated steroids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Tertiary alcohols</alternative-parent>
    <substituent>11-beta-hydroxysteroid</substituent>
    <substituent>11-hydroxysteroid</substituent>
    <substituent>17-hydroxysteroid</substituent>
    <substituent>20-oxosteroid</substituent>
    <substituent>21-hydroxysteroid</substituent>
    <substituent>3-oxo-delta-1,4-steroid</substituent>
    <substituent>3-oxosteroid</substituent>
    <substituent>9-halo-steroid</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Alkyl fluoride</substituent>
    <substituent>Alkyl halide</substituent>
    <substituent>Alpha-hydroxy ketone</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Cyclic ketone</substituent>
    <substituent>Delta-1,4-steroid</substituent>
    <substituent>Fluorohydrin</substituent>
    <substituent>Halo-steroid</substituent>
    <substituent>Halohydrin</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Oxosteroid</substituent>
    <substituent>Pregnane-skeleton</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Progestogin-skeleton</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tertiary alcohol</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001216</drugbank-id>
      <name>Dexamethasone phosphate</name>
      <unii>2BP70L44PR</unii>
      <cas-number>312-93-6</cas-number>
      <inchikey>VQODGRNSFPNSQE-CXSFZGCWSA-N</inchikey>
      <average-mass>472.441</average-mass>
      <monoisotopic-mass>472.166232653</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000843</drugbank-id>
      <name>Dexamethasone sodium phosphate</name>
      <unii>AI9376Y64P</unii>
      <cas-number>2392-39-4</cas-number>
      <inchikey>PLCQGRYPOISRTQ-UHFFFAOYSA-L</inchikey>
      <average-mass>516.4046</average-mass>
      <monoisotopic-mass>516.130121939</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone</synonym>
    <synonym language="english" coder="">1-Dehydro-16α-methyl-9α-fluorohydrocortisone</synonym>
    <synonym language="english" coder="">16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol</synonym>
    <synonym language="english" coder="">16α-Methyl-9α-fluoro-1-dehydrocortisol</synonym>
    <synonym language="english" coder="">9alpha-Fluoro-16alpha-methylprednisolone</synonym>
    <synonym language="english" coder="">9α-Fluoro-16α-methylprednisolone</synonym>
    <synonym language="spanish" coder="inn">Dexametasona</synonym>
    <synonym language="french" coder="inn">Dexaméthasone</synonym>
    <synonym language="english" coder="inn">Dexamethasone</synonym>
    <synonym language="latin" coder="inn">Dexamethasonum</synonym>
  </synonyms>
  <products>
    <product>
      <name>999 Itch Relief</name>
      <labeller>China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>12753-930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Accufix II Dec Model 033-212</name>
      <labeller>Telectronics Pacing Systems Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02150654</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-27</ended-marketing-on>
      <dosage-form>Implant</dosage-form>
      <strength/>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>AK-Trol</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2943</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-01-05</started-marketing-on>
      <ended-marketing-on>2000-06-30</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050065</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Apo-dexamethasone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250055</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-dexamethasone</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261081</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Baycadron</name>
      <labeller>Wockhardt</labeller>
      <ndc-id/>
      <ndc-product-code>64679-810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ciprodex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4928</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA021537</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ciprodex</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-969</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA021537</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ciprodex</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA021537</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ciprodex</name>
      <labeller>Clinical Solutions Wholsesale</labeller>
      <ndc-id/>
      <ndc-product-code>58118-9825</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-15</started-marketing-on>
      <ended-marketing-on>2017-06-28</ended-marketing-on>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA021537</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ciprodex</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-8533</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA021537</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ciprodex</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number>NDA021537</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ciprodex</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252716</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cortaren Corticosteroid/Anti-Inflammatory System</name>
      <labeller>It3 Medical Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70529-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cresophene Liq</name>
      <labeller>Septodont</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00379689</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>2012-07-07</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Dental</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cushings Syndrome Diagnostic</name>
      <labeller>Integrated Pharma Solutions Llc</labeller>
      <ndc-id/>
      <ndc-product-code>61219-996</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-02</started-marketing-on>
      <ended-marketing-on>2017-10-17</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-10-30</started-marketing-on>
      <ended-marketing-on>2007-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA011664</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-10-30</started-marketing-on>
      <ended-marketing-on>2007-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA011664</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Wraser Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66992-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-11</started-marketing-on>
      <ended-marketing-on>2017-09-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Pragma Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58463-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Pragma Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58463-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Pragma Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58463-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Pragma Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58463-016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron</name>
      <labeller>Pragma Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58463-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron DP</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-11</started-marketing-on>
      <ended-marketing-on>2017-09-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Decadron Phosphate Eye Ear Sol 0.1%</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00016217</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1960-12-31</started-marketing-on>
      <ended-marketing-on>1998-04-21</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Decadron Phosphate Inj 4mg/ml</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00213624</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Decadron Tab 0.5mg</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00016462</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Decadron Tab 4mg</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00354309</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>2003-08-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dex-Moxi</name>
      <labeller>Imprimis Njof, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71384-512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dex-Moxi PF</name>
      <labeller>ImprimisRx NJ</labeller>
      <ndc-id/>
      <ndc-product-code>70261-512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intraocular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dex-Moxi-Ketor</name>
      <labeller>Imprimis Njof, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71384-513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0927</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084611</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1744</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0218</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088316</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040700</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-290</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-728</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088306</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-745</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-382</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66336-479</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-5729</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0336</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Blenheim Pharmacal, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10544-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66267-067</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-1147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091188</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-01</started-marketing-on>
      <ended-marketing-on>2017-11-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-2696</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-01</started-marketing-on>
      <ended-marketing-on>2010-10-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Red Pharm Drug, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67296-1090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>STI Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>68850-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-09-21</started-marketing-on>
      <ended-marketing-on>2013-09-30</ended-marketing-on>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-3275</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-07-27</started-marketing-on>
      <ended-marketing-on>2013-07-31</ended-marketing-on>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-4186</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-22</started-marketing-on>
      <ended-marketing-on>2018-06-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088316</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>STI Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>54879-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>ECR Pharmaceuticals Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0095-0086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-01</started-marketing-on>
      <ended-marketing-on>2017-07-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040700</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-550</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-21</started-marketing-on>
      <ended-marketing-on>2018-10-16</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>RedPharm Drug</labeller>
      <ndc-id/>
      <ndc-product-code>67296-0326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>ECR Pharmaceuticals Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0095-0089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040700</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>ECR Pharmaceuticals Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0095-0087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040700</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>ECR Pharmaceuticals Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0095-0088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040700</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088160</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0177</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55700-263</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-10</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9939</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088160</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9938</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Fera Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>48102-045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Fera Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>48102-046</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Fera Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>48102-047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Fera Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>48102-048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-374</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>H.J. Harkins Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52959-392</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088160</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>H.J. Harkins Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52959-547</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-4914</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-4901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Morton Grove Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60432-466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088254</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-383</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on>2017-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088160</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49999-059</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43063-266</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7267</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-561</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7806</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-15</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088316</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088306</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-509</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Elixir</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090891</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Par Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088148</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Par Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on>2019-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088160</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Par Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on>2020-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Par Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-04-28</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Par Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-373</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-11-28</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-4179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084611</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-4180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-4181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088306</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-4182</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-4183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-4184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-4186</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088316</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-3177</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-8179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084611</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-8180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084613</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-8174</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088306</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-8181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-8176</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA087916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-8175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-8183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088316</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>medsource pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>45865-989</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone</name>
      <labeller>Pharma Stulln Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02023865</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.1 %</strength>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone 1.5 mg</name>
      <labeller>Larken Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68047-702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201270</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Intensol</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-5026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution, concentrate</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088252</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Intensol</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-3176</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution, concentrate</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088252</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Omega Unidose</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387743</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intrasynovial; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sod Phos Inj 4mg/ml</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00716715</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-21</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sod Phosph Inj 10mg/ml USP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00874582</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intrasynovial; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>DEXAMETHASONE Sodium Phosphate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6099</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA081126</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-3006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on>2018-07-20</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-847</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA088771</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Phoenix Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57319-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Butler Animal Health Supply</labeller>
      <ndc-id/>
      <ndc-product-code>11695-1411</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-068</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA088771</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DEXAMETHASONE Sodium Phosphate</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-3524</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-08-31</started-marketing-on>
      <ended-marketing-on>2011-03-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA081126</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55045-1755</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA088771</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0871</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-07-21</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA087440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables &amp; Vaccines</labeller>
      <ndc-id/>
      <ndc-product-code>52584-905</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on>2012-01-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA087440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables &amp; Vaccines</labeller>
      <ndc-id/>
      <ndc-product-code>52584-930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on>2011-12-31</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA087440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>61314-294</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA088771</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-4648</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-3040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-1224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-4901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2016-11-08</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA087440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-4905</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2016-11-08</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA087440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-4930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2016-11-08</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA087440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-15</started-marketing-on>
      <ended-marketing-on>2016-08-15</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-4728</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2014-12-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-917</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-01</started-marketing-on>
      <ended-marketing-on>2013-04-04</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1866</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0872</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0250</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on>2016-10-31</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-17</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2732</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2015-02-28</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2733</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Bauch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Auro Medics Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55150-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Auro Medics Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55150-238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Auro Medics Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>55150-239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0621</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0414</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-619</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-23</started-marketing-on>
      <ended-marketing-on>2016-09-29</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables &amp; Vaccines</labeller>
      <ndc-id/>
      <ndc-product-code>52584-516</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-01</started-marketing-on>
      <ended-marketing-on>2017-02-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables &amp; Vaccines</labeller>
      <ndc-id/>
      <ndc-product-code>52584-165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-18</started-marketing-on>
      <ended-marketing-on>2017-02-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0627</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code>76045-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA203129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on>2017-07-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-9371</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-9387</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040802</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone sodium phosphate</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>67457-419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone sodium phosphate</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>67457-418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone sodium phosphate</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>67457-484</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone sodium phosphate</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>67457-483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040802</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0192</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0177</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040802</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-4547</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2015-01-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-4543</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-4545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2015-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-4541</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040802</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-979</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-04</started-marketing-on>
      <ended-marketing-on>2018-10-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-9364</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables and Vaccines, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52584-421</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables and Vaccines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52584-420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040802</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables and Vaccines, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52584-422</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-423</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-422</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-421</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040802</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0641-6145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA084282</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0641-6146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA084282</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0641-0367</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>HF Acquisition Co LLC, DBA HealthFirst</labeller>
      <ndc-id/>
      <ndc-product-code>51662-1343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3541</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7153</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2363</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA040069</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0532</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA040803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7164</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA084282</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-8338</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Somerset Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70069-025</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA211036</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>AuroMedics Pharma LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55150-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mg/10mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA210967</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>HF Acquisition Co LLC, DBA HealthFirst</labeller>
      <ndc-id/>
      <ndc-product-code>51662-1297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA084282</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Medical Purchasing Solutions, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71872-7171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA084282</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1399</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA208690</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA208689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA208689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1452</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA208689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables &amp; Vaccines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52584-239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>General Injectables &amp; Vaccines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52584-238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4567</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>HF Acquisition Co LLC, DBA HealthFirst</labeller>
      <ndc-id/>
      <ndc-product-code>51662-1391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>HF Acquisition Co LLC, DBA HealthFirst</labeller>
      <ndc-id/>
      <ndc-product-code>51662-1370</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Civica, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72572-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA084282</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Civica, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72572-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>HF Acquisition Co LLC, DBA HealthFirst</labeller>
      <ndc-id/>
      <ndc-product-code>51662-1432</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Somerset Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70069-021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA207442</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Somerset Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70069-022</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA207521</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Somerset Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70069-023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA207521</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Somerset Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70069-024</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA207521</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76045-109</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA209192</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-516</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA040491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate 0.1%</name>
      <labeller>Rivex Ophthalmics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02212978</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-05-07</started-marketing-on>
      <ended-marketing-on>2003-07-28</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-4069</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% / Tretinoin 0.025%</name>
      <labeller>Sincerus Florida</labeller>
      <ndc-id/>
      <ndc-product-code>72934-4070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate Inj USP 4mg/ml</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00664227</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intrasynovial; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate Injection Sdz</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02385678</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intrasynovial; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate Injection Sdz</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02385686</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intrasynovial; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate Injection, USP</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02412888</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate Injection, USP</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02412896</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphate Injection, USP</name>
      <labeller>Sterimax Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01977547</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intra-articular; Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone Sodium Phosphates</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2011-10-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>ANDA087440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone Tablets</name>
      <labeller>Par Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49884-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-11-28</started-marketing-on>
      <ended-marketing-on>2009-12-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088481</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexamethasone-omega</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02204266</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethasone-omega</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02204274</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexamethsone</name>
      <labeller>Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>51655-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084612</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexasone 0.5mg</name>
      <labeller>Valeant Canada Lp Valeant Canada S.E.C.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00295094</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>2014-07-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexasone 0.75mg</name>
      <labeller>Valeant Canada Lp Valeant Canada S.E.C.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00285471</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>2014-07-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexasone 4mg</name>
      <labeller>Valeant Canada Lp Valeant Canada S.E.C.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00489158</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2016-07-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dexlido Kit</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-767</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexlido-M Kit</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-348</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA040491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexlido-M Kit</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-769</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DexMoxiKetor PF</name>
      <labeller>ImprimisRx NJ</labeller>
      <ndc-id/>
      <ndc-product-code>70261-513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intraocular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexopin</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-218</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dextenza</name>
      <labeller>Ocular Therapeutix, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70382-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Insert</dosage-form>
      <strength>0.4 mg/1</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA208742</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexycu</name>
      <labeller>Icon Bioscience, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71997-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>517 ug/0.005mL</strength>
      <route>Intraocular</route>
      <fda-application-number>NDA208912</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dexycu</name>
      <labeller>EyePoint Pharmaceuticals US, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71879-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>517 ug/0.005mL</strength>
      <route>Intraocular</route>
      <fda-application-number>NDA208912</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dioptrol Ointment</name>
      <labeller>Pharma Stulln Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02023849</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dioptrol Suspension</name>
      <labeller>Pharma Stulln Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02023806</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dmt Suik</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dom-dexamethasone Tablet 4mg</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239534</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>DoubleDex Kit</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-766</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dxevo</name>
      <labeller>Skylar Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70362-707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-25</started-marketing-on>
      <ended-marketing-on>2019-03-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201270</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dxevo</name>
      <labeller>Skylar Laboratories, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70362-702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201270</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dxevo</name>
      <labeller>Phlight Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70569-151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201270</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Encor Dec Model 033-159 Imp 0.5mg/imp</name>
      <labeller>Telectronics Pacing Systems Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02097281</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-27</ended-marketing-on>
      <dosage-form>Implant</dosage-form>
      <strength/>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Encor Dec Model 033-443 Imp 0.5mg/imp</name>
      <labeller>Telectronics Pacing Systems Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02095122</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-27</ended-marketing-on>
      <dosage-form>Implant</dosage-form>
      <strength/>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Encor Dec Model 033-448 Imp 0.5mg/imp</name>
      <labeller>Telectronics Pacing Systems Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02095149</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-27</ended-marketing-on>
      <dosage-form>Implant</dosage-form>
      <strength/>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Encor Dec Model 033-757 Imp 0.5mg/imp</name>
      <labeller>Telectronics Pacing Systems Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02095114</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Implant</dosage-form>
      <strength/>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Encor Dec Model 033-856 Imp 0.5mg/imp</name>
      <labeller>Telectronics Pacing Systems Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02095130</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Implant</dosage-form>
      <strength/>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gati-Dex</name>
      <labeller>Imprimis Njof, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71384-506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hexadrol Phosphate</name>
      <labeller>Organon</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-04</started-marketing-on>
      <ended-marketing-on>1998-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>NDA014694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hexadrol Phosphate</name>
      <labeller>Organon</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0797</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-04</started-marketing-on>
      <ended-marketing-on>1998-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <fda-application-number>NDA014694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hexadrol Phosphate Inj 10mg/ml</name>
      <labeller>Organon Teknika Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00732893</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2001-09-18</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hexadrol Phosphate Inj 4mg/ml</name>
      <labeller>Organon Teknika Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00732885</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2001-09-18</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>HiDex 6-day</name>
      <labeller>Gentex Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>15014-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoCort 11-Day</name>
      <labeller>Allegis Holdings, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71297-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-10</started-marketing-on>
      <ended-marketing-on>2017-12-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoCort 11-Day</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-06</started-marketing-on>
      <ended-marketing-on>2017-03-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoCort 7-Day</name>
      <labeller>Allegis Holdings, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71297-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-10</started-marketing-on>
      <ended-marketing-on>2017-12-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoCort 7-Day</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-06</started-marketing-on>
      <ended-marketing-on>2017-03-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ludaxine</name>
      <labeller>It3 Medical Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70529-053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Perineural</route>
      <fda-application-number>ANDA206781</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mardex 25 Kit</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mas Care-pak Dexamethasone</name>
      <labeller>Mas Management Group Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69677-071</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA040491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maxidex</name>
      <labeller>Alcon</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0616</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength>0.5 mg/1g</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maxidex</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0998-0615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA013422</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maxidex</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00042560</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>0.1 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Maxidex</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00042579</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength>0.1 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Maxitrol</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0998-0630</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050023</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maxitrol</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1972-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050065</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Maxitrol</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00358177</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Maxitrol</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00042676</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1963-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Methedex</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-3003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on>2012-02-28</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neo-poly-dex</name>
      <labeller>Butler Animal Health Supply</labeller>
      <ndc-id/>
      <ndc-product-code>11695-1436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neo-poly-dex</name>
      <labeller>Butler Animal Health Supply</labeller>
      <ndc-id/>
      <ndc-product-code>11695-1403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neodecadron Eye Ear Soln 0.1%</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00140732</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-14</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Neofordex</name>
      <labeller>Laboratoires Ctrs</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004071</ema-product-code>
      <ema-ma-number>EU/1/15/1053/001</ema-ma-number>
      <started-marketing-on>2016-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-595</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062721</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>MWI/VetOne</labeller>
      <ndc-id/>
      <ndc-product-code>13985-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1192</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062721</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-02</started-marketing-on>
      <ended-marketing-on>2016-11-29</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Fera Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>48102-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-20</started-marketing-on>
      <ended-marketing-on>2013-06-14</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9384</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-11</started-marketing-on>
      <ended-marketing-on>2016-11-29</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Rxv</labeller>
      <ndc-id/>
      <ndc-product-code>14049-466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on>2016-06-24</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Mwi</labeller>
      <ndc-id/>
      <ndc-product-code>13985-744</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-289</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-7938</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on>2013-08-31</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1957</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3068</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-551</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Paddock Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0574-4160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Putney, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>26637-941</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-795</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-669</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1744</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9373</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Lake Erie Medical &amp; Surgical Supply DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49999-141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Sandoz Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>61314-630</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>61314-631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2198</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Direct_Rx</labeller>
      <ndc-id/>
      <ndc-product-code>72189-038</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Phoenix Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57319-347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>MWI/VetOne</labeller>
      <ndc-id/>
      <ndc-product-code>13985-028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Rxv</labeller>
      <ndc-id/>
      <ndc-product-code>14049-830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on>2016-06-24</ended-marketing-on>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-9510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66267-958</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>medsource pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>45865-796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-498</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4375</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9702</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064135</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin Sulfate, Polymyxin B Sulfate and Dexamethasone</name>
      <labeller>STAT RX LLC USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA062341</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Netildex</name>
      <labeller>Knight Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02493187</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Netildex</name>
      <labeller>Knight Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02493195</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Neuromaquel Neuroma/Anti-Inflammatory System</name>
      <labeller>It3 Medical Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70529-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA084916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Npd</name>
      <labeller>Phoenix Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57319-307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ocudex Liq 0.1%</name>
      <labeller>Herdt Et Charton Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01995022</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-09-17</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic; Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Odan-dexamethasone</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00627763</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Odan-trol</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00626597</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ozurdex</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001140</ema-product-code>
      <ema-ma-number>EU/1/10/638/001</ema-ma-number>
      <started-marketing-on>2010-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Implant</dosage-form>
      <strength>700 mcg</strength>
      <route>Intravitreal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Ozurdex</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-3348</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Implant</dosage-form>
      <strength>0.7 mg/1</strength>
      <route>Intravitreal</route>
      <fda-application-number>NDA022315</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ozurdex</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02363445</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Implant</dosage-form>
      <strength>0.7 mg</strength>
      <route>Intravitreal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-dexamethasone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237044</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-17</started-marketing-on>
      <ended-marketing-on>2004-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-dexamethasone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237045</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-17</started-marketing-on>
      <ended-marketing-on>2004-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-dexamethasone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237046</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-17</started-marketing-on>
      <ended-marketing-on>2004-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-dexamethasone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02260298</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-06</started-marketing-on>
      <ended-marketing-on>2004-12-07</ended-marketing-on>
      <dosage-form>Elixir</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-dexamethasone</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02260301</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-06</started-marketing-on>
      <ended-marketing-on>2004-12-07</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS Dexamethasone Elixir 0.5mg/5ml</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01946897</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS Dexamethasone Tab 0.5mg USP</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01964976</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS Dexamethasone Tab 0.75mg USP</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01964968</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-09-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS Dexamethasone Tab 4mg</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01964070</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-09-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-dexamethasone</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279363</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-dexamethasone Sod Phosphate Dps 1mg/ml</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00785261</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-dexamethasone Sod Phosphate Inj 10mg/ml</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00783900</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-dexamethasone Sod Phosphate Inj 4mg/ml</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00751863</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intra-articular; Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-dexamethasone - 4</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311267</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-04</started-marketing-on>
      <ended-marketing-on>2019-04-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>R.O.-dexsone</name>
      <labeller>Richmond Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01947044</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-11</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-dexamethasone</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240687</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-29</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-dexamethasone</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240684</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-29</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-dexamethasone Tablets, USP</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240685</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-29</started-marketing-on>
      <ended-marketing-on>2009-07-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>ReadySharp Anesthetics plus Dexamethasone</name>
      <labeller>Terrain Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53225-4210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA016964</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ReadySharp Dexamethasone</name>
      <labeller>Terrain Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53225-3660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ropidex</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sandoz Dexamethasone</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00739839</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>2017-08-01</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Opticort</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247920</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-16</started-marketing-on>
      <ended-marketing-on>2019-08-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02224623</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Ear/eye Ointment</name>
      <labeller>Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00173606</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Sterile Ear/eye Drops</name>
      <labeller>Hoechst Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01987712</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>2004-07-30</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <labeller>Aventis Pharma Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02224631</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-25</started-marketing-on>
      <ended-marketing-on>2006-07-28</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <labeller>Hoechst Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01987720</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-20</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>TaperDex 12-day</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-149</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TaperDex 12-day</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TaperDex 6-day</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TaperDex 6-day</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TaperDex 7-day</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-628</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050616</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobradex</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-223</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-2285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-4400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-2590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050616</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2788</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-10-15</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050616</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-09-15</started-marketing-on>
      <ended-marketing-on>2017-01-31</ended-marketing-on>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0647</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0648</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050616</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00778915</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>TobraDex</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00778907</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tobradex ST</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0652</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050818</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6286</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-984</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-416</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9342</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Bauch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-295</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-03</started-marketing-on>
      <ended-marketing-on>2014-06-03</ended-marketing-on>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-02</started-marketing-on>
      <ended-marketing-on>2016-04-30</ended-marketing-on>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-02</started-marketing-on>
      <ended-marketing-on>2017-02-28</ended-marketing-on>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1655</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1893</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1914</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064134</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tobramycin and Dexamethasone</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>61314-647</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050592</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TopiDex</name>
      <labeller>Topicare Management, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70112-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA040491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Viadox</name>
      <labeller>It3 Medical Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70529-045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA087702</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zema Pak</name>
      <labeller>Macoven Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>44183-509</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2014-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zema Pak</name>
      <labeller>Macoven Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>44183-507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2011-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zema Pak</name>
      <labeller>Macoven Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>44183-508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2011-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA084610</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ZoDex</name>
      <labeller>Xspire Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>42195-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-16</started-marketing-on>
      <ended-marketing-on>2018-06-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ZonaCort 11-Day</name>
      <labeller>Key Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70868-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-01</started-marketing-on>
      <ended-marketing-on>2017-12-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ZonaCort 7-Day</name>
      <labeller>Key Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70868-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-01</started-marketing-on>
      <ended-marketing-on>2017-12-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA088237</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Neofordex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ozurdex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Baycadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>DEXAMETHASONE Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neo-poly-dex</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Npd</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neo-poly-dex</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ciprodex</name>
      <ingredients>Ciprofloxacin + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Sulfate, Polymyxin B Sulfate and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>DEXAMETHASONE Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Ciprodex</name>
      <ingredients>Ciprofloxacin + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Tobradex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>AK-Trol</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>999 Itch Relief</name>
      <ingredients>Dexamethasone + Levomenthol + Synthetic camphor</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Hexadrol Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Hexadrol Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethsone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexlido-M Kit</name>
      <ingredients>Bupivacaine + Dexamethasone + Lidocaine + Povidone-iodine</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Zema Pak</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Zema Pak</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Zema Pak</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Intensol</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>LoCort 7-Day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>LoCort 11-Day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>ZonaCort 7-Day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>ZonaCort 11-Day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ciprodex</name>
      <ingredients>Ciprofloxacin + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>DoubleDex Kit</name>
      <ingredients>Dexamethasone + Povidone-iodine</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dmt Suik</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Decadron DP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Cushings Syndrome Diagnostic</name>
      <ingredients>Benzalkonium + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>LoCort 7-Day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>LoCort 11-Day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Methedex</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Mas Care-pak Dexamethasone</name>
      <ingredients>Dexamethasone + Povidone-iodine</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ciprodex</name>
      <ingredients>Ciprofloxacin + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>ZoDex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>ReadySharp Anesthetics plus Dexamethasone</name>
      <ingredients>Bupivacaine + Dexamethasone + Lidocaine</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphates</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Cortaren Corticosteroid/Anti-Inflammatory System</name>
      <ingredients>Bupivacaine + Dexamethasone + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Neuromaquel Neuroma/Anti-Inflammatory System</name>
      <ingredients>Bupivacaine + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>TaperDex 6-day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TaperDex 12-day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dex-Moxi</name>
      <ingredients>Dexamethasone + Moxifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dex-Moxi-Ketor</name>
      <ingredients>Dexamethasone + Ketorolac + Moxifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>Gati-Dex</name>
      <ingredients>Dexamethasone + Gatifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone sodium phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone sodium phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone sodium phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone sodium phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TopiDex</name>
      <ingredients>Dexamethasone + Povidone-iodine</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dex-Moxi PF</name>
      <ingredients>Dexamethasone + Moxifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>DexMoxiKetor PF</name>
      <ingredients>Dexamethasone + Ketorolac + Moxifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Tablets</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexycu</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexlido Kit</name>
      <ingredients>Dexamethasone + Lidocaine + Povidone-iodine</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Viadox</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ludaxine</name>
      <ingredients>Bupivacaine + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexlido-M Kit</name>
      <ingredients>Bupivacaine + Dexamethasone + Lidocaine + Povidone-iodine</ingredients>
    </mixture>
    <mixture>
      <name>Mardex 25 Kit</name>
      <ingredients>Bupivacaine + Dexamethasone + Povidone-iodine</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Maxidex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexycu</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>HiDex 6-day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dxevo</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dxevo</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% / Tretinoin 0.025%</name>
      <ingredients>Dexamethasone + Finasteride + Minoxidil + Tretinoin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5%</name>
      <ingredients>Dexamethasone + Finasteride + Minoxidil</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TaperDex 7-day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexopin</name>
      <ingredients>Dexamethasone + Povidone-iodine + Ropivacaine</ingredients>
    </mixture>
    <mixture>
      <name>Ropidex</name>
      <ingredients>Dexamethasone + Povidone-iodine + Ropivacaine</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Maxitrol</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Tobradex ST</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Maxitrol</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Ciprodex</name>
      <ingredients>Ciprofloxacin + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Maxidex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Ciprodex</name>
      <ingredients>Ciprofloxacin + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dextenza</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TaperDex 6-day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TaperDex 12-day</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dxevo</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone 1.5 mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ozurdex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Dexamethasone</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Tobramycin and Dexamethasone</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>ReadySharp Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Intensol</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-dexamethasone Sod Phosphate Inj 10mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PMS Dexamethasone Tab 4mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PMS Dexamethasone Tab 0.75mg USP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PMS Dexamethasone Tab 0.5mg USP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone-omega</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone-omega</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate Inj USP 4mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Apo-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Pro-dexamethasone - 4</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ozurdex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Hexadrol Phosphate Inj 4mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sod Phos Inj 4mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>R.O.-dexsone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron Phosphate Inj 4mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ocudex Liq 0.1%</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Encor Dec Model 033-443 Imp 0.5mg/imp</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Encor Dec Model 033-159 Imp 0.5mg/imp</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Encor Dec Model 033-448 Imp 0.5mg/imp</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Accufix II Dec Model 033-212</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Encor Dec Model 033-856 Imp 0.5mg/imp</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Encor Dec Model 033-757 Imp 0.5mg/imp</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Hexadrol Phosphate Inj 10mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexasone 0.5mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexasone 0.75mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Neodecadron Eye Ear Soln 0.1%</name>
      <ingredients>Dexamethasone + Neomycin</ingredients>
    </mixture>
    <mixture>
      <name>Decadron Tab 4mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron Phosphate Eye Ear Sol 0.1%</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Decadron Tab 0.5mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate 0.1%</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-dexamethasone Tablets, USP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate Injection Sdz</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate Injection Sdz</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate Injection, USP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate Injection, USP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sodium Phosphate Injection, USP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexasone 4mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Maxitrol</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Maxitrol</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Maxidex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ciprodex</name>
      <ingredients>Ciprofloxacin + Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>TobraDex</name>
      <ingredients>Dexamethasone + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Odan-trol</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Odan-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PMS Dexamethasone Elixir 0.5mg/5ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Maxidex</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dioptrol Suspension</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dioptrol Ointment</name>
      <ingredients>Dexamethasone + Neomycin + Polymyxin B</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Sod Phosph Inj 10mg/ml USP</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Dexamethasone Omega Unidose</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Cresophene Liq</name>
      <ingredients>Camphor + Dexamethasone + Parachlorophenol + Thymol</ingredients>
    </mixture>
    <mixture>
      <name>Dom-dexamethasone Tablet 4mg</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Opticort</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>PMS-dexamethasone Sod Phosphate Inj 4mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PHL-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Dexamethasone</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>PMS-dexamethasone Sod Phosphate Dps 1mg/ml</name>
      <ingredients>Dexamethasone</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Sterile Ear/eye Drops</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Ear/eye Ointment</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Netildex</name>
      <ingredients>Dexamethasone + Netilmicin</ingredients>
    </mixture>
    <mixture>
      <name>Netildex</name>
      <ingredients>Dexamethasone + Netilmicin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Advanced Pharmaceutical Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Akorn Inc.</name>
      <url>http://www.akorn.com</url>
    </packager>
    <packager>
      <name>Alcon Laboratories</name>
      <url>http://www.alcon.com</url>
    </packager>
    <packager>
      <name>Allergan Inc.</name>
      <url>http://www.allergan.com</url>
    </packager>
    <packager>
      <name>Amend</name>
      <url/>
    </packager>
    <packager>
      <name>American Regent</name>
      <url>http://www.americanregent.com</url>
    </packager>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>Apotheca Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>APP Pharmaceuticals</name>
      <url>http://www.apppharma.com</url>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Atlantic Biologicals Corporation</name>
      <url>http://www.atlanticbiologicals.com</url>
    </packager>
    <packager>
      <name>Bausch &amp; Lomb Inc.</name>
      <url>http://www.bausch.com</url>
    </packager>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>Bimeda Inc.</name>
      <url>http://www.bimeda.com</url>
    </packager>
    <packager>
      <name>Blansett Pharmacal Co. Inc.</name>
      <url>http://www.blansett.com</url>
    </packager>
    <packager>
      <name>Bryant Ranch Prepack</name>
      <url>http://bryantranchprepack.com</url>
    </packager>
    <packager>
      <name>C.O. Truxton Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Carlisle Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Clint Pharmaceutical Inc.</name>
      <url>http://www.clintpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Consolidated Midland Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>Darby Dental Supply Co. Inc.</name>
      <url>http://www.darbydental.com</url>
    </packager>
    <packager>
      <name>Direct Dispensing Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>ECR Pharmaceuticals</name>
      <url>http://www.ecrpharma.com</url>
    </packager>
    <packager>
      <name>Falcon Pharmaceuticals Ltd.</name>
      <url>http://www.falconpharma.com</url>
    </packager>
    <packager>
      <name>General Injectables and Vaccines Inc.</name>
      <url>http://www.giv.com</url>
    </packager>
    <packager>
      <name>Generics Puerto Rico Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Keene Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Luitpold Pharmaceuticals Inc.</name>
      <url>http://www.luitpold.com</url>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Martica Enterprises Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Martin Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Merck &amp; Co.</name>
      <url>http://www.merck.com</url>
    </packager>
    <packager>
      <name>Merit Pharmaceuticals</name>
      <url>http://www.meritpharm.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>MWI Veterinary Supply Co.</name>
      <url>http://www.mwivet.com</url>
    </packager>
    <packager>
      <name>National Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Neuman Distributors Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Nord Ost Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Ocusoft</name>
      <url>http://www.ocusoft.com</url>
    </packager>
    <packager>
      <name>Paddock Labs</name>
      <url>http://www.paddocklabs.com</url>
    </packager>
    <packager>
      <name>Par Pharmaceuticals</name>
      <url>http://www.parpharm.com</url>
    </packager>
    <packager>
      <name>PCA LLC</name>
      <url/>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Pharmedix</name>
      <url>http://www.pharmedixrx.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Preferred Pharmaceuticals Inc.</name>
      <url>http://www.preferredpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Prescript Pharmaceuticals</name>
      <url>http://www.prescript.net</url>
    </packager>
    <packager>
      <name>Primedics Laboratories</name>
      <url/>
    </packager>
    <packager>
      <name>Qualitest</name>
      <url>http://www.worldoftest.com</url>
    </packager>
    <packager>
      <name>Raz Co. Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Redpharm Drug</name>
      <url/>
    </packager>
    <packager>
      <name>Remedy Repack</name>
      <url>http://www.remedyrepack.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Robar Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Roxane Labs</name>
      <url>http://www.roxane.com</url>
    </packager>
    <packager>
      <name>San Jose Surgical Supply Inc.</name>
      <url>http://www.sjsurgical.com</url>
    </packager>
    <packager>
      <name>Sandhills Packaging Inc.</name>
      <url>http://www.sandhillspackaging.com</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>St Mary's Medical Park Pharmacy</name>
      <url/>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
    <packager>
      <name>Strides Arcolab Limited</name>
      <url>http://www.stridesarco.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Veratex Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>Wa Butler Co.</name>
      <url/>
    </packager>
    <packager>
      <name>Wockhardt Ltd.</name>
      <url>http://www.wockhardtin.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Dexamethasone 6 mg tablet</description>
      <cost currency="USD">1.01</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 4 mg/ml vial</description>
      <cost currency="USD">1.04</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Pms-Dexamethasone Sodium Phosp 10 mg/ml</description>
      <cost currency="USD">1.34</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Sandoz Dexamethasone Sod. Phosphate 0.1 % Solution</description>
      <cost currency="USD">1.38</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Maxidex 0.1 % Suspension</description>
      <cost currency="USD">1.73</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dexamethasone Sodium Phosphate 4 mg/ml</description>
      <cost currency="USD">1.77</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Maxidex 0.1% eye drops</description>
      <cost currency="USD">2.36</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dexamethasone 10 mg/ml vial</description>
      <cost currency="USD">2.56</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Maxidex 0.1 % Ointment</description>
      <cost currency="USD">2.69</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Dexasol 0.1% eye drops</description>
      <cost currency="USD">3.38</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dexamethasone 0.1% eye drop</description>
      <cost currency="USD">3.43</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dexamethasone Sodium Phosphate 4 mg/ml 1 Vial = 5ml</description>
      <cost currency="USD">4.0</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dexamethasone Sodium Phosphate 10 mg/ml</description>
      <cost currency="USD">4.78</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dexamethasone Sodium Phosphate 4 mg/ml Solution 5ml Vial</description>
      <cost currency="USD">13.99</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Dexamethasone sod ph powder</description>
      <cost currency="USD">14.24</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Dexamethasone acetate powd</description>
      <cost currency="USD">15.12</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Dexamethasone Sodium Phosphate 0.1% Solution 5ml Bottle</description>
      <cost currency="USD">19.99</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Dexamethasone powder</description>
      <cost currency="USD">21.27</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Dexamethasone micronized powd</description>
      <cost currency="USD">41.31</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Dexamethasone Sodium Phosphate 4 mg/ml Solution (1 Box = 25x1ml Vials)</description>
      <cost currency="USD">41.99</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Maxidex 0.1% Suspension 5ml Bottle</description>
      <cost currency="USD">53.57</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Maxitrol 5-10000-0.1 Suspension 5ml Bottle</description>
      <cost currency="USD">75.88</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Maxitrol 0.1-5-10000 Ointment 3.5 gm Tube</description>
      <cost currency="USD">87.3</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Maxidex 0.1% Suspension 15ml Bottle</description>
      <cost currency="USD">97.96</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Ozurdex 0.7 mg implant</description>
      <cost currency="USD">1554.0</cost>
      <unit>implant</unit>
    </price>
    <price>
      <description>Ratio-Dexamethasone 0.5 mg Tablet</description>
      <cost currency="USD">0.18</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Dexamethasone 0.5 mg Tablet</description>
      <cost currency="USD">0.2</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Dexamethasone 0.5 mg Tablet</description>
      <cost currency="USD">0.21</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 0.5 mg tablet</description>
      <cost currency="USD">0.31</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 1.5 mg tablet</description>
      <cost currency="USD">0.35</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 0.75 mg tablet</description>
      <cost currency="USD">0.38</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 0.5 mg/5ml Elixir</description>
      <cost currency="USD">0.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Pms-Dexamethasone 2 mg Tablet</description>
      <cost currency="USD">0.43</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Dexamethasone 0.75 mg Tablet</description>
      <cost currency="USD">0.47</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 1 mg tablet</description>
      <cost currency="USD">0.49</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 4 mg tablet</description>
      <cost currency="USD">0.6</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexamethasone 1 mg/1 ml soln</description>
      <cost currency="USD">0.65</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Dexamethasone 2 mg tablet</description>
      <cost currency="USD">0.68</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Dexamethasone 4 mg Tablet</description>
      <cost currency="USD">0.8</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Dexamethasone 4 mg Tablet</description>
      <cost currency="USD">0.8</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ratio-Dexamethasone 4 mg Tablet</description>
      <cost currency="USD">0.8</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Dexasone 4 mg Tablet</description>
      <cost currency="USD">0.86</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adrenal Cortex Hormones</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Adrenals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents Causing Muscle Toxicity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Acne Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Acne Preparations for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Inflammatory Agents</category>
      <mesh-id>D000893</mesh-id>
    </category>
    <category>
      <category>Antiemetics</category>
      <mesh-id>D000932</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents, Hormonal</category>
      <mesh-id>D018931</mesh-id>
    </category>
    <category>
      <category>Autonomic Agents</category>
      <mesh-id>D001337</mesh-id>
    </category>
    <category>
      <category>BCRP/ABCG2 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>BSEP/ABCB11 inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Corticosteroid Hormone Receptor Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Corticosteroids</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Corticosteroids for Local Oral Treatment</category>
      <mesh-id/>
    </category>
    <category>
      <category>Corticosteroids for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Corticosteroids for Systemic Use, Plain</category>
      <mesh-id/>
    </category>
    <category>
      <category>Corticosteroids, Dermatological Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Corticosteroids, Moderately Potent (Group II)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2A6 Inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2B6 Inducers</category>
      <mesh-id>D065695</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2B6 Inducers (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inducers</category>
      <mesh-id>D065697</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inducers (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inducers</category>
      <mesh-id>D065696</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inducers (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2E1 Inducers</category>
      <mesh-id>D065700</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2E1 Inducers (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Inducers</category>
      <mesh-id>D065701</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Inducers (strong)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inducers</category>
      <mesh-id>D065701</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inducers (moderate)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inducers (strong)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A5 Inducers</category>
      <mesh-id>D065701</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A5 Inducers (moderate)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A5 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A7 Inducers</category>
      <mesh-id>D065701</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A7 Inducers (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A7 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inducers</category>
      <mesh-id>D065693</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Gastrointestinal Agents</category>
      <mesh-id>D005765</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hyperglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Inducers of Drug Clearance</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nasal Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>OAT3/SLC22A8 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ophthalmological and Otological Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Otologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Pregnadienes</category>
      <mesh-id>D011245</mesh-id>
    </category>
    <category>
      <category>Pregnadienetriols</category>
      <mesh-id>D011246</mesh-id>
    </category>
    <category>
      <category>Pregnanes</category>
      <mesh-id>D011278</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
    <category>
      <category>Steroids, Fluorinated</category>
      <mesh-id>D013259</mesh-id>
    </category>
    <category>
      <category>Stomatological Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vasoprotectives</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Elixir</form>
      <route>Oral</route>
      <strength>0.5 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Auricular (otic)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension / drops</form>
      <route>Auricular (otic)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Dental</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intraocular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>0.5 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>1.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>4 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>6 mg/1</strength>
    </dosage>
    <dosage>
      <form>Solution, concentrate</form>
      <route>Oral</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intrasynovial; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <strength>4 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intramuscular</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intramuscular; Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intramuscular; Intravenous</route>
      <strength>100 mg/10mL</strength>
    </dosage>
    <dosage>
      <form>Injection, emulsion</form>
      <route>Intramuscular; Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <strength>4 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>4 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>4 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>4 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <strength>4 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intrasynovial; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intra-articular; Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Insert</form>
      <route>Ophthalmic</route>
      <strength>0.4 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intraocular</route>
      <strength>517 ug/0.005mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Implant</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Perineural</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Ophthalmic</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Ophthalmic</route>
      <strength>0.5 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Ophthalmic</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Ophthalmic</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic; Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Implant</form>
      <route>Intravitreal</route>
      <strength>0.7 mg/1</strength>
    </dosage>
    <dosage>
      <form>Implant</form>
      <route>Intravitreal</route>
      <strength>0.7 mg</strength>
    </dosage>
    <dosage>
      <form>Implant</form>
      <route>Intravitreal</route>
      <strength>700 mcg</strength>
    </dosage>
    <dosage>
      <form>Elixir</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intra-articular; Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R01AD53">
      <level code="R01AD">Corticosteroids</level>
      <level code="R01A">DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</level>
      <level code="R01">NASAL PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="D07XB05">
      <level code="D07XB">Corticosteroids, moderately potent, other combinations</level>
      <level code="D07X">CORTICOSTEROIDS, OTHER COMBINATIONS</level>
      <level code="D07">CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
    <atc-code code="S03BA01">
      <level code="S03BA">Corticosteroids</level>
      <level code="S03B">CORTICOSTEROIDS</level>
      <level code="S03">OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="R01AD03">
      <level code="R01AD">Corticosteroids</level>
      <level code="R01A">DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</level>
      <level code="R01">NASAL PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="D10AA03">
      <level code="D10AA">Corticosteroids, combinations for treatment of acne</level>
      <level code="D10A">ANTI-ACNE PREPARATIONS FOR TOPICAL USE</level>
      <level code="D10">ANTI-ACNE PREPARATIONS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
    <atc-code code="S01CB01">
      <level code="S01CB">Corticosteroids/antiinfectives/mydriatics in combination</level>
      <level code="S01C">ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="S02CA06">
      <level code="S02CA">Corticosteroids and antiinfectives in combination</level>
      <level code="S02C">CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION</level>
      <level code="S02">OTOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="S03CA01">
      <level code="S03CA">Corticosteroids and antiinfectives in combination</level>
      <level code="S03C">CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION</level>
      <level code="S03">OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="C05AA09">
      <level code="C05AA">Corticosteroids</level>
      <level code="C05A">AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE</level>
      <level code="C05">VASOPROTECTIVES</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
    <atc-code code="D07CB04">
      <level code="D07CB">Corticosteroids, moderately potent, combinations with antibiotics</level>
      <level code="D07C">CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS</level>
      <level code="D07">CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
    <atc-code code="H02AB02">
      <level code="H02AB">Glucocorticoids</level>
      <level code="H02A">CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN</level>
      <level code="H02">CORTICOSTEROIDS FOR SYSTEMIC USE</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
    <atc-code code="S01BA01">
      <level code="S01BA">Corticosteroids, plain</level>
      <level code="S01B">ANTIINFLAMMATORY AGENTS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="A01AC02">
      <level code="A01AC">Corticosteroids for local oral treatment</level>
      <level code="A01A">STOMATOLOGICAL PREPARATIONS</level>
      <level code="A01">STOMATOLOGICAL PREPARATIONS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="S01CA01">
      <level code="S01CA">Corticosteroids and antiinfectives in combination</level>
      <level code="S01C">ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="D07AB19">
      <level code="D07AB">Corticosteroids, moderately potent (group II)</level>
      <level code="D07A">CORTICOSTEROIDS, PLAIN</level>
      <level code="D07">CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
    <atc-code code="S02BA06">
      <level code="S02BA">Corticosteroids</level>
      <level code="S02B">CORTICOSTEROIDS</level>
      <level code="S02">OTOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:08.00</ahfs-code>
    <ahfs-code>52:08.08</ahfs-code>
    <ahfs-code>68:04.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1m2z</pdb-entry>
    <pdb-entry>1p93</pdb-entry>
    <pdb-entry>3gn8</pdb-entry>
    <pdb-entry>3mne</pdb-entry>
    <pdb-entry>3mno</pdb-entry>
    <pdb-entry>3mnp</pdb-entry>
    <pdb-entry>4uda</pdb-entry>
    <pdb-entry>4udc</pdb-entry>
    <pdb-entry>6nwk</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01234.pdf?1265922808</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01234.pdf?1265922745</msds>
  <patents>
    <patent>
      <number>8846650</number>
      <country>United States</country>
      <approved>2014-09-30</approved>
      <expires>2025-06-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9149486</number>
      <country>United States</country>
      <approved>2015-10-06</approved>
      <expires>2022-09-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6359016</number>
      <country>United States</country>
      <approved>2002-03-19</approved>
      <expires>2020-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6284804</number>
      <country>United States</country>
      <approved>2001-09-04</approved>
      <expires>2020-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6726918</number>
      <country>United States</country>
      <approved>2004-04-27</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6899717</number>
      <country>United States</country>
      <approved>2005-05-31</approved>
      <expires>2023-11-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8034366</number>
      <country>United States</country>
      <approved>2011-10-11</approved>
      <expires>2023-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8506987</number>
      <country>United States</country>
      <approved>2013-08-13</approved>
      <expires>2023-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9012437</number>
      <country>United States</country>
      <approved>2015-04-21</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8043628</number>
      <country>United States</country>
      <approved>2011-10-25</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8088407</number>
      <country>United States</country>
      <approved>2012-01-03</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9283178</number>
      <country>United States</country>
      <approved>2016-03-15</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9192511</number>
      <country>United States</country>
      <approved>2015-11-24</approved>
      <expires>2023-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8063031</number>
      <country>United States</country>
      <approved>2011-11-22</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7033605</number>
      <country>United States</country>
      <approved>2006-04-25</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7767223</number>
      <country>United States</country>
      <approved>2010-08-03</approved>
      <expires>2021-11-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8034370</number>
      <country>United States</country>
      <approved>2011-10-11</approved>
      <expires>2023-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7795316</number>
      <country>United States</country>
      <approved>2010-09-14</approved>
      <expires>2028-08-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8101582</number>
      <country>United States</country>
      <approved>2012-01-24</approved>
      <expires>2027-12-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8450287</number>
      <country>United States</country>
      <approved>2013-05-28</approved>
      <expires>2027-12-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9345714</number>
      <country>United States</country>
      <approved>2016-05-24</approved>
      <expires>2022-09-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9402805</number>
      <country>United States</country>
      <approved>2016-08-02</approved>
      <expires>2022-09-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9592242</number>
      <country>United States</country>
      <approved>2017-03-14</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9775849</number>
      <country>United States</country>
      <approved>2017-10-03</approved>
      <expires>2020-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6960346</number>
      <country>United States</country>
      <approved>2005-11-01</approved>
      <expires>2023-07-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7560120</number>
      <country>United States</country>
      <approved>2009-07-14</approved>
      <expires>2022-09-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10028965</number>
      <country>United States</country>
      <approved>2018-07-24</approved>
      <expires>2034-05-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10022502</number>
      <country>United States</country>
      <approved>2018-07-17</approved>
      <expires>2020-09-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10076526</number>
      <country>United States</country>
      <approved>2018-09-18</approved>
      <expires>2023-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8563027</number>
      <country>United States</country>
      <approved>2013-10-22</approved>
      <expires>2030-02-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8409606</number>
      <country>United States</country>
      <approved>2013-04-02</approved>
      <expires>2030-05-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10159683</number>
      <country>United States</country>
      <approved>2018-12-25</approved>
      <expires>2034-05-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9254267</number>
      <country>United States</country>
      <approved>2016-02-09</approved>
      <expires>2024-09-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
    <food-interaction>Avoid taking with grapefruit juice.</food-interaction>
    <food-interaction>Take with food to reduce irritation.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may increase the immunosuppressive activities of Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06688</drugbank-id>
      <name>Sipuleucel-T</name>
      <description>The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>The metabolism of Lomitapide can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The metabolism of Eliglustat can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The metabolism of Ibrutinib can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The metabolism of Cilostazol can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The metabolism of Colchicine can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The metabolism of Fentanyl can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The metabolism of Iloperidone can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01256</drugbank-id>
      <name>Retapamulin</name>
      <description>The metabolism of Retapamulin can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The metabolism of Tofacitinib can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The metabolism of Vardenafil can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The metabolism of Zopiclone can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09067</drugbank-id>
      <name>Corticorelin ovine triflutate</name>
      <description>The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Dexamethasone is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Lovastatin can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The metabolism of Brexpiprazole can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The metabolism of Cabozantinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The metabolism of Dienogest can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The metabolism of Everolimus can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00990</drugbank-id>
      <name>Exemestane</name>
      <description>The metabolism of Exemestane can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The metabolism of Gefitinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The metabolism of Guanfacine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Imatinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The metabolism of Irinotecan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The metabolism of Ixabepilone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The metabolism of Lapatinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04835</drugbank-id>
      <name>Maraviroc</name>
      <description>The metabolism of Maraviroc can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The metabolism of Quetiapine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Vilazodone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Daclatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The metabolism of Alfuzosin can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The metabolism of Alprazolam can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Amphotericin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00221</drugbank-id>
      <name>Isoetharine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Isoetharine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Norepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Phenylpropanolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Orciprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Dobutamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Ritodrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Terbutaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00901</drugbank-id>
      <name>Bitolterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Bitolterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Formoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Salbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01102</drugbank-id>
      <name>Arbutamine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Arbutamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Arformoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01291</drugbank-id>
      <name>Pirbuterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Pirbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Ephedra sinica root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Procaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Clenbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Droxidopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06814</drugbank-id>
      <name>Protokylol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Protokylol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08957</drugbank-id>
      <name>Hexoprenaline</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Hexoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Olodaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Doxofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Racepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Etafedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11871</drugbank-id>
      <name>PF-00610355</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with PF-00610355.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12100</drugbank-id>
      <name>Abediterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Abediterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Levosalbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Dexamethasone may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Dexamethasone may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Dexamethasone may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>Dexamethasone may increase the anticoagulant activities of 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>Dexamethasone may increase the anticoagulant activities of Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Dexamethasone may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Dexamethasone may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>Dexamethasone may increase the anticoagulant activities of Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>Dexamethasone may increase the anticoagulant activities of Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>Dexamethasone may increase the anticoagulant activities of Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00168</drugbank-id>
      <name>Aspartame</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Aspartame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefotiam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Liothyronine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00345</drugbank-id>
      <name>Aminohippuric acid</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Aminohippuric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefalotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefotaxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00536</drugbank-id>
      <name>Guanidine</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Guanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Oxytetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00650</drugbank-id>
      <name>Leucovorin</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Leucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Acyclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Dinoprostone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Famotidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01051</drugbank-id>
      <name>Novobiocin</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Novobiocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01053</drugbank-id>
      <name>Benzylpenicillin</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Benzylpenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Melatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Ouabain.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefadroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefamandole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefazolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Ceftizoxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefacetrile.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Ceftibuten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Liotrix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01597</drugbank-id>
      <name>Cilastatin</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cilastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01606</drugbank-id>
      <name>Tazobactam</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Tazobactam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01650</drugbank-id>
      <name>trans-2-hydroxycinnamic acid</name>
      <description>The excretion of Dexamethasone can be decreased when combined with trans-2-hydroxycinnamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Topiroxostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03553</drugbank-id>
      <name>Glutaric Acid</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Glutaric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04519</drugbank-id>
      <name>Caprylic acid</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Caprylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05016</drugbank-id>
      <name>Ataluren</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Ataluren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cefaloridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11751</drugbank-id>
      <name>Cabotegravir</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Cabotegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12866</drugbank-id>
      <name>Pradigastat</name>
      <description>The excretion of Dexamethasone can be decreased when combined with Pradigastat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The metabolism of Ifosfamide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Perampanel can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08735</drugbank-id>
      <name>R,S-Warfarin alcohol</name>
      <description>The metabolism of R,S-Warfarin alcohol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08736</drugbank-id>
      <name>S,R-Warfarin alcohol</name>
      <description>The metabolism of S,R-Warfarin alcohol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The metabolism of (S)-Warfarin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Tacrolimus can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08867</drugbank-id>
      <name>Ulipristal</name>
      <description>The metabolism of Ulipristal can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Atorvastatin can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The serum concentration of Cobicistat can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09101</drugbank-id>
      <name>Elvitegravir</name>
      <description>The serum concentration of Elvitegravir can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Dexamethasone may increase the thrombogenic activities of Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14019</drugbank-id>
      <name>Fosnetupitant</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Fosnetupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of thromboembolism can be increased when Dexamethasone is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The metabolism of Abiraterone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Dexamethasone may increase the immunosuppressive activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00089</drugbank-id>
      <name>Capromab pendetide</name>
      <description>Dexamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>The risk or severity of ulceration can be increased when Dexamethasone is combined with Nicorandil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00023</drugbank-id>
      <name>Asparaginase Escherichia coli</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Escherichia coli.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08886</drugbank-id>
      <name>Asparaginase Erwinia chrysanthemi</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00146</drugbank-id>
      <name>Calcifediol</name>
      <description>The therapeutic efficacy of Calcifediol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00153</drugbank-id>
      <name>Ergocalciferol</name>
      <description>The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01070</drugbank-id>
      <name>Dihydrotachysterol</name>
      <description>The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01436</drugbank-id>
      <name>Alfacalcidol</name>
      <description>The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04258</drugbank-id>
      <name>Seocalcitol</name>
      <description>The therapeutic efficacy of Seocalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04796</drugbank-id>
      <name>Inecalcitol</name>
      <description>The therapeutic efficacy of Inecalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04891</drugbank-id>
      <name>Becocalcidiol</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05295</drugbank-id>
      <name>Eldecalcitol</name>
      <description>The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06117</drugbank-id>
      <name>1alpha,24S-Dihydroxyvitamin D2</name>
      <description>The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06194</drugbank-id>
      <name>Elocalcitol</name>
      <description>The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06272</drugbank-id>
      <name>Maxacalcitol</name>
      <description>The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06410</drugbank-id>
      <name>Doxercalciferol</name>
      <description>The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13097</drugbank-id>
      <name>1alpha-Hydroxyvitamin D5</name>
      <description>The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13689</drugbank-id>
      <name>Tacalcitol</name>
      <description>The therapeutic efficacy of Tacalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11094</drugbank-id>
      <name>Vitamin D</name>
      <description>The therapeutic efficacy of Vitamin D can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00136</drugbank-id>
      <name>Calcitriol</name>
      <description>The therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00910</drugbank-id>
      <name>Paricalcitol</name>
      <description>The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The serum concentration of Triptolide can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The serum concentration of Norethisterone can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The serum concentration of Drospirenone can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04066</drugbank-id>
      <name>para-Coumaric Acid</name>
      <description>The serum concentration of para-Coumaric Acid can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04682</drugbank-id>
      <name>Octylphenoxy polyethoxyethanol</name>
      <description>The serum concentration of Octylphenoxy polyethoxyethanol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06266</drugbank-id>
      <name>Lonidamine</name>
      <description>The serum concentration of Lonidamine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>The serum concentration of Isosorbide can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11507</drugbank-id>
      <name>Cloprostenol</name>
      <description>The serum concentration of Cloprostenol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13044</drugbank-id>
      <name>Gossypol</name>
      <description>The serum concentration of Gossypol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13310</drugbank-id>
      <name>Ormeloxifene</name>
      <description>The serum concentration of Ormeloxifene can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>The serum concentration of Norgestrienone can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14678</drugbank-id>
      <name>Norethindrone enanthate</name>
      <description>The serum concentration of Norethindrone enanthate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The serum concentration of Estradiol benzoate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The serum concentration of Estradiol cypionate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The serum concentration of Estradiol valerate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The serum concentration of Levonorgestrel can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Ethynodiol diacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Norgestimate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Mestranol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06713</drugbank-id>
      <name>Norelgestromin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Norelgestromin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Gestodene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Norethynodrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Norgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Gestrinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nomegestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Lynestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Chlormadinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Quingestanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Demegestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13866</drugbank-id>
      <name>Etynodiol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Etynodiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nomegestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Norfloxacin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Pefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Rosoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Enrofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Orbifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Sarafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Difloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Rufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Pipemidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Delafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Levofloxacin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The risk or severity of tendinopathy can be increased when Grepafloxacin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Erlotinib can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Dexamethasone may increase the hypokalemic activities of Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Dexamethasone may increase the hypokalemic activities of Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Benzthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Dexamethasone may increase the hypokalemic activities of Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Epitizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Dexamethasone may increase the hypokalemic activities of Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00621</drugbank-id>
      <name>Oxandrolone</name>
      <description>The risk or severity of fluid retention can be increased when Dexamethasone is combined with Oxandrolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01185</drugbank-id>
      <name>Fluoxymesterone</name>
      <description>The risk or severity of fluid retention can be increased when Dexamethasone is combined with Fluoxymesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06718</drugbank-id>
      <name>Stanozolol</name>
      <description>The risk or severity of fluid retention can be increased when Dexamethasone is combined with Stanozolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12461</drugbank-id>
      <name>GLPG-0492</name>
      <description>The risk or severity of fluid retention can be increased when Dexamethasone is combined with GLPG-0492.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>The risk or severity of fluid retention can be increased when Dexamethasone is combined with Danazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>The risk or severity of fluid retention can be increased when Dexamethasone is combined with Oxymetholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic acid</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Bismuth subsalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>Dersalazine</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Dersalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06807</drugbank-id>
      <name>Phenyl aminosalicylate</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Phenyl aminosalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09543</drugbank-id>
      <name>Methyl salicylate</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Methyl salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13509</drugbank-id>
      <name>Aloxiprin</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Aloxiprin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Choline salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14026</drugbank-id>
      <name>Thiosalicylic acid</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Thiosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Aluminium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Sodium bicarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Magaldrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Aluminium acetoacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Hydrotalcite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Magnesium peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Almasilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Aluminium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Aloglutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Calcium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>The bioavailability of Dexamethasone can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Zafirlukast can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The metabolism of Lorazepam can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The metabolism of Phentermine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The metabolism of Azithromycin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Ticlopidine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The metabolism of Ziprasidone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The metabolism of Metoprolol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00426</drugbank-id>
      <name>Famciclovir</name>
      <description>The metabolism of Famciclovir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The metabolism of Prochlorperazine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Duloxetine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The metabolism of Chlorpromazine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Albendazole can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The metabolism of Cephalexin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The metabolism of Doxazosin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The metabolism of Fenofibrate can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The metabolism of Atazanavir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The metabolism of Rosuvastatin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of St. John's Wort can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01411</drugbank-id>
      <name>Pranlukast</name>
      <description>The metabolism of Pranlukast can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>The metabolism of Allylestrenol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The metabolism of Zuclopenthixol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The metabolism of Cobimetinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The metabolism of Rufinamide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The metabolism of Lacosamide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The metabolism of Vorapaxar can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>The metabolism of Suvorexant can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The metabolism of Tasimelteon can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The metabolism of Nintedanib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09274</drugbank-id>
      <name>Artesunate</name>
      <description>The metabolism of Artesunate can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The metabolism of Tenofovir alafenamide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>The metabolism of Dihydroergocornine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The metabolism of Ribociclib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The metabolism of Duvelisib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The metabolism of Dacomitinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The metabolism of Gilteritinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12515</drugbank-id>
      <name>9-aminocamptothecin</name>
      <description>The metabolism of 9-aminocamptothecin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12952</drugbank-id>
      <name>Methylprednisone</name>
      <description>The metabolism of Methylprednisone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>The metabolism of Dihydroergocristine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>The metabolism of Dihydroergocryptine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Medical Cannabis can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The metabolism of Tenofovir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Piretanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Azosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Polmacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Flurbiprofen axetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The therapeutic efficacy of Ramipril can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The therapeutic efficacy of Sulpiride can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Profenamine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00527</drugbank-id>
      <name>Cinchocaine</name>
      <description>The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00677</drugbank-id>
      <name>Isoflurophate</name>
      <description>The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00711</drugbank-id>
      <name>Diethylcarbamazine</name>
      <description>The therapeutic efficacy of Diethylcarbamazine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The therapeutic efficacy of Procaine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The therapeutic efficacy of Perindopril can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00944</drugbank-id>
      <name>Demecarium</name>
      <description>The therapeutic efficacy of Demecarium can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00981</drugbank-id>
      <name>Physostigmine</name>
      <description>The therapeutic efficacy of Physostigmine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>The therapeutic efficacy of Edrophonium can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The therapeutic efficacy of Memantine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01122</drugbank-id>
      <name>Ambenonium</name>
      <description>The therapeutic efficacy of Ambenonium can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01381</drugbank-id>
      <name>Ginkgo biloba</name>
      <description>The therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02365</drugbank-id>
      <name>1,10-Phenanthroline</name>
      <description>The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04864</drugbank-id>
      <name>Huperzine A</name>
      <description>The therapeutic efficacy of Huperzine A can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04892</drugbank-id>
      <name>Phenserine</name>
      <description>The therapeutic efficacy of Phenserine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05386</drugbank-id>
      <name>Regramostim</name>
      <description>The therapeutic efficacy of Regramostim can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06756</drugbank-id>
      <name>Glycine betaine</name>
      <description>The therapeutic efficacy of Glycine betaine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11390</drugbank-id>
      <name>Coumaphos</name>
      <description>The therapeutic efficacy of Coumaphos can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11397</drugbank-id>
      <name>Dichlorvos</name>
      <description>The therapeutic efficacy of Dichlorvos can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11412</drugbank-id>
      <name>Fenthion</name>
      <description>The therapeutic efficacy of Fenthion can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11473</drugbank-id>
      <name>Metrifonate</name>
      <description>The therapeutic efficacy of Metrifonate can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12482</drugbank-id>
      <name>Acotiamide</name>
      <description>The therapeutic efficacy of Acotiamide can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13058</drugbank-id>
      <name>Methanesulfonyl Fluoride</name>
      <description>The therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13495</drugbank-id>
      <name>Paraoxon</name>
      <description>The therapeutic efficacy of Paraoxon can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13503</drugbank-id>
      <name>Tyrothricin</name>
      <description>The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13668</drugbank-id>
      <name>Ipidacrine</name>
      <description>The therapeutic efficacy of Ipidacrine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13694</drugbank-id>
      <name>Distigmine</name>
      <description>The therapeutic efficacy of Distigmine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14031</drugbank-id>
      <name>Tretamine</name>
      <description>The therapeutic efficacy of Tretamine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15317</drugbank-id>
      <name>Posiphen</name>
      <description>The therapeutic efficacy of Posiphen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00545</drugbank-id>
      <name>Pyridostigmine</name>
      <description>The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The therapeutic efficacy of Minaprine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00989</drugbank-id>
      <name>Rivastigmine</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02845</drugbank-id>
      <name>Methylphosphinic Acid</name>
      <description>The therapeutic efficacy of Methylphosphinic Acid can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The therapeutic efficacy of Galantamine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The therapeutic efficacy of Capsaicin can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The risk or severity of myopathy and weakness can be increased when Metocurine iodide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The risk or severity of myopathy and weakness can be increased when Gallamine triethiodide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of myopathy and weakness can be increased when Tubocurarine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Decamethonium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The risk or severity of myopathy and weakness can be increased when Metocurine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>The risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03793</drugbank-id>
      <name>Benzoic acid</name>
      <description>The therapeutic efficacy of Benzoic acid can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06819</drugbank-id>
      <name>Phenylbutyric acid</name>
      <description>The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09269</drugbank-id>
      <name>Phenylacetic acid</name>
      <description>The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The metabolism of Osimertinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of edema formation can be increased when Trilostane is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00984</drugbank-id>
      <name>Nandrolone phenpropionate</name>
      <description>The risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01434</drugbank-id>
      <name>19-norandrostenedione</name>
      <description>The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01471</drugbank-id>
      <name>Bolasterone</name>
      <description>The risk or severity of edema formation can be increased when Bolasterone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01481</drugbank-id>
      <name>1-Testosterone</name>
      <description>The risk or severity of edema formation can be increased when 1-Testosterone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01485</drugbank-id>
      <name>4-Hydroxytestosterone</name>
      <description>The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01521</drugbank-id>
      <name>Clostebol</name>
      <description>The risk or severity of edema formation can be increased when Clostebol is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01524</drugbank-id>
      <name>Androstenediol</name>
      <description>The risk or severity of edema formation can be increased when Androstenediol is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01541</drugbank-id>
      <name>Boldenone</name>
      <description>The risk or severity of edema formation can be increased when Boldenone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01554</drugbank-id>
      <name>Bolandiol</name>
      <description>The risk or severity of edema formation can be increased when Bolandiol is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01564</drugbank-id>
      <name>Calusterone</name>
      <description>The risk or severity of edema formation can be increased when Calusterone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>The risk or severity of edema formation can be increased when Stanolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05107</drugbank-id>
      <name>16-Bromoepiandrosterone</name>
      <description>The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06250</drugbank-id>
      <name>Fluasterone</name>
      <description>The risk or severity of edema formation can be increased when Fluasterone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07768</drugbank-id>
      <name>Epitestosterone</name>
      <description>The risk or severity of edema formation can be increased when Epitestosterone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08619</drugbank-id>
      <name>Testosterone succinate</name>
      <description>The risk or severity of edema formation can be increased when Testosterone succinate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08804</drugbank-id>
      <name>Nandrolone decanoate</name>
      <description>The risk or severity of edema formation can be increased when Nandrolone decanoate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>The risk or severity of edema formation can be increased when Formestane is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11429</drugbank-id>
      <name>Mibolerone</name>
      <description>The risk or severity of edema formation can be increased when Mibolerone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12194</drugbank-id>
      <name>Atamestane</name>
      <description>The risk or severity of edema formation can be increased when Atamestane is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13169</drugbank-id>
      <name>Nandrolone</name>
      <description>The risk or severity of edema formation can be increased when Nandrolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13587</drugbank-id>
      <name>Mesterolone</name>
      <description>The risk or severity of edema formation can be increased when Mesterolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13710</drugbank-id>
      <name>Metenolone</name>
      <description>The risk or severity of edema formation can be increased when Metenolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13947</drugbank-id>
      <name>Testosterone enantate benzilic acid hydrazone</name>
      <description>The risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13958</drugbank-id>
      <name>Trestolone acetate</name>
      <description>The risk or severity of edema formation can be increased when Trestolone acetate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05830</drugbank-id>
      <name>Trestolone</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Trestolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Prasterone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Testosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Testosterone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01456</drugbank-id>
      <name>5-androstenedione</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with 5-androstenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01536</drugbank-id>
      <name>Androstenedione</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Androstenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Methyltestosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The risk or severity of edema formation can be increased when Dexamethasone is combined with Testosterone undecanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>Ocrelizumab may increase the immunosuppressive activities of Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13615</drugbank-id>
      <name>Mifamurtide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The metabolism of Pitolisant can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The serum concentration of aripiprazole, an active metabolite of Dexamethasone, can be decreased when used in combination with Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The metabolism of Hydrocodone can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Dexamethasone may increase the excretion rate of Pravastatin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>Dexamethasone may increase the excretion rate of Olmesartan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Dexamethasone may increase the excretion rate of Atenolol which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Dexamethasone may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>Dexamethasone may increase the excretion rate of Atropine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>Dexamethasone may increase the excretion rate of Fluorescein which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Dexamethasone may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Dexamethasone may increase the excretion rate of Naproxen which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Dexamethasone may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Dexamethasone may increase the excretion rate of Telmisartan which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>Dexamethasone may increase the excretion rate of Ezetimibe which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dexamethasone may increase the excretion rate of Dipyridamole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>Dexamethasone may increase the excretion rate of Ursodeoxycholic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>Dexamethasone may increase the excretion rate of Glycochenodeoxycholic Acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>Dexamethasone may increase the excretion rate of Cholic Acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>Dexamethasone may increase the excretion rate of Taurocholic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>Dexamethasone may increase the excretion rate of Pitavastatin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09374</drugbank-id>
      <name>Indocyanine green acid form</name>
      <description>Dexamethasone may increase the excretion rate of Indocyanine green acid form which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>Dexamethasone may increase the excretion rate of Benzbromarone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>Dexamethasone may increase the excretion rate of Pilsicainide which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13751</drugbank-id>
      <name>Glycyrrhizic acid</name>
      <description>Dexamethasone may increase the excretion rate of Glycyrrhizic acid which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00301</drugbank-id>
      <name>Flucloxacillin</name>
      <description>Dexamethasone may increase the excretion rate of Flucloxacillin which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Dexamethasone may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>Dexamethasone may increase the excretion rate of Sulfinpyrazone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14583</drugbank-id>
      <name>Segesterone acetate</name>
      <description>The metabolism of Segesterone acetate can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00052</drugbank-id>
      <name>Somatotropin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00666</drugbank-id>
      <name>Nafarelin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Iloprost is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06693</drugbank-id>
      <name>Mevastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Mevastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06817</drugbank-id>
      <name>Raltegravir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Raltegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08983</drugbank-id>
      <name>Etofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Etofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09055</drugbank-id>
      <name>Acipimox</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Acipimox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09064</drugbank-id>
      <name>Ciprofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Ciprofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13393</drugbank-id>
      <name>Emetine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Emetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13433</drugbank-id>
      <name>Simfibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Simfibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13460</drugbank-id>
      <name>Ronifibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Ronifibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13780</drugbank-id>
      <name>Aluminium clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Aluminium clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13849</drugbank-id>
      <name>Clofibride</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Clofibride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Fenofibric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Ipecac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The metabolism of Sildenafil can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>The metabolism of Dofetilide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The metabolism of Eletriptan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The metabolism of Indinavir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>The metabolism of Methysergide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The metabolism of Dihydroergotamine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The metabolism of Terfenadine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The metabolism of Nisoldipine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The metabolism of Levothyroxine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The metabolism of Meperidine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Imipramine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The metabolism of Buspirone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The metabolism of Darifenacin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The metabolism of Nortriptyline can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Carbamazepine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The metabolism of Clonidine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The metabolism of Ethosuximide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Cisapride can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The metabolism of Astemizole can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The metabolism of Simvastatin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The metabolism of Aprepitant can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The metabolism of Ergotamine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The metabolism of Eplerenone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The metabolism of Alfentanil can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>The metabolism of Tadalafil can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The metabolism of Conivaptan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The metabolism of Sirolimus can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The metabolism of Triazolam can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The metabolism of Quinidine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The metabolism of Cyclobenzaprine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The metabolism of Tipranavir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The metabolism of Busulfan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Felodipine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Pimozide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The metabolism of Clindamycin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The metabolism of Levacetylmethadol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The metabolism of Paclitaxel can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The metabolism of Saquinavir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Dasatinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The metabolism of Darunavir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The metabolism of Lopinavir can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The metabolism of Tolvaptan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The metabolism of Rivaroxaban can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06237</drugbank-id>
      <name>Avanafil</name>
      <description>The metabolism of Avanafil can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The metabolism of Temsirolimus can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06717</drugbank-id>
      <name>Fosaprepitant</name>
      <description>The metabolism of Fosaprepitant can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The metabolism of Lurasidone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The metabolism of Ticagrelor can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The metabolism of Rilpivirine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The metabolism of Tianeptine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11742</drugbank-id>
      <name>Ebastine</name>
      <description>The metabolism of Ebastine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The metabolism of Esketamine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The metabolism of Milnacipran can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The metabolism of Levomilnacipran can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The metabolism of Argatroban can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Voriconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02520</drugbank-id>
      <name>Ditiocarb</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Ditiocarb.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11779</drugbank-id>
      <name>Danoprevir</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Danoprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Dexamethasone may increase the immunosuppressive activities of Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The metabolism of Clonazepam can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The therapeutic efficacy of Siponimod can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Dexamethasone may increase the hepatotoxic activities of Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Dexamethasone may increase the hepatotoxic activities of Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The metabolism of Erdafitinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Alpelisib can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12240</drugbank-id>
      <name>Polatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be decreased when Dexamethasone is combined with Polatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The serum concentration of Deflazacort can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Tezacaftor can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The serum concentration of Ivacaftor can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The serum concentration of Eszopiclone can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>The metabolism of Pexidartinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The metabolism of Entrectinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>The metabolism of Lefamulin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine may increase the excretion rate of Dexamethasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The metabolism of Dronedarone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15444</drugbank-id>
      <name>Elexacaftor</name>
      <description>The serum concentration of Elexacaftor can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of hypertension can be increased when Flunisolide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of hypertension can be increased when Betamethasone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of hypertension can be increased when Fluticasone propionate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of hypertension can be increased when Fluocinolone acetonide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of hypertension can be increased when Triamcinolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of hypertension can be increased when Prednisone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of hypertension can be increased when Fludrocortisone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of hypertension can be increased when Mometasone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of hypertension can be increased when Prednisolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of hypertension can be increased when Methylprednisolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The risk or severity of hypertension can be increased when Diflorasone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The risk or severity of hypertension can be increased when Alclometasone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The risk or severity of hypertension can be increased when Medrysone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The risk or severity of hypertension can be increased when Amcinonide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of hypertension can be increased when Fluorometholone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of hypertension can be increased when Desoximetasone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>The risk or severity of hypertension can be increased when Ulobetasol is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The risk or severity of hypertension can be increased when Flumethasone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The risk or severity of hypertension can be increased when Clocortolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The risk or severity of hypertension can be increased when Flurandrenolide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14596</drugbank-id>
      <name>Loteprednol etabonate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The risk or severity of hypertension can be increased when Rimexolone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of hypertension can be increased when Clobetasol propionate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of hypertension can be increased when Fluocinonide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The risk or severity of hypertension can be increased when Prednicarbate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Desonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Halcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Clobetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone butyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone probutate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Hydrocortisone valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Prednisolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The serum concentration of Isoniazid can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Acetyldigitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Deslanoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Lanatoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Gitoformate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05144</drugbank-id>
      <name>PEV3A</name>
      <description>The therapeutic efficacy of PEV3A can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06400</drugbank-id>
      <name>Vitespen</name>
      <description>The therapeutic efficacy of Vitespen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10062</drugbank-id>
      <name>Rabies virus inactivated antigen, B</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10076</drugbank-id>
      <name>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10276</drugbank-id>
      <name>Rotavirus vaccine</name>
      <description>The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10342</drugbank-id>
      <name>Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10583</drugbank-id>
      <name>Clostridium tetani toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10584</drugbank-id>
      <name>Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10600</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10769</drugbank-id>
      <name>Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10794</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10803</drugbank-id>
      <name>Typhoid Vi polysaccharide vaccine</name>
      <description>The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10989</drugbank-id>
      <name>Hepatitis A Vaccine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10990</drugbank-id>
      <name>Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11038</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11040</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11041</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11044</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11603</drugbank-id>
      <name>Human rabies virus immune globulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11627</drugbank-id>
      <name>Hepatitis B Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12568</drugbank-id>
      <name>Tecemotide</name>
      <description>The therapeutic efficacy of Tecemotide can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14384</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14385</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14394</drugbank-id>
      <name>Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14445</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14449</drugbank-id>
      <name>Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14619</drugbank-id>
      <name>Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14620</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14711</drugbank-id>
      <name>Vaccinia virus strain new york city board of health live antigen</name>
      <description>The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15274</drugbank-id>
      <name>Pertussis vaccine</name>
      <description>The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15461</drugbank-id>
      <name>Yersinia pestis 195/p antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Rubella virus vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Varicella Zoster Vaccine (Live/attenuated).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Bacillus calmette-guerin substrain tice live antigen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Bacillus calmette-guerin substrain connaught live antigen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Yellow Fever Vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Anthrax vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Typhoid Vaccine Live.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Bacillus calmette-guerin substrain danish 1331 live antigen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with BCG vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Human adenovirus e serotype 4 strain cl-68578 antigen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Vibrio cholerae CVD 103-HgR strain live antigen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Adenovirus type 7 vaccine live.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13924</drugbank-id>
      <name>Varicella Zoster Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15483</drugbank-id>
      <name>Modified vaccinia ankara</name>
      <description>The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15035</drugbank-id>
      <name>Zanubrutinib</name>
      <description>The metabolism of Zanubrutinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14975</drugbank-id>
      <name>Voxelotor</name>
      <description>The serum concentration of Voxelotor can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>Ephedrine may increase the excretion rate of Dexamethasone which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The metabolism of Ketorolac can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The metabolism of Dexibuprofen can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The metabolism of Torasemide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The metabolism of Piroxicam can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00799</drugbank-id>
      <name>Tazarotene</name>
      <description>The metabolism of Tazarotene can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The metabolism of Irbesartan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The metabolism of Licofelone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The metabolism of Beraprost can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06510</drugbank-id>
      <name>Muraglitazar</name>
      <description>The metabolism of Muraglitazar can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Aminophenazone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The metabolism of Paramethadione can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Terbinafine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The metabolism of Almotriptan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08502</drugbank-id>
      <name>Capravirine</name>
      <description>The metabolism of Capravirine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The metabolism of Perospirone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The metabolism of Riociguat can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The metabolism of Brigatinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The metabolism of Thiopental can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00092</drugbank-id>
      <name>Alefacept</name>
      <description>The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The risk or severity of adverse effects can be increased when Carmustine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The risk or severity of adverse effects can be increased when Amsacrine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The risk or severity of adverse effects can be increased when Mitomycin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of adverse effects can be increased when Vindesine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The risk or severity of adverse effects can be increased when Floxuridine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of adverse effects can be increased when Tioguanine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of adverse effects can be increased when Vinorelbine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of adverse effects can be increased when Sorafenib is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The risk or severity of adverse effects can be increased when Streptozocin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Trifluridine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The risk or severity of adverse effects can be increased when Teniposide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of adverse effects can be increased when Epirubicin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of adverse effects can be increased when Altretamine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Zidovudine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of adverse effects can be increased when Cisplatin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The risk or severity of adverse effects can be increased when Pentostatin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of adverse effects can be increased when Methotrexate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of adverse effects can be increased when Vinblastine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of adverse effects can be increased when Linezolid is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of adverse effects can be increased when Clofarabine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of adverse effects can be increased when Tretinoin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The risk or severity of adverse effects can be increased when Methimazole is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The risk or severity of adverse effects can be increased when Etoposide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The risk or severity of adverse effects can be increased when Temozolomide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of adverse effects can be increased when Penicillamine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The risk or severity of adverse effects can be increased when Azacitidine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of adverse effects can be increased when Carboplatin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of adverse effects can be increased when Cytarabine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The risk or severity of adverse effects can be increased when Azathioprine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The risk or severity of adverse effects can be increased when Melphalan is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of adverse effects can be increased when Fludarabine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The risk or severity of adverse effects can be increased when Flucytosine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of adverse effects can be increased when Capecitabine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Procarbazine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Idarubicin is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The risk or severity of adverse effects can be increased when Estramustine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of adverse effects can be increased when Lomustine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01423</drugbank-id>
      <name>Stepronin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Stepronin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Castanospermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02806</drugbank-id>
      <name>2-Methoxyethanol</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with 2-Methoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05259</drugbank-id>
      <name>Glatiramer</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Glatiramer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>omega interferon</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with omega interferon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06662</drugbank-id>
      <name>Abetimus</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Abetimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06681</drugbank-id>
      <name>Belatacept</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Belatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08908</drugbank-id>
      <name>Dimethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Dimethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11693</drugbank-id>
      <name>Voclosporin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Voclosporin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11708</drugbank-id>
      <name>Peficitinib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Peficitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12612</drugbank-id>
      <name>Ozanimod</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ozanimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13068</drugbank-id>
      <name>9-(N-methyl-L-isoleucine)-cyclosporin A</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13241</drugbank-id>
      <name>Begelomab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Begelomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14219</drugbank-id>
      <name>Monomethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Monomethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The risk or severity of adverse effects can be increased when Dexamethasone is combined with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Afatinib can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Paliperidone can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ledipasvir can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The serum concentration of Vincristine can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Acarbose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Miglitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Mitiglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Exenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Pramlintide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Glymidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with AICA ribonucleotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Buformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Vildagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Voglibose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with NBI-6024.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with AMG-222.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Bisegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Liraglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Gosogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Benfluorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Albiglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Lixisenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Ipragliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Dutogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Allicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Tofogliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with 2,4-thiazolidinedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Bempedoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Teneligliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Omarigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Carmegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Gemigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Anagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Evogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Sotagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Remogliflozin etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Guar gum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Semaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Taspoglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Englitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Tirzepatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Gastric inhibitory polypeptide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of hyperglycemia can be increased when Quinine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The risk or severity of hyperglycemia can be increased when Glyburide is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Sitagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Saxagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Alogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Netoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Rivoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Ciglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Balaglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09237</drugbank-id>
      <name>Levamlodipine</name>
      <description>The serum concentration of Levamlodipine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11951</drugbank-id>
      <name>Lemborexant</name>
      <description>The serum concentration of Lemborexant can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>The serum concentration of Darolutamide can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15091</drugbank-id>
      <name>Upadacitinib</name>
      <description>The metabolism of Upadacitinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>The serum concentration of Lumateperone can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Bosutinib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The serum concentration of Edoxaban can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The serum concentration of Naloxegol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Prucalopride can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Silodosin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The serum concentration of Topotecan can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The serum concentration of Rifaximin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The serum concentration of Betrixaban can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Rifampicin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Dexamethasone may decrease the excretion rate of Digoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>Dexamethasone may decrease the excretion rate of Metildigoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>Dexamethasone may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The serum concentration of Midazolam can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Tenofovir disoproxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Cetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00360</drugbank-id>
      <name>Sapropterin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Sapropterin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Amodiaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Metronidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Ceftriaxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The serum concentration of Octreotide can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00126</drugbank-id>
      <name>Ascorbic acid</name>
      <description>The serum concentration of Ascorbic acid can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Olanzapine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Timolol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Tacrine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The serum concentration of Raloxifene can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Alitretinoin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The serum concentration of Lamotrigine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Nizatidine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Mannitol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Clomifene can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Acebutolol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Nadolol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Neostigmine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Sphingosine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Rhodamine 6G can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Estriol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Debrisoquine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Fidaxomicin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The serum concentration of Talinolol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Valspodar can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The serum concentration of Elagolix can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The serum concentration of Letermovir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The serum concentration of Bromperidol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Lusutrombopag can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The serum concentration of Pibrentasvir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The serum concentration of Glecaprevir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>The serum concentration of Stanolone acetate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>The serum concentration of Valinomycin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Cefoperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02010</drugbank-id>
      <name>Staurosporine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Staurosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02587</drugbank-id>
      <name>Colforsin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Colforsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Quercetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04540</drugbank-id>
      <name>Cholesterol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Cholesterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04851</drugbank-id>
      <name>Biricodar</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Biricodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04877</drugbank-id>
      <name>Voacamine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Voacamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Elacridar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04960</drugbank-id>
      <name>Tipifarnib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Tipifarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06191</drugbank-id>
      <name>Zosuquidar</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Zosuquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06240</drugbank-id>
      <name>Tariquidar</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Tariquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>Annamycin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Annamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06448</drugbank-id>
      <name>Lonafarnib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Lonafarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06733</drugbank-id>
      <name>Bafilomycin A1</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Bafilomycin A1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06734</drugbank-id>
      <name>Bafilomycin B1</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Bafilomycin B1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Glycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11387</drugbank-id>
      <name>Chloroform</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Chloroform.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11430</drugbank-id>
      <name>Monensin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Monensin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11544</drugbank-id>
      <name>Salinomycin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Salinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Sarecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12582</drugbank-id>
      <name>Piperine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Piperine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12799</drugbank-id>
      <name>Laniquidar</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Laniquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14056</drugbank-id>
      <name>Nigericin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nigericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14061</drugbank-id>
      <name>Hycanthone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Hycanthone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14062</drugbank-id>
      <name>Concanamycin A</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Concanamycin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14067</drugbank-id>
      <name>Dofequidar</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Dofequidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14069</drugbank-id>
      <name>ONT-093</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with ONT-093.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14070</drugbank-id>
      <name>HM-30181</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with HM-30181.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14071</drugbank-id>
      <name>Desmethylsertraline</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Desmethylsertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14072</drugbank-id>
      <name>Reversin 121</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Reversin 121.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Protriptyline can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The serum concentration of Amoxapine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00520</drugbank-id>
      <name>Caspofungin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Caspofungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Clofazimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The serum concentration of Levetiracetam can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The serum concentration of Oxcarbazepine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The serum concentration of Flecainide can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The serum concentration of Anastrozole can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Cimetidine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Reboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Mefloquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Ivermectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01103</drugbank-id>
      <name>Quinacrine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Quinacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01117</drugbank-id>
      <name>Atovaquone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Atovaquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The serum concentration of Tramadol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated estrogens can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The serum concentration of Morphine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Clobazam can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Clozapine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The serum concentration of Cerivastatin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Loratadine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The serum concentration of Celecoxib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Amprenavir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The serum concentration of Clopidogrel can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Tetracycline can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The serum concentration of Olopatadine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Diazepam can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The serum concentration of Donepezil can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The serum concentration of Ondansetron can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Naloxone can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The serum concentration of Domperidone can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The serum concentration of Metoclopramide can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The serum concentration of Posaconazole can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Ketazolam can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The serum concentration of Indacaterol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Telaprevir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Romidepsin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Simeprevir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Ambrisentan can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The serum concentration of Apixaban can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Axitinib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The serum concentration of Odanacatib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Crizotinib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The serum concentration of Regorafenib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Dabrafenib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The serum concentration of Lenvatinib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The serum concentration of Dasabuvir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The serum concentration of Paritaprevir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The serum concentration of Selexipag can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Venetoclax can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The serum concentration of Asunaprevir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Velpatasvir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The serum concentration of Curcumin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The serum concentration of Rifamycin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The serum concentration of Glasdegib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Abemaciclib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Voxilaprevir can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The serum concentration of Rucaparib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The serum concentration of Copanlisib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Fedratinib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The serum concentration of Estradiol acetate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The serum concentration of Estradiol dienanthate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The serum concentration of Ivosidenib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The serum concentration of Larotrectinib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Ergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Istradefylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The serum concentration of Topiramate can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Trastuzumab deruxtecan can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Safinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11703</drugbank-id>
      <name>Acalabrutinib</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Acalabrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Valproic acid can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06419</drugbank-id>
      <name>Cethromycin</name>
      <description>The metabolism of Cethromycin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01126</drugbank-id>
      <name>Dutasteride</name>
      <description>The metabolism of Dutasteride can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04856</drugbank-id>
      <name>Dexloxiglumide</name>
      <description>The metabolism of Dexloxiglumide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04957</drugbank-id>
      <name>Azimilide</name>
      <description>The metabolism of Azimilide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Nevirapine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The metabolism of Dapsone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The metabolism of Oxycodone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Flutamide can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The metabolism of Dextromethorphan can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The metabolism of Lercanidipine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The metabolism of Disulfiram can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The metabolism of Cocaine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The metabolism of Salmeterol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The metabolism of Zaleplon can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The metabolism of Telithromycin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The metabolism of Oxybutynin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The metabolism of Fluvastatin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>The metabolism of Chlorpheniramine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01216</drugbank-id>
      <name>Finasteride</name>
      <description>The metabolism of Finasteride can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The metabolism of Halofantrine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06267</drugbank-id>
      <name>Udenafil</name>
      <description>The metabolism of Udenafil can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06652</drugbank-id>
      <name>Vicriviroc</name>
      <description>The metabolism of Vicriviroc can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The metabolism of Artemether can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The metabolism of Cannabidiol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The metabolism of Benidipine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11737</drugbank-id>
      <name>Icotinib</name>
      <description>The metabolism of Icotinib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>The metabolism of Valbenazine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The metabolism of Deutetrabenazine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12301</drugbank-id>
      <name>Doravirine</name>
      <description>The metabolism of Doravirine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The metabolism of Nabiximols can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14542</drugbank-id>
      <name>Hydrocortisone phosphate</name>
      <description>The metabolism of Hydrocortisone phosphate can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Dexamethasone can be decreased when combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The metabolism of Enflurane can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The metabolism of Isoflurane can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06728</drugbank-id>
      <name>Aniline</name>
      <description>The metabolism of Aniline can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The metabolism of Trimethadione can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Chlorzoxazone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Ethanol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The metabolism of Felbamate can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The metabolism of Methoxyflurane can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The metabolism of Halothane can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The metabolism of Sevoflurane can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The metabolism of Nilvadipine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The metabolism of Prasugrel can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13132</drugbank-id>
      <name>Artemisinin</name>
      <description>The metabolism of Artemisinin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The metabolism of Brompheniramine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Antipyrine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The metabolism of Ketamine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Mexiletine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Cinnarizine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Efavirenz can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The metabolism of Methylphenobarbital can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The metabolism of Benzphetamine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The metabolism of Perhexiline can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The metabolism of Ethylmorphine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Flunitrazepam can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>The metabolism of Clotiazepam can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Lorcaserin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The metabolism of Ospemifene can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04975</drugbank-id>
      <name>Banoxantrone</name>
      <description>The metabolism of Banoxantrone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The metabolism of Brivaracetam can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The metabolism of Mianserin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The metabolism of Clomethiazole can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The metabolism of Ketobemidone can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Seratrodast can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The metabolism of Bupropion can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The metabolism of Desipramine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The metabolism of Melitracen can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The metabolism of Lofepramine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The metabolism of Dosulepin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09327</drugbank-id>
      <name>Tegafur-uracil</name>
      <description>The metabolism of Tegafur-uracil can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The metabolism of Montelukast can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The metabolism of Letrozole can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04977</drugbank-id>
      <name>Plitidepsin</name>
      <description>The metabolism of Plitidepsin can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Dexamethasone can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Abatacept can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Afelimomab can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Apremilast can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Canakinumab can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Tocilizumab can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Rilonacept can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Golimumab can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Certolizumab pegol can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Secukinumab can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Siltuximab can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Emapalumab can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The serum concentration of Tegaserod can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Cenobamate can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15328</drugbank-id>
      <name>Ubrogepant</name>
      <description>The serum concentration of Ubrogepant can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06404</drugbank-id>
      <name>Human C1-esterase inhibitor</name>
      <description>The risk or severity of thromboembolism can be increased when Dexamethasone is combined with Human C1-esterase inhibitor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09228</drugbank-id>
      <name>Conestat alfa</name>
      <description>The risk or severity of thromboembolism can be increased when Dexamethasone is combined with Conestat alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Dexamethasone may decrease the excretion rate of Folic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Dexamethasone may decrease the excretion rate of Allopurinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Dexamethasone may decrease the excretion rate of Sumatriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>Dexamethasone may decrease the excretion rate of Lamivudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>Dexamethasone may decrease the excretion rate of Riluzole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03496</drugbank-id>
      <name>Alvocidib</name>
      <description>Dexamethasone may decrease the excretion rate of Alvocidib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>Dexamethasone may decrease the excretion rate of Camptothecin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>Dexamethasone may decrease the excretion rate of Dolutegravir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>Dexamethasone may decrease the excretion rate of Fimasartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>Dexamethasone may decrease the excretion rate of Ombitasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>Dexamethasone may decrease the excretion rate of Moxidectin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>Dexamethasone may decrease the excretion rate of Talazoparib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>Dexamethasone may decrease the excretion rate of Revefenacin which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.93</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.9</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.05e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>saquinavir</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>392.4611</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>392.199902243</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C22H29FO5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>UREBDLICKHMUKA-CXSFZGCWSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>94.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>102.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>40.71</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.42</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>89 mg/L (at 25 °C)</value>
      <source>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>260-264</value>
      <source>ChemSpider</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.83</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.64</value>
      <source>ADME Research, USCD</source>
    </property>
    <property>
      <kind>caco2 Permeability</kind>
      <value>-4.75</value>
      <source>ADME Research, USCD</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7600</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12030</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7598</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7602</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>41879</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5743</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508930</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C15643</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00292</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5541</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>18207</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449247</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>DEX</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000007</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>2768</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>2768</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Dexamethasone</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL384467</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/dexameth.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dec1118.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/dexamethasone-drops.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01234</drugbank-id>
        <name>Dexamethasone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01644</drugbank-id>
        <name>6-alpha-OH DEXAMETHASONE</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01234</drugbank-id>
        <name>Dexamethasone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01645</drugbank-id>
        <name>6-beta-OH DEXAMETHASONE</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01234</drugbank-id>
        <name>Dexamethasone</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02919</drugbank-id>
        <name>11-dehydrodexamethasone</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0000131</drugbank-id>
          <name>Corticosteroid 11-beta-dehydrogenase isozyme 2</name>
          <uniprot-id>P80365</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02919</drugbank-id>
        <name>11-dehydrodexamethasone</name>
      </left-element>
      <right-element>
        <drugbank-id>DB01234</drugbank-id>
        <name>Dexamethasone</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0000329</drugbank-id>
          <name>Corticosteroid 11-beta-dehydrogenase isozyme 1</name>
          <uniprot-id>P28845</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="4">
      <id>BE0000794</id>
      <name>Glucocorticoid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6567</ref-id>
            <pubmed-id>16835395</pubmed-id>
            <citation>Warne JP, John CD, Christian HC, Morris JF, Flower RJ, Sugden D, Solito E, Gillies GE, Buckingham JC: Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1264-73. Epub 2006 Jul 11.</citation>
          </article>
          <article>
            <ref-id>A4503</ref-id>
            <pubmed-id>16891588</pubmed-id>
            <citation>Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21.</citation>
          </article>
          <article>
            <ref-id>A6568</ref-id>
            <pubmed-id>16956592</pubmed-id>
            <citation>Funato H, Kobayashi A, Watanabe Y: Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res. 2006 Oct 30;1117(1):125-34. Epub 2006 Sep 7.</citation>
          </article>
          <article>
            <ref-id>A6569</ref-id>
            <pubmed-id>16963802</pubmed-id>
            <citation>Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E: Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep. 2006 Jul-Aug;58(4):551-8.</citation>
          </article>
          <article>
            <ref-id>A6570</ref-id>
            <pubmed-id>16971495</pubmed-id>
            <citation>Wang D, Zhang H, Lang F, Yun CC: Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404. Epub 2006 Sep 13.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P04150" source="Swiss-Prot">
        <name>Glucocorticoid receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic genes expression.</specific-function>
        <gene-name>NR3C1</gene-name>
        <locus>5q31.3</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.31</theoretical-pi>
        <molecular-weight>85658.57</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7978</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR3C1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X03225</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31680</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04150</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GCR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GR</synonym>
          <synonym>GRL</synonym>
          <synonym>Nuclear receptor subfamily 3 group C member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001584|Glucocorticoid receptor
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK
LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN
VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN
SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV
YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG
SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL
CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK
CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE
PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW
MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY
EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK
LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020486|Glucocorticoid receptor (NR3C1)
ATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCAGCAGTGTGCTTGCT
CAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAG
GTTTCTGCGTCTTCACCCTCACTGGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGA
CTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAA
GCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAAT
GACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG
CTTTTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAAG
AGTTCAGCATCCACTGCTGTGTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCAC
TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAAT
GTGAAATTGTATACCACAGACCAAAGCACCTTTGACATTTTGCAGGATTTGGAGTTTTCT
TCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTGGAGATCAGACCTGTTGATAGAT
GAAAACTGTTTGCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAAC
TCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATAAT
GGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTGAAAACAGAAAAA
GAAGATTTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCACAGTT
TACTGTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTCT
GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCC
CTTTCTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCGTTGGT
TCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCTCTGGGGACT
CTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCA
GATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTC
TGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGC
TGTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTACCTATGTGCTGGAAGG
AATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATCGAAAA
TGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAAATAAAAGGAATT
CAGCAGGCCACTACAGGAGTCTCACAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA
GTTCCTGCAACGTTACCACAACTCACCCCTACCCTGGTGTCACTGTTGGAGGTTATTGAA
CCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATG
ACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGAAATGGGCAAAGGCA
ATACCAGGTTTCAGGAACTTACACCTGGATGACCAAATGACCCTACTGCAGTACTCCTGG
ATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCAAGTGCAAACCTG
CTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGCATGTAC
GACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTAT
GAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCTAAGGACGGTCTG
AAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCC
ATTGTCAAGAGGGAAGGAAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAA
CTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACTATTGCTTCCAAACATTT
TTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAG
ATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAAAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF02155</identifier>
            <name>GCR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid-activated RNA polymerase II transcription factor binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to steroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000074</id>
      <name>Nuclear receptor subfamily 0 group B member 1</name>
      <organism>Humans</organism>
      <actions>
        <action>stimulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12562</ref-id>
            <pubmed-id>16857744</pubmed-id>
            <citation>Gummow BM, Scheys JO, Cancelli VR, Hammer GD: Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol Endocrinol. 2006 Nov;20(11):2711-23. Epub 2006 Jul 20.</citation>
          </article>
          <article>
            <ref-id>A12563</ref-id>
            <pubmed-id>17526944</pubmed-id>
            <citation>Yu CC, Li PH: In vivo inhibition of steroidogenic acute regulatory protein expression by dexamethasone parallels induction of the negative transcription factor DAX-1. Endocrine. 2006 Dec;30(3):313-23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P51843" source="Swiss-Prot">
        <name>Nuclear receptor subfamily 0 group B member 1</name>
        <general-function>Transcription factor binding</general-function>
        <specific-function>Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency (By similarity).</specific-function>
        <gene-name>NR0B1</gene-name>
        <locus>Xp21.3-p21.2</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.12</theoretical-pi>
        <molecular-weight>51717.185</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7960</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR0B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U31929</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>786532</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>635</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P51843</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NR0B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AHC</synonym>
          <synonym>DAX1</synonym>
          <synonym>DSS-AHC critical region on the X chromosome protein 1</synonym>
          <synonym>Nuclear receptor DAX-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000148|Nuclear receptor subfamily 0 group B member 1
MAGENHQWQGSILYNMLMSAKQTRAAPEAPETRLVDQCWGCSCGDEPGVGREGLLGGRNV
ALLYRCCFCGKDHPRQGSILYSMLTSAKQTYAAPKAPEATLGPCWGCSCGSDPGVGRAGL
PGGRPVALLYRCCFCGEDHPRQGSILYSLLTSSKQTHVAPAAPEARPGGAWWDRSYFAQR
PGGKEALPGGRATALLYRCCFCGEDHPQQGSTLYCVPTSTNQAQAAPEERPRAPWWDTSS
GALRPVALKSPQVVCEAASAGLLKTLRFVKYLPCFQVLPLDQQLVLVRNCWASLLMLELA
QDRLQFETVEVSEPSMLQKILTTRRRETGGNEPLPVPTLQHHLAPPAEARKVPSASQVQA
IKCFLSKCWSLNISTKEYAYLKGTVLFNPDVPGLQCVKYIQGLQWGTQQILSEHTRMTHQ
GPHDRFIELNSTLFLLRFINANVIAELFFRPIIGTVSMDDMMLEMLCTKI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010151|Nuclear receptor subfamily 0 group B member 1 (NR0B1)
ATGGCGGGCGAGAACCACCAGTGGCAGGGCAGCATCCTCTACAACATGCTTATGAGCGCG
AAGCAAACGCGCGCGGCTCCTGAGGCTCCAGAGACGCGGCTGGTGGATCAGTGCTGGGGC
TGTTCGTGCGGCGATGAGCCCGGGGTGGGCAGAGAGGGGCTGCTGGGCGGGCGGAACGTG
GCGCTCCTGTACCGCTGCTGCTTTTGCGGTAAAGACCACCCACGGCAGGGCAGCATCCTC
TACAGCATGCTGACGAGCGCAAAGCAAACGTACGCGGCACCGAAGGCGCCCGAGGCGACG
CTGGGTCCGTGCTGGGGCTGTTCGTGCGGCTCTGATCCCGGGGTGGGCAGAGCGGGGCTT
CCGGGTGGGCGGCCCGTGGCACTCCTGTACCGCTGCTGCTTTTGTGGTGAAGACCACCCG
CGGCAGGGCAGCATCCTCTACAGCTTGCTCACTAGCTCAAAGCAAACGCACGTGGCTCCG
GCAGCGCCCGAGGCACGGCCAGGGGGCGCGTGGTGGGACCGCTCCTACTTCGCGCAGAGG
CCAGGGGGTAAAGAGGCGCTACCAGGCGGGCGGGCCACGGCGCTTCTGTACCGCTGCTGC
TTTTGCGGTGAAGACCACCCGCAGCAGGGCAGCACCCTCTACTGCGTGCCCACGAGCACA
AATCAAGCGCAGGCGGCTCCGGAGGAGCGGCCGAGGGCCCCCTGGTGGGACACCTCCTCT
GGTGCGCTGCGGCCGGTGGCGCTCAAGAGTCCACAGGTGGTCTGCGAGGCAGCCTCAGCG
GGCCTGTTGAAGACGCTGCGCTTCGTCAAGTACTTGCCCTGCTTCCAGGTGCTGCCCCTG
GACCAGCAGCTGGTGCTGGTGCGCAACTGCTGGGCGTCCCTGCTCATGCTTGAGCTGGCC
CAGGACCGCTTGCAGTTCGAGACTGTGGAAGTCTCGGAGCCCAGCATGCTGCAGAAGATC
CTCACCACCAGGCGGCGGGAGACCGGGGGCAACGAGCCACTGCCCGTGCCCACGCTGCAG
CACCATTTGGCACCGCCGGCGGAGGCCAGGAAGGTGCCCTCCGCCTCCCAGGTCCAAGCC
ATCAAGTGCTTTCTTTCCAAATGCTGGAGTCTGAACATCAGTACCAAGGAGTACGCCTAC
CTCAAGGGGACCGTGCTCTTTAACCCGGACGTGCCGGGCCTGCAGTGCGTGAAGTACATT
CAGGGACTCCAGTGGGGAACTCAGCAAATACTCAGTGAACACACCAGGATGACGCACCAA
GGGCCCCATGACAGATTCATCGAACTTAATAGTACCCTTTTCCTGCTGAGATTCATCAAT
GCCAATGTCATTGCTGAACTGTTCTTCAGGCCCATCATCGGCACAGTCAGCATGGATGAT
ATGATGCTGGAAATGCTCTGTACAAAGATATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF14046</identifier>
            <name>NR_Repeat</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>polysomal ribosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>AF-2 domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA hairpin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein domain specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription corepressor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adrenal gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hypothalamus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Leydig cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male sex determination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of intracellular steroid hormone receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pituitary gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Sertoli cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spermatogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000422</id>
      <name>Annexin A1</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A11173</ref-id>
            <pubmed-id>16883066</pubmed-id>
            <citation>Morand EF, Hall P, Hutchinson P, Yang YH: Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006;2006(2):73835.</citation>
          </article>
          <article>
            <ref-id>A11174</ref-id>
            <pubmed-id>17076770</pubmed-id>
            <citation>John CD, Theogaraj E, Christian HC, Morris JF, Smith SF, Buckingham JC: Time-specific effects of perinatal glucocorticoid treatment on anterior pituitary morphology, annexin 1 expression and adrenocorticotrophic hormone secretion in the adult female rat. J Neuroendocrinol. 2006 Dec;18(12):949-59.</citation>
          </article>
          <article>
            <ref-id>A11175</ref-id>
            <pubmed-id>17158208</pubmed-id>
            <citation>Davies E, Omer S, Buckingham JC, Morris JF, Christian HC: Expression and externalization of annexin 1 in the adrenal gland: structure and function of the adrenal gland in annexin 1-null mutant mice. Endocrinology. 2007 Mar;148(3):1030-8. Epub 2006 Dec 7.</citation>
          </article>
          <article>
            <ref-id>A11176</ref-id>
            <pubmed-id>17644190</pubmed-id>
            <citation>Wang C, Wang J, Guo HF, Liu RY: Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett. 2007 Aug 15;111(2):103-10. Epub 2007 Jul 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04083" source="Swiss-Prot">
        <name>Annexin A1</name>
        <general-function>Structural molecule activity</general-function>
        <specific-function>Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing (PubMed:25664854). Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades (PubMed:15187149, PubMed:25664854). Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors (PubMed:15187149). Contributes to the adaptive immune response by enhancing signaling cascades that are triggered by T-cell activation, regulates differentiation and proliferation of activated T-cells (PubMed:17008549). Promotes the differentiation of T-cells into Th1 cells and negatively regulates differentiation into Th2 cells (PubMed:17008549). Has no effect on unstimulated T cells (PubMed:17008549). Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration (PubMed:15187149). Negatively regulates hormone exocytosis via activation of the formyl peptide receptors and reorganization of the actin cytoskeleton (PubMed:19625660). Has high affinity for Ca(2+) and can bind up to eight Ca(2+) ions (By similarity). Displays Ca(2+)-dependent binding to phospholipid membranes (PubMed:2532504, PubMed:8557678). Plays a role in the formation of phagocytic cups and phagosomes. Plays a role in phagocytosis by mediating the Ca(2+)-dependent interaction between phagosomes and the actin cytoskeleton (By similarity).</specific-function>
        <gene-name>ANXA1</gene-name>
        <locus>9q12-q21.2|9q12-q21.2</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.04</theoretical-pi>
        <molecular-weight>38713.855</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:533</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ANXA1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>BC001275</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>12654863</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04083</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ANXA1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Annexin I</synonym>
          <synonym>Annexin-1</synonym>
          <synonym>ANX1</synonym>
          <synonym>Calpactin II</synonym>
          <synonym>Calpactin-2</synonym>
          <synonym>Chromobindin-9</synonym>
          <synonym>Lipocortin I</synonym>
          <synonym>LPC1</synonym>
          <synonym>p35</synonym>
          <synonym>Phospholipase A2 inhibitory protein</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010292|Annexin A1
MAMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAALHKAIMVKGV
DEATIIDILTKRNNAQRQQIKAAYLQETGKPLDETLKKALTGHLEEVVLALLKTPAQFDA
DELRAAMKGLGTDEDTLIEILASRTNKEIRDINRVYREELKRDLAKDITSDTSGDFRNAL
LSLAKGDRSEDFGVNEDLADSDARALYEAGERRKGTDVNVFNTILTTRSYPQLRRVFQKY
TKYSKHDMNKVLDLELKGDIEKCLTAIVKCATSKPAFFAEKLHQAMKGVGTRHKALIRIM
VSRSEIDMNDIKAFYQKMYGISLCQAILDETKGDYEKILVALCGGN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010293|Annexin A1 (ANXA1)
ATGGCAATGGTATCAGAATTCCTCAAGCAGGCCTGGTTTATTGAAAATGAAGAGCAGGAA
TATGTTCAAACTGTGAAGTCATCCAAAGGTGGTCCCGGATCAGCGGTGAGCCCCTATCCT
ACCTTCAATCCATCCTCGGATGTCGCTGCCTTGCATAAGGCCATAATGGTTAAAGGTGTG
GATGAAGCAACCATCATTGACATTCTAACTAAGCGAAACAATGCACAGCGTCAACAGATC
AAAGCAGCATATCTCCAGGAAACAGGAAAGCCCCTGGATGAAACACTGAAGAAAGCCCTT
ACAGGTCACCTTGAGGAGGTTGTTTTAGCTCTGCTAAAAACTCCAGCGCAATTTGATGCT
GATGAACTTCGTGCTGCCATGAAGGGCCTTGGAACTGATGAAGATACTCTAATTGAGATT
TTGGCATCAAGAACTAACAAAGAAATCAGAGACATTAACAGGGTCTACAGAGAGGAACTG
AAGAGAGATCTGGCCAAAGACATAACCTCAGACACATCTGGAGATTTTCGGAACGCTTTG
CTTTCTCTTGCTAAGGGTGACCGATCTGAGGACTTTGGTGTGAATGAAGACTTGGCTGAT
TCAGATGCCAGGGCCTTGTATGAAGCAGGAGAAAGGAGAAAGGGGACAGACGTAAACGTG
TTCAATACCATCCTTACCACCAGAAGCTATCCACAACTTCGCAGAGTGTTTCAGAAATAC
ACCAAGTACAGTAAGCATGACATGAACAAAGTTCTGGACCTGGAGTTGAAAGGTGACATT
GAGAAATGCCTCACAGCTATCGTGAAGTGCGCCACAAGCAAACCAGCTTTCTTTGCAGAG
AAGCTTCATCAAGCCATGAAAGGTGTTGGAACTCGCCATAAGGCATTGATCAGGATTATG
GTTTCCCGTTCTGAAATTGACATGAATGATATCAAAGCATTCTATCAGAAGATGTATGGT
ATCTCCCTTTGCCAAGCCATCCTGGATGAAACCAAAGGAGATTATGAGAAAATCCTGGTG
GCTCTTTGTGGAGGAAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00191</identifier>
            <name>Annexin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cornified envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>focal adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mast cell granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>motile cilium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phagocytic cup</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>annealing helicase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium-dependent phospholipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium-dependent protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>double-stranded DNA-dependent ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>helicase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipase A2 inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein binding, bridging</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>single-stranded DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>single-stranded RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural molecule activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>actin cytoskeleton reorganization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adaptive immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alpha-beta T cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to glucocorticoid stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA duplex unwinding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA rewinding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocrine pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrous cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gliogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>granulocyte chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hepatocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myoblast migration involved in skeletal muscle regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-8 secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of phospholipase A2 activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of T-helper 2 cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil clearance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptide cross-linking</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-2 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neutrophil apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of prostaglandin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 1 cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vesicle fusion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of wound healing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prolactin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostate gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of interleukin-1 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to interleukin-1</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to peptide hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to X-ray</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="17">
      <id>BE0000005</id>
      <name>Nitric oxide synthase, inducible</name>
      <organism>Humans</organism>
      <actions>
        <action>negative modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12559</ref-id>
            <pubmed-id>17379310</pubmed-id>
            <citation>Soderberg M, Raffalli-Mathieu F, Lang MA: Regulation of the murine inducible nitric oxide synthase gene by dexamethasone involves a heterogeneous nuclear ribonucleoprotein I (hnRNPI) dependent pathway. Mol Immunol. 2007 May;44(12):3204-10. Epub 2007 Mar 26.</citation>
          </article>
          <article>
            <ref-id>A12560</ref-id>
            <pubmed-id>17494951</pubmed-id>
            <citation>Huang H, Lavoie-Lamoureux A, Moran K, Lavoie JP: IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1147-54.</citation>
          </article>
          <article>
            <ref-id>A12561</ref-id>
            <pubmed-id>17503181</pubmed-id>
            <citation>Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35228" source="Swiss-Prot">
        <name>Nitric oxide synthase, inducible</name>
        <general-function>Tetrahydrobiopterin binding</general-function>
        <specific-function>Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM.</specific-function>
        <gene-name>NOS2</gene-name>
        <locus>17q11.2-q12</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.01</theoretical-pi>
        <molecular-weight>131116.3</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7873</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NOS2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L09210</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>292242</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1250</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35228</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NOS2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.13.39</synonym>
          <synonym>HEP-NOS</synonym>
          <synonym>Hepatocyte NOS</synonym>
          <synonym>Inducible NO synthase</synonym>
          <synonym>Inducible NOS</synonym>
          <synonym>iNOS</synonym>
          <synonym>NOS type II</synonym>
          <synonym>NOS2A</synonym>
          <synonym>Peptidyl-cysteine S-nitrosylase NOS2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000010|Nitric oxide synthase, inducible
MACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLSKQQNESPQPL
VETGKKSPESLVKLDATPLSSPRHVRIKNWGSGMTFQDTLHHKAKGILTCRSKSCLGSIM
TPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETTGTYQ
LTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTNNGNI
RSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWKPKYG
RFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVG
GLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINI
AVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPADWIWLVPPMSGSITPVFHQEM
LNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVT
ILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPG
NGEKLKKSLFMLKELNNKFRYAVFGLGSSMYPRFCAFAHDIDQKLSHLGASQLTPMGEGD
ELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTSNVTWDPHHYRLVQDSQPLDL
SKALSSMHAKNVFTMRLKSRQNLQSPTSSRATILVELSCEDGQGLNYLPGEHLGVCPGNQ
PALVQGILERVVDGPTPHQTVRLEALDESGSYWVSDKRLPPCSLSQALTYFLDITTPPTQ
LLLQKLAQVATEEPERQRLEALCQPSEYSKWKFTNSPTFLEVLEEFPSLRVSAGFLLSQL
PILKPRFYSISSSRDHTPTEIHLTVAVVTYHTRDGQGPLHHGVCSTWLNSLKPQDPVPCF
VRNASGFHLPEDPSHPCILIGPGTGIAPFRSFWQQRLHDSQHKGVRGGRMTLVFGCRRPD
EDHIYQEEMLEMAQKGVLHAVHTAYSRLPGKPKVYVQDILRQQLASEVLRVLHKEPGHLY
VCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQKRYHEDIFGAVFPYEAKKDR
VAVQPSSLEMSAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020444|Nitric oxide synthase, inducible (NOS2)
ATGGCCTGTCCTTGGAAATTTCTGTTCAAGACCAAATTCCACCAGTATGCAATGAATGGG
GAAAAAGACATCAACAACAATGTGGAGAAAGCCCCCTGTGCCACCTCCAGTCCAGTGACA
CAGGATGACCTTCAGTATCACAACCTCAGCAAGCAGCAGAATGAGTCCCCGCAGCCCCTC
GTGGAGACGGGAAAGAAGTCTCCAGAATCTCTGGTCAAGCTGGATGCAACCCCATTGTCC
TCCCCACGGCATGTGAGGATCAAAAACTGGGGCAGCGGGATGACTTTCCAAGACACACTT
CACCATAAGGCCAAAGGGATTTTAACTTGCAGGTCCAAATCTTGCCTGGGGTCCATTATG
ACTCCCAAAAGTTTGACCAGAGGACCCAGGGACAAGCCTACCCCTCCAGATGAGCTTCTA
CCTCAAGCTATCGAATTTGTCAACCAATATTACGGCTCCTTCAAAGAGGCAAAAATAGAG
GAACATCTGGCCAGGGTGGAAGCGGTAACAAAGGAGATAGAAACAACAGGAACCTACCAA
CTGACGGGAGATGAGCTCATCTTCGCCACCAAGCAGGCCTGGCGCAATGCCCCACGCTGC
ATTGGGAGGATCCAGTGGTCCAACCTGCAGGTCTTCGATGCCCGCAGCTGTTCCACTGCC
CGGGAAATGTTTGAACACATCTGCAGACACGTGCGTTACTCCACCAACAATGGCAACATC
AGGTCGGCCATCACCGTGTTCCCCCAGCGGAGTGATGGCAAGCACGACTTCCGGGTGTGG
AATGCTCAGCTCATCCGCTATGCTGGCTACCAGATGCCAGATGGCAGCATCAGAGGGGAC
CCTGCCAACGTGGAATTCACTCAGCTGTGCATCGACCTGGGCTGGAAGCCCAAGTACGGC
CGCTTCGATGTGGTCCCCCTGGTCCTGCAGGCCAATGGCCGTGACCCTGAGCTCTTCGAA
ATCCCACCTGACCTTGTGCTTGAGGTGGCCATGGAACATCCCAAATACGAGTGGTTTCGG
GAACTGGAGCTAAAGTGGTACGCCCTGCCTGCAGTGGCCAACATGCTGCTTGAGGTGGGC
GGCCTGGAGTTCCCAGGGTGCCCCTTCAATGGCTGGTACATGGGCACAGAGATCGGAGTC
CGGGACTTCTGTGACGTCCAGCGCTACAACATCCTGGAGGAAGTGGGCAGGAGAATGGGC
CTGGAAACGCACAAGCTGGCCTCGCTCTGGAAAGACCAGGCTGTCGTTGAGATCAACATT
GCTGTGCTCCATAGTTTCCAGAAGCAGAATGTGACCATCATGGACCACCACTCGGCTGCA
GAATCCTTCATGAAGTACATGCAGAATGAATACCGGTCCCGTGGGGGCTGCCCGGCAGAC
TGGATTTGGCTGGTCCCTCCCATGTCTGGGAGCATCACCCCCGTGTTTCACCAGGAGATG
CTGAACTACGTCCTGTCCCCTTTCTACTACTATCAGGTAGAGGCCTGGAAAACCCATGTC
TGGCAGGACGAGAAGCGGAGACCCAAGAGAAGAGAGATTCCATTGAAAGTCTTGGTCAAA
GCTGTGCTCTTTGCCTGTATGCTGATGCGCAAGACAATGGCGTCCCGAGTCAGAGTCACC
ATCCTCTTTGCGACAGAGACAGGAAAATCAGAGGCGCTGGCCTGGGACCTGGGGGCCTTA
TTCAGCTGTGCCTTCAACCCCAAGGTTGTCTGCATGGATAAGTACAGGCTGAGCTGCCTG
GAGGAGGAACGGCTGCTGTTGGTGGTGACCAGTACGTTTGGCAATGGAGACTGCCCTGGC
AATGGAGAGAAACTGAAGAAATCGCTCTTCATGCTGAAAGAGCTCAACAACAAATTCAGG
TACGCTGTGTTTGGCCTCGGCTCCAGCATGTACCCTCGGTTCTGCGCCTTTGCTCATGAC
ATTGATCAGAAGCTGTCCCACCTGGGGGCCTCTCAGCTCACCCCGATGGGAGAAGGGGAT
GAGCTCAGTGGGCAGGAGGACGCCTTCCGCAGCTGGGCCGTGCAAACCTTCAAGGCAGCC
TGTGAGACGTTTGATGTCCGAGGCAAACAGCACATTCAGATCCCCAAGCTCTACACCTCC
AATGTGACCTGGGACCCGCACCACTACAGGCTCGTGCAGGACTCACAGCCTTTGGACCTC
AGCAAAGCCCTCAGCAGCATGCATGCCAAGAACGTGTTCACCATGAGGCTCAAATCTCGG
CAGAATCTACAAAGTCCGACATCCAGCCGTGCCACCATCCTGGTGGAACTCTCCTGTGAG
GATGGCCAAGGCCTGAACTACCTGCCGGGGGAGCACCTTGGGGTTTGCCCAGGCAACCAG
CCGGCCCTGGTCCAAGGTATCCTGGAGCGAGTGGTGGATGGCCCCACACCCCACCAGACA
GTGCGCCTGGAGGCCCTGGATGAGAGTGGCAGCTACTGGGTCAGTGACAAGAGGCTGCCC
CCCTGCTCACTCAGCCAGGCCCTCACCTACTTCCTGGACATCACCACACCCCCAACCCAG
CTGCTGCTCCAAAAGCTGGCCCAGGTGGCCACAGAAGAGCCTGAGAGACAGAGGCTGGAG
GCCCTGTGCCAGCCCTCAGAGTACAGCAAGTGGAAGTTCACCAACAGCCCCACATTCCTG
GAGGTGCTAGAGGAGTTCCCGTCCCTGCGGGTGTCTGCTGGCTTCCTGCTTTCCCAGCTC
CCCATTCTGAAGCCCAGGTTCTACTCCATCAGCTCCTCCCGGGATCACACGCCCACAGAG
ATCCACCTGACTGTGGCCGTGGTCACCTACCACACCCGAGATGGCCAGGGTCCCCTGCAC
CACGGCGTCTGCAGCACATGGCTCAACAGCCTGAAGCCCCAAGACCCAGTGCCCTGCTTT
GTGCGGAATGCCAGCGGCTTCCACCTCCCCGAGGATCCCTCCCATCCTTGCATCCTCATC
GGGCCTGGCACAGGCATCGCGCCCTTCCGCAGTTTCTGGCAGCAACGGCTCCATGACTCC
CAGCACAAGGGAGTGCGGGGAGGCCGCATGACCTTGGTGTTTGGGTGCCGCCGCCCAGAT
GAGGACCACATCTACCAGGAGGAGATGCTGGAGATGGCCCAGAAGGGGGTGCTGCATGCG
GTGCACACAGCCTATTCCCGCCTGCCTGGCAAGCCCAAGGTCTATGTTCAGGACATCCTG
CGGCAGCAGCTGGCCAGCGAGGTGCTCCGTGTGCTCCACAAGGAGCCAGGCCACCTCTAT
GTTTGCGGGGATGTGCGCATGGCCCGGGACGTGGCCCACACCCTGAAGCAGCTGGTGGCT
GCCAAGCTGAAATTGAATGAGGAGCAGGTCGAGGACTATTTCTTTCAGCTCAAGAGCCAG
AAGCGCTATCACGAAGATATCTTTGGTGCTGTATTTCCTTACGAGGCGAAGAAGGACAGG
GTGGCGGTGCAGCCCAGCAGCCTGGAGATGTCAGCGCTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00667</identifier>
            <name>FAD_binding_1</name>
          </pfam>
          <pfam>
            <identifier>PF00258</identifier>
            <name>Flavodoxin_1</name>
          </pfam>
          <pfam>
            <identifier>PF00175</identifier>
            <name>NAD_binding_1</name>
          </pfam>
          <pfam>
            <identifier>PF02898</identifier>
            <name>NO_synthase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cortical cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arginine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavin adenine dinucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>FMN binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NADP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NADPH-hemoprotein reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nitric-oxide synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>tetrahydrobiopterin binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arginine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to interferon-gamma</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-negative bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response in mucosa</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nitric oxide mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-cysteine S-nitrosylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phagosome maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of guanylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of killing of cells of other organism</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of leukocyte mediated cytotoxicity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>superoxide metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="17">
      <id>BE0000956</id>
      <name>Nuclear receptor subfamily 1 group I member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19965</ref-id>
            <pubmed-id>16054614</pubmed-id>
            <citation>Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75469" source="Swiss-Prot">
        <name>Nuclear receptor subfamily 1 group I member 2</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes.</specific-function>
        <gene-name>NR1I2</gene-name>
        <locus>3q12-q13.3</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.44</theoretical-pi>
        <molecular-weight>49761.245</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7968</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR1I2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF061056</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3511138</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O75469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NR1I2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Orphan nuclear receptor PAR1</synonym>
          <synonym>Orphan nuclear receptor PXR</synonym>
          <synonym>Pregnane X receptor</synonym>
          <synonym>PXR</synonym>
          <synonym>Steroid and xenobiotic receptor</synonym>
          <synonym>SXR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001903|Nuclear receptor subfamily 1 group I member 2
MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATGYHFNVMTCEG
CKGFFRRAMKRNARLRCPFRKGACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEE
RRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDAQMKTFDTTFSHFKNFRLPGVLSS
GCELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLL
PHMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWE
CGRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYVLMQAISLFSPDRPGVLQHR
VVDQLQEQFAITLKSYIECNRPQPAHRFLFLKIMAMLTELRSINAQHTQRLLRIQDIHPF
ATPLMQELFGITGS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010672|Nuclear receptor subfamily 1 group I member 2 (NR1I2)
CTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACA
GAGTCTGTTCCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGTCGGAGGTCCCCAAATC
TGCCGTGTATGTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGA
TGCAAGGGCTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCCCTTCCGG
AAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCTGCCGCCTGCGC
AAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACGAGGCCGTGGAGGAG
AGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACAGGGACTCAGCCACTGGGAGTG
CAGGGGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGATGGACGCTCAGATGAAA
ACCTTTGACACTACCTTCTCCCATTTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGT
GGCTGCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGC
CAGGTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGC
AGTGTCTGGAACTACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTG
CCCCACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTC
ATCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCT
TTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAG
TGTGGCCGGCTGTCCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTG
GAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTAT
GTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCCAGGTGTGCTGCAGCACCGC
GTGGTGGACCAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAAT
CGGCCCCAGCCTGCTCATAGGTTCTTGTTCCTGAAGATCATGGCTATGCTCACCGAGCTC
CGCAGCATCAATGCTCAGCACACCCAGCGGCTGCTGCGCATCCAGGACATACACCCCTTT
GCTACGCCCCTCATGCAGGAGTTGTTCGGCATCACAGGTAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug export</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="4">
      <id>BE0000131</id>
      <name>Corticosteroid 11-beta-dehydrogenase isozyme 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10059</ref-id>
            <pubmed-id>9141556</pubmed-id>
            <citation>Diederich S, Hanke B, Oelkers W, Bahr V: Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11beta-reduction. J Clin Endocrinol Metab. 1997 May;82(5):1598-602.</citation>
          </article>
          <article>
            <ref-id>A188556</ref-id>
            <pubmed-id>9618784</pubmed-id>
            <citation>Diederich S, Hanke B, Burkhardt P, Muller M, Schoneshofer M, Bahr V, Oelkers W: Metabolism of synthetic corticosteroids by 11 beta-hydroxysteroid-dehydrogenases in man. Steroids. 1998 May-Jun;63(5-6):271-7. doi: 10.1016/s0039-128x(98)00039-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P80365" source="Swiss-Prot">
        <name>Corticosteroid 11-beta-dehydrogenase isozyme 2</name>
        <general-function>Steroid binding</general-function>
        <specific-function>Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids.</specific-function>
        <gene-name>HSD11B2</gene-name>
        <locus>16q22</locus>
        <cellular-location>Microsome</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.58</theoretical-pi>
        <molecular-weight>44126.06</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5209</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HSD11B2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U14631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>565082</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P80365</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DHI2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.1.1.-</synonym>
          <synonym>11-beta-HSD</synonym>
          <synonym>11-beta-HSD type II</synonym>
          <synonym>11-beta-HSD2</synonym>
          <synonym>11-beta-hydroxysteroid dehydrogenase type 2</synonym>
          <synonym>11-beta-hydroxysteroid dehydrogenase type II</synonym>
          <synonym>11-DH2</synonym>
          <synonym>11-HSD type II</synonym>
          <synonym>HSD11K</synonym>
          <synonym>NAD-dependent 11-beta-hydroxysteroid dehydrogenase</synonym>
          <synonym>SDR9C3</synonym>
          <synonym>Short chain dehydrogenase/reductase family 9C member 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009955|Corticosteroid 11-beta-dehydrogenase isozyme 2
MERWPWPSGGAWLLVAARALLQLLRSDLRLGRPLLAALALLAALDWLCQRLLPPPAALAV
LAAAGWIALSRLARPQRLPVATRAVLITGCDSGFGKETAKKLDSMGFTVLATVLELNSPG
AIELRTCCSPRLRLLQMDLTKPGDISRVLEFTKAHTTSTGLWGLVNNAGHNEVVADAELS
PVATFRSCMEVNFFGALELTKGLLPLLRSSRGRIVTVGSPAGDMPYPCLGAYGTSKAAVA
LLMDTFSCELLPWGVKVSIIQPGCFKTESVRNVGQWEKRKQLLLANLPQELLQAYGKDYI
EHLHGQFLHSLRLAMSDLTPVVDAITDALLAARPRRRYYPGQGLGLMYFIHYYLPEGLRR
RFLQAFFISHCLPRALQPGQPGTTPPQDAAQDPNLSPGPSPAVAR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009956|Corticosteroid 11-beta-dehydrogenase isozyme 2 (HSD11B2)
ATGGAGCGCTGGCCTTGGCCGTCGGGCGGCGCCTGGCTGCTCGTGGCTGCCCGCGCGCTG
CTGCAGCTGCTGCGCTCAGACCTGCGTCTGGGCCGCCCGCTGCTGGCGGCGCTGGCGCTG
CTGGCCGCGCTCGACTGGCTGTGCCAGCGCCTGCTGCCCCCGCCGGCCGCACTCGCCGTG
CTGGCCGCCGCCGGCTGGATCGCGTTGTCCCGCCTGGCGCGCCCGCAGCGCCTGCCGGTG
GCCACTCGCGCGGTGCTCATCACCGGCTGTGACTCTGGTTTTGGCAAGGAGACGGCCAAG
AAACTGGACTCCATGGGCTTCACGGTGCTGGCCACCGTATTGGAGTTGAACAGCCCCGGT
GCCATCGAGCTGCGTACCTGCTGCTCCCCTCGCCTAAGGCTGCTGCAGATGGACCTGACC
AAACCAGGAGACATTAGCCGCGTGCTAGAGTTCACCAAGGCCCACACCACCAGCACCGGC
CTGTGGGGCCTCGTCAACAACGCAGGCCACAATGAAGTAGTTGCTGATGCGGAGCTGTCT
CCAGTGGCCACTTTCCGTAGCTGCATGGAGGTGAATTTCTTTGGCGCGCTCGAGCTGACC
AAGGGCCTCCTGCCCCTGCTGCGCAGCTCAAGGGGCCGCATCGTGACTGTGGGGAGCCCA
GCGGGGGACATGCCATATCCGTGCTTGGGGGCCTATGGAACCTCCAAAGCGGCCGTGGCG
CTACTCATGGACACATTCAGCTGTGAACTCCTTCCCTGGGGGGTCAAGGTCAGCATCATC
CAGCCTGGCTGCTTCAAGACAGAGTCAGTGAGAAACGTGGGTCAGTGGGAAAAGCGCAAG
CAATTGCTGCTGGCCAACCTGCCTCAAGAGCTGCTGCAGGCCTACGGCAAGGACTACATC
GAGCACTTGCATGGGCAGTTCCTGCACTCGCTACGCCTGGCCATGTCCGACCTCACCCCA
GTTGTAGATGCCATCACAGATGCGCTGCTGGCAGCTCGGCCCCGCCGCCGCTATTACCCC
GGCCAGGGCCTGGGGCTCATGTACTTCATCCACTACTACCTGCCTGAAGGCCTGCGGCGC
CGCTTCCTGCAGGCCTTCTTCATCAGTCACTGTCTGCCTCGAGCACTGCAGCCTGGCCAG
CCTGGCACTACCCCACCACAGGACGCAGCCCAGGACCCAAACCTGAGCCCCGGCCCTTCC
CCAGCAGTGGCTCGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00106</identifier>
            <name>adh_short</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NAD binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood volume by renal aldosterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to food</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to insulin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14735</ref-id>
            <pubmed-id>10490933</pubmed-id>
            <citation>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</citation>
          </article>
          <article>
            <ref-id>A174748</ref-id>
            <pubmed-id>8689938</pubmed-id>
            <citation>Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing KF: Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos. 1995 Dec;23(12):1315-24.</citation>
          </article>
          <article>
            <ref-id>A174751</ref-id>
            <pubmed-id>8866917</pubmed-id>
            <citation>Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, Sewing KF: Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.</citation>
          </article>
          <article>
            <ref-id>A174754</ref-id>
            <pubmed-id>17207564</pubmed-id>
            <citation>Miranda SR, Meyer SA: Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7. doi: 10.1016/j.fct.2006.11.011. Epub 2006 Nov 26.</citation>
          </article>
          <article>
            <ref-id>A174757</ref-id>
            <pubmed-id>9010633</pubmed-id>
            <citation>Yamaguchi Y, Kirita S, Baba T, Aoyama J, Touchi A, Tukey RH, Guengerich FP, Matsubara T: Identification of rat and human cytochrome P450 forms involved in the metabolism of the thromboxane A2 receptor antagonist (+)-S-145. Drug Metab Dispos. 1997 Jan;25(1):75-80.</citation>
          </article>
          <article>
            <ref-id>A174760</ref-id>
            <pubmed-id>11231298</pubmed-id>
            <citation>Gomez-Lechon MJ, Donato T, Jover R, Rodriguez C, Ponsoda X, Glaise D, Castell JV, Guguen-Guillouzo C: Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur J Biochem. 2001 Mar;268(5):1448-59.</citation>
          </article>
          <article>
            <ref-id>A174763</ref-id>
            <pubmed-id>8386241</pubmed-id>
            <citation>Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, Beaune P, Pompon D, et al.: Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther. 1993 Apr;265(1):366-72.</citation>
          </article>
          <article>
            <ref-id>A174766</ref-id>
            <pubmed-id>11061575</pubmed-id>
            <citation>McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C: In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000 Oct;68(4):356-66. doi: 10.1067/mcp.2000.110215.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L10184</ref-id>
            <title>Dexamethasone monograph, Boehringer Ingelheim</title>
            <url>https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Dexamethasone/Dexamethasone%20Tablets%20Solution%20and%20Intensol.pdf</url>
          </link>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
          <link>
            <ref-id>L10710</ref-id>
            <title>FDA Approved Drug Products: Hemady Dexamethasone Oral Tablets</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength>moderate</induction-strength>
    </enzyme>
    <enzyme position="7">
      <id>BE0000329</id>
      <name>Corticosteroid 11-beta-dehydrogenase isozyme 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10059</ref-id>
            <pubmed-id>9141556</pubmed-id>
            <citation>Diederich S, Hanke B, Oelkers W, Bahr V: Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11beta-reduction. J Clin Endocrinol Metab. 1997 May;82(5):1598-602.</citation>
          </article>
          <article>
            <ref-id>A188556</ref-id>
            <pubmed-id>9618784</pubmed-id>
            <citation>Diederich S, Hanke B, Burkhardt P, Muller M, Schoneshofer M, Bahr V, Oelkers W: Metabolism of synthetic corticosteroids by 11 beta-hydroxysteroid-dehydrogenases in man. Steroids. 1998 May-Jun;63(5-6):271-7. doi: 10.1016/s0039-128x(98)00039-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28845" source="Swiss-Prot">
        <name>Corticosteroid 11-beta-dehydrogenase isozyme 1</name>
        <general-function>11-beta-hydroxysteroid dehydrogenase [nad(p)] activity</general-function>
        <specific-function>Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7-ketocholesterol to 7-beta-hydroxycholesterol (By similarity).</specific-function>
        <gene-name>HSD11B1</gene-name>
        <locus>1q32-q41</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>8-24</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.77</theoretical-pi>
        <molecular-weight>32400.665</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5208</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HSD11B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M76665</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>179475</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2763</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28845</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DHI1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.1.1.146</synonym>
          <synonym>11-beta-HSD1</synonym>
          <synonym>11-beta-hydroxysteroid dehydrogenase 1</synonym>
          <synonym>11-DH</synonym>
          <synonym>HSD11</synonym>
          <synonym>HSD11L</synonym>
          <synonym>SDR26C1</synonym>
          <synonym>Short chain dehydrogenase/reductase family 26C member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010089|Corticosteroid 11-beta-dehydrogenase isozyme 1
MAFMKKYLLPILGLFMAYYYYSANEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAH
VVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNH
ITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMV
AAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEE
CALEIIKGGALRQEEVYYDSSLWTTLLIRNPCRKILEFLYSTSYNMDRFINK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010090|Corticosteroid 11-beta-dehydrogenase isozyme 1 (HSD11B1)
ATGGCTTTTATGAAAAAATATCTCCTCCCCATTCTGGGGCTCTTCATGGCCTACTACTAC
TATTCTGCAAACGAGGAATTCAGACCAGAGATGCTCCAAGGAAAGAAAGTGATTGTCACA
GGGGCCAGCAAAGGGATCGGAAGAGAGATGGCTTATCATCTGGCGAAGATGGGAGCCCAT
GTGGTGGTGACAGCGAGGTCAAAAGAAACTCTACAGAAGGTGGTATCCCACTGCCTGGAG
CTTGGAGCAGCCTCAGCACACTACATTGCTGGCACCATGGAAGACATGACCTTCGCAGAG
CAATTTGTTGCCCAAGCAGGAAAGCTCATGGGAGGACTAGACATGCTCATTCTCAACCAC
ATCACCAACACTTCTTTGAATCTTTTTCATGATGATATTCACCATGTGCGCAAAAGCATG
GAAGTCAACTTCCTCAGTTACGTGGTCCTGACTGTAGCTGCCTTGCCCATGCTGAAGCAG
AGCAATGGAAGCATTGTTGTCGTCTCCTCTCTGGCTGGGAAAGTGGCTTATCCAATGGTT
GCTGCCTATTCTGCAAGCAAGTTTGCTTTGGATGGGTTCTTCTCCTCCATCAGAAAGGAA
TATTCAGTGTCCAGGGTCAATGTATCAATCACTCTCTGTGTTCTTGGCCTCATAGACACA
GAAACAGCCATGAAGGCAGTTTCTGGGATAGTCCATATGCAAGCAGCTCCAAAGGAGGAA
TGTGCCCTGGAGATCATCAAAGGGGGAGCTCTGCGCCAAGAAGAAGTGTATTATGACAGC
TCACTCTGGACCACTCTTCTGATCAGAAATCCATGCAGGAAGATCCTGGAATTTCTCTAC
TCAACGAGCTATAATATGGACAGATTCATAAACAAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00106</identifier>
            <name>adh_short</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>11-beta-hydroxysteroid dehydrogenase (NADP+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="8">
      <id>BE0002362</id>
      <name>Cytochrome P450 3A5</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A22142</ref-id>
            <pubmed-id>10696073</pubmed-id>
            <citation>Hukkanen J, Lassila A, Paivarinta K, Valanne S, Sarpo S, Hakkola J, Pelkonen O, Raunio H: Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 2000 Mar;22(3):360-6.</citation>
          </article>
          <article>
            <ref-id>A21030</ref-id>
            <pubmed-id>12538830</pubmed-id>
            <citation>Hukkanen J, Vaisanen T, Lassila A, Piipari R, Anttila S, Pelkonen O, Raunio H, Hakkola J: Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20815" source="Swiss-Prot">
        <name>Cytochrome P450 3A5</name>
        <general-function>Oxygen binding</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
        <gene-name>CYP3A5</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.09</theoretical-pi>
        <molecular-weight>57108.065</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2638</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J04813</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181346</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1338</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20815</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIIA5</synonym>
          <synonym>Cytochrome P450 HLp2</synonym>
          <synonym>Cytochrome P450-PCN3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004639|Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016766|Cytochrome P450 3A5 (CYP3A5)
ATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG
CCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT
GACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT
GTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA
GCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA
AAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG
AGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC
ATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT
CTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG
TTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC
CTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT
TCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA
ATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC
AATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG
AATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT
GTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT
CTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT
AAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA
CTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT
GGAGAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>moderate</induction-strength>
    </enzyme>
    <enzyme position="8">
      <id>BE0003612</id>
      <name>Cytochrome P450 3A7</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A174754</ref-id>
            <pubmed-id>17207564</pubmed-id>
            <citation>Miranda SR, Meyer SA: Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7. doi: 10.1016/j.fct.2006.11.011. Epub 2006 Nov 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P24462" source="Swiss-Prot">
        <name>Cytochrome P450 3A7</name>
        <general-function>Oxygen binding</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
        <gene-name>CYP3A7</gene-name>
        <locus>7q21-q22.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.59</theoretical-pi>
        <molecular-weight>57525.03</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2640</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D00408</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>220149</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P24462</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIIA7</synonym>
          <synonym>Cytochrome P450-HFLA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006949|Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019448|Cytochrome P450 3A7 (CYP3A7)
ATGGATCTCATCCCAAACTTGGCCGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGATA
CTCCTCTATCTATATGGAACCCGTACACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATGCTTTGTCCTTCCGTAAGGGCTATTGGACGTTT
GACATGGAATGTTATAAAAAGTATAGAAAAGTCTGGGGTATTTATGACTGTCAACAGCCT
ATGCTGGCTATCACAGATCCCGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTCGGGCCAGTGGGATTTATGAAAAATGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGAATACGATCATTGCTGTCTCCAACATTCACCAGCGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAACACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAGCATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTAATCCATTAGATCCATTCGTT
CTCTCAATAAAAGTCTTTCCATTCCTTACCCCAATTCTTGAAGCATTAAATATCACTGTG
TTTCCAAGAAAAGTTATAAGTTTTCTAACAAAATCTGTAAAACAGATAAAAGAAGGTCGC
CTCAAAGAGACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT
TCAAAAGACTCTGAGACCCACAAAGCTCTGTCTGATCTGGAGCTCATGGCCCAATCAATT
ATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATATATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAAGTGCAGAAGGAAATTGATACAGTTTTACCC
AATAAGGCACCACCCACCTATGATACTGTGCTACAGTTGGAGTATCTTGACATGGTGGTG
AATGAAACACTCAGATTATTCCCAGTTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT
GTTGAAATCAATGGGATGTTTATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGTT
CTTCATCATGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGGTTCAGT
AAAAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA
AACTGCATTGGCATGAGGTTTGCTCTCGTGAACATGAAACTTGCTCTAGTCAGAGTCCTT
CAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTACGCTTTGGA
GGACTTCTTCTAACAGAAAAACCCATTGTTCTAAAGGCTGAGTCAAGGGATGAGACCTTT
GTAGATATGGAGCCCATTCACATGGACTTTTTAAGAAGCTTGGCATTCCAGGGCCCACAC
CTCTGCTTTTTTTGGGAACTACTTTGTCCTACCATCAGATCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="9">
      <id>BE0000344</id>
      <name>Steroid 17-alpha-hydroxylase/17,20 lyase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182738</ref-id>
            <pubmed-id>8385739</pubmed-id>
            <citation>Trzeciak WH, LeHoux JG, Waterman MR, Simpson ER: Dexamethasone inhibits corticotropin-induced accumulation of CYP11A and CYP17 messenger RNAs in bovine adrenocortical cells. Mol Endocrinol. 1993 Feb;7(2):206-13. doi: 10.1210/mend.7.2.8385739.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05093" source="Swiss-Prot">
        <name>Steroid 17-alpha-hydroxylase/17,20 lyase</name>
        <general-function>Steroid 17-alpha-monooxygenase activity</general-function>
        <specific-function>Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.</specific-function>
        <gene-name>CYP17A1</gene-name>
        <locus>10q24.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.87</theoretical-pi>
        <molecular-weight>57369.995</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP17A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14564</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1361</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05093</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP17A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.19</synonym>
          <synonym>17-alpha-hydroxyprogesterone aldolase</synonym>
          <synonym>CYP17</synonym>
          <synonym>CYPXVII</synonym>
          <synonym>Cytochrome P450 17A1</synonym>
          <synonym>Cytochrome P450-C17</synonym>
          <synonym>Cytochrome P450c17</synonym>
          <synonym>S17AH</synonym>
          <synonym>Steroid 17-alpha-monooxygenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018942|Steroid 17-alpha-hydroxylase/17,20 lyase
MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKY
GPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAH
WQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVIS
LICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRN
DLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIF
GAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREV
LRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNP
AGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIP
KVVFLIDSFKVKIKVRQAWREAQAEGST</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018943|Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)
ATGTGGGAGCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTGTTTTGGCCCAAGAGA
AGGTGCCCTGGTGCCAAGTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTG
CCATTCCTCCCCAGACACGGCCATATGCATAACAACTTCTTCAAGCTGCAGAAAAAATAT
GGCCCCATCTATTCGGTTCGTATGGGCACCAAGACTACAGTGATTGTCGGCCACCACCAG
CTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAGGACTTCTCTGGGCGGCCTCAAATGGCA
ACTCTAGACATCGCGTCCAACAACCGTAAGGGTATCGCCTTCGCTGACTCTGGCGCACAC
TGGCAGCTGCATCGAAGGCTGGCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAG
AAGCTGGAGAAGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACCCAC
AACGGACAGTCCATAGACATCTCCTTTCCTGTCTTCGTGGCGGTAACCAATGTCATCTCC
TTGATCTGCTTCAATACCTCCTACAAGAATGGGGACCCTGAGTTGAATGTCATACAGAAT
TACAATGAAGGCATCATAGACAACCTGAGCAAAGACAGCCTGGTGGACCTAGTCCCCTGG
TTGAAGATTTTCCCCAACAAAACCCTGGAAAAATTAAAGAGCCATGTTAAAATACGAAAT
GATCTGCTGAATAAAATACTTGAAAATTACAAGGAGAAATTCCGGAGTGACTCTATCACC
AACATGCTGGACACACTGATGCAAGCCAAGATGAACTCAGATAATGGCAATGCTGGCCCA
GATCAAGACTCAGAGCTGCTTTCAGATAACCACATTCTCACCACCATAGGGGACATCTTT
GGGGCTGGCGTGGAGACCACCACCTCTGTGGTTAAATGGACCCTGGCCTTCCTGCTGCAC
AATCCTCAGGTGAAGAAGAAGCTCTACGAGGAGATTGACCAGAATGTGGGTTTCAGCCGC
ACACCAACTATCAGTGACCGTAACCGTCTCCTCCTGCTGGAGGCCACCATCCGAGAGGTG
CTTCGCCTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAAGGCCAACGTTGACTCCAGC
ATCGGTGAGTTTGCTGTGGACAAGGGCACAGAAGTTATCATCAATCTGTGGGCGCTGCAT
CACAATGAGAAGGAGTGGCACCAGCCGGATCAGTTCATGCCTGAGCGTTTCTTGAATCCA
GCGGGGACCCAGCTCATCTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGC
TCCTGTATAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCCTCATCATGGCCTGGCTGCTG
CAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCTCCCTGGAAGGCATCCCC
AAGGTGGTCTTTCTGATCGACTCTTTCAAAGTGAAGATCAAGGTGCGCCAGGCCTGGAGG
GAAGCCCAGGCTGAGGGTAGCACCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>17-alpha-hydroxyprogesterone aldolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid 17-alpha-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>progesterone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sex differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="10">
      <id>BE0003543</id>
      <name>Cytochrome P450 1A1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38991</ref-id>
            <pubmed-id>11286621</pubmed-id>
            <citation>Baron JM, Holler D, Schiffer R, Frankenberg S, Neis M, Merk HF, Jugert FK: Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol. 2001 Apr;116(4):541-8. doi: 10.1046/j.1523-1747.2001.01298.x.</citation>
          </article>
          <article>
            <ref-id>A182735</ref-id>
            <pubmed-id>15620718</pubmed-id>
            <citation>Monostory K, Kohalmy K, Prough RA, Kobori L, Vereczkey L: The effect of synthetic glucocorticoid, dexamethasone on CYP1A1 inducibility in adult rat and human hepatocytes. FEBS Lett. 2005 Jan 3;579(1):229-35. doi: 10.1016/j.febslet.2004.11.080.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04798" source="Swiss-Prot">
        <name>Cytochrome P450 1A1</name>
        <general-function>Vitamin d 24-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
        <gene-name>CYP1A1</gene-name>
        <locus>15q24.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.47</theoretical-pi>
        <molecular-weight>58164.815</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2595</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>K03191</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181276</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04798</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIA1</synonym>
          <synonym>Cytochrome P450 form 6</synonym>
          <synonym>Cytochrome P450-C</synonym>
          <synonym>Cytochrome P450-P1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006827|Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012466|Cytochrome P450 1A1 (CYP1A1)
ATGCTTTTCCCAATCTCCATGTCGGCCACGGAGTTTCTTCTGGCCTCTGTCATCTTCTGT
CTGGTATTCTGGGTAATCAGGGCCTCAAGACCTCAGGTCCCCAAAGGCCTGAAGAATCCA
CCAGGGCCATGGGGCTGGCCTCTGATTGGGCACATGCTGACCCTGGGAAAGAACCCGCAC
CTGGCACTGTCAAGGATGAGCCAGCAGTATGGGGACGTGCTGCAGATCCGAATTGGCTCC
ACACCCGTGGTGGTGCTGAGCGGCCTGGACACCATCCGGCAGGCCCTGGTGCGGCAGGGC
GATGATTTCAAGGGCCGGCCCGACCTCTACACCTTCACCCTCATCAGTAATGGTCAGAGC
ATGTCCTTCAGCCCAGACTCTGGACCAGTGTGGGCTGCCCGCCGGCGCCTGGCCCAGAAT
GGCCTGAAAAGTTTCTCCATTGCCTCTGACCCAGCCTCCTCAACCTCCTGCTACCTGGAA
GAGCATGTGAGCAAGGAGGCTGAGGTCCTGATAAGCACGTTGCAGGAGCTGATGGCAGGG
CCTGGGCACTTTAACCCCTACAGGTATGTGGTGGTATCAGTGACCAATGTCATCTGTGCC
ATTTGCTTTGGCCGGCGCTATGACCACAACCACCAAGAACTGCTTAGCCTAGTCAACCTG
AATAATAATTTCGGGGAGGTGGTTGGCTCTGGAAACCCAGCTGACTTCATCCCTATTCTT
CGCTACCTACCCAACCCTTCCCTGAATGCCTTCAAGGACCTGAATGAGAAGTTCTACAGC
TTCATGCAGAAGATGGTCAAGGAGCACTACAAAACCTTTGAGAAGGGCCACATCCGGGAC
ATCACAGACAGCCTGATTGAGCACTGTCAGGAGAAGCAGCTGGATGAGAACGCCAATGTC
CAGCTGTCAGATGAGAAGATCATTAACATCGTCTTGGACCTCTTTGGAGCTGGGTTTGAC
ACAGTCACAACTGCTATCTCCTGGAGCCTCATGTATTTGGTGATGAACCCCAGGGTACAG
AGAAAGATCCAAGAGGAGCTAGACACAGTGATTGGCAGGTCACGGCGGCCCCGGCTCTCT
GACAGATCCCATCTGCCCTATATGGAGGCCTTCATCCTGGAGACCTTCCGACACTCTTCC
TTCGTCCCCTTCACCATCCCCCACAGCACAACAAGAGACACAAGTTTGAAAGGCTTTTAC
ATCCCCAAGGGGCGTTGTGTCTTTGTAAACCAGTGGCAGATCAACCATGACCAGAAGCTA
TGGGTCAACCCATCTGAGTTCCTACCTGAACGGTTTCTCACCCCTGATGGTGCTATCGAC
AAGGTGTTAAGTGAGAAGGTGATTATCTTTGGCATGGGCAAGCGGAAGTGTATCGGTGAG
ACCATTGCCCGCTGGGAGGTCTTTCTCTTCCTGGCTATCCTGCTGCAACGGGTGGAATTC
AGCGTGCCACTGGGCGTGAAGGTGGACATGACCCCCATCTATGGGCTAACCATGAAGCAT
GCCTGCTGTGAGCACTTCCAAATGCAGCTGCGCTCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavonoid 3'-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on diphenols and related substances as donors</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>9-cis-retinoic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>amine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>camera-type eye development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo development ending in birth or egg hatching</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hepatocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insecticide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal process involved in parturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to arsenic-containing substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to food</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to herbicide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hyperoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to iron(III) ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nematode</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="11">
      <id>BE0003336</id>
      <name>Cytochrome P450 2A6</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A22135</ref-id>
            <pubmed-id>17978169</pubmed-id>
            <citation>Onica T, Nichols K, Larin M, Ng L, Maslen A, Dvorak Z, Pascussi JM, Vilarem MJ, Maurel P, Kirby GM: Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Mol Pharmacol. 2008 Feb;73(2):451-60. Epub 2007 Oct 31.</citation>
          </article>
          <article>
            <ref-id>A184469</ref-id>
            <pubmed-id>10923861</pubmed-id>
            <citation>Meunier V, Bourrie M, Julian B, Marti E, Guillou F, Berger Y, Fabre G: Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica. 2000 Jun;30(6):589-607. doi: 10.1080/004982500406426 .</citation>
          </article>
          <article>
            <ref-id>A184472</ref-id>
            <pubmed-id>16719377</pubmed-id>
            <citation>Waxman DJ, Chang TK: Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation. Methods Mol Biol. 2006;320:91-6. doi: 10.1385/1-59259-998-2:91.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11509" source="Swiss-Prot">
        <name>Cytochrome P450 2A6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.</specific-function>
        <gene-name>CYP2A6</gene-name>
        <locus>19q13.2</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.69</theoretical-pi>
        <molecular-weight>56501.005</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2610</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2A6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X13897</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1321</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11509</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2A6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,4-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Coumarin 7-hydroxylase</synonym>
          <synonym>CYP2A3</synonym>
          <synonym>CYPIIA6</synonym>
          <synonym>Cytochrome P450 IIA3</synonym>
          <synonym>Cytochrome P450(I)</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037226|Cytochrome P450 2A6
MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMK
ISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSN
GERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSN
VISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQL
LQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFI
GGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQ
RFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLNEK
GQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGF
ATIPRNYTMSFLPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021356|Cytochrome P450 2A6 (CYP2A6)
ATGCTGGCCTCAGGGATGCTTCTGGTGGCCTTGCTGGTCTGCCTGACTGTAATGGTCTTG
ATGTCTGTTTGGCAGCAGAGGAAGAGCAAGGGGAAGCTGCCTCCGGGACCCACCCCATTG
CCCTTCATTGGAAACTACCTGCAGCTGAACACAGAGCAGATGTACAACTCCCTCATGAAG
ATCAGTGAGCGCTATGGCCCCGTGTTCACCATTCACTTGGGGCCCCGGCGGGTCGTGGTG
CTGTGTGGACATGATGCCGTCAGGGAGGCTCTGGTGGACCAGGCTGAGGAGTTCAGCGGG
CGAGGCGAGCAAGCCACCTTCGACTGGGTCTTCAAAGGCTATGGCGTGGTATTCAGCAAC
GGGGAGCGCGCCAAGCAGCTCCGGCGCTTCTCCATCGCCACCCTGCGGGACTTCGGGGTG
GGCAAGCGAGGCATCGAGGAGCGCATCCAGGAGGAGGCGGGCTTCCTCATCGACGCCCTC
CGGGGCACTGGCGGCGCCAATATCGATCCCACCTTCTTCCTGAGCCGCACAGTCTCCAAT
GTCATCAGCTCCATTGTCTTTGGGGACCGCTTTGACTATAAGGACAAAGAGTTCCTGTCA
CTGTTGCGCATGATGCTAGGAATCTTCCAGTTCACGTCAACCTCCACGGGGCAGCTCTAT
GAGATGTTCTCTTCGGTGATGAAACACCTGCCAGGACCACAGCAACAGGCCTTTCAGTTG
CTGCAAGGGCTGGAGGACTTCATAGCCAAGAAGGTGGAGCACAACCAGCGCACGCTGGAT
CCCAATTCCCCACGGGACTTCATTGACTCCTTTCTCATCCGCATGCAGGAGGAGGAGAAG
AACCCCAACACGGAGTTCTACTTGAAAAACCTGGTGATGACCACGTTGAACCTCTTCATT
GGGGGCACCGAGACCGTCAGCACCACCCTGCGCTATGGCTTCTTGCTGCTCATGAAGCAC
CCAGAGGTGGAGGCCAAGGTCCATGAGGAGATTGACAGAGTGATCGGCAAGAACCGGCAG
CCCAAGTTTGAGGACCGGGCCAAGATGCCCTACATGGAGGCAGTGATCCACGAGATCCAA
AGATTTGGAGACGTGATCCCCATGAGTTTGGCCCGCAGAGTCAAAAAGGACACCAAGTTT
CGGGATTTCTTCCTCCCTAAGGGCACCGAAGTGTACCCTATGCTGGGCTCTGTGCTGAGA
GACCCCAGTTTCTTCTCCAACCCCCAGGACTTCAATCCCCAGCACTTCCTGAATGAGAAG
GGGCAGTTTAAGAAGAGTGATGCTTTTGTGCCCTTTTCCATCGGAAAGCGGAACTGTTTC
GGAGAAGGCCTGGCCAGAATGGAGCTCTTTCTCTTCTTCACCACCGTCATGCAGAACTTC
CGCCTCAAGTCCTCCCAGTCACCTAAGGACATTGACGTGTCCCCCAAACACGTGGGCTTT
GCCACGATCCCACGAAACTACACCATGAGCTTCCTGCCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic microtubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>coumarin 7-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="12">
      <id>BE0003549</id>
      <name>Cytochrome P450 2B6</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38991</ref-id>
            <pubmed-id>11286621</pubmed-id>
            <citation>Baron JM, Holler D, Schiffer R, Frankenberg S, Neis M, Merk HF, Jugert FK: Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol. 2001 Apr;116(4):541-8. doi: 10.1046/j.1523-1747.2001.01298.x.</citation>
          </article>
          <article>
            <ref-id>A184085</ref-id>
            <pubmed-id>18781911</pubmed-id>
            <citation>Wang H, Tompkins LM: CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008 Sep;9(7):598-610.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20813" source="Swiss-Prot">
        <name>Cytochrome P450 2B6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.</specific-function>
        <gene-name>CYP2B6</gene-name>
        <locus>19q13.2</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.44</theoretical-pi>
        <molecular-weight>56277.81</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2615</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M29874</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181296</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1324</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20813</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2B6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,4-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>CYPIIB6</synonym>
          <synonym>Cytochrome P450 IIB1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006839|Cytochrome P450 2B6
MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFRE
KYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNR
WKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIIC
SIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQE
INAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGT
ETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFS
DLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGAL
KKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKI
PPTYQIRFLPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019435|Cytochrome P450 2B6 (CYP2B6)
ATGGAACTCAGCGTCCTCCTCTTCCTTGCACTCCTCACAGGACTCTTGCTACTCCTGGTT
CAGCGCCACCCTAACACCCATGACCGCCTCCCACCAGGGCCCCGCCCTCTGCCCCTTTTG
GGAAACCTTCTGCAGATGGATAGAAGAGGCCTACTCAAATCCTTTCTGAGGTTCCGAGAG
AAATATGGGGACGTCTTCACGGTACACCTGGGACCGAGGCCCGTGGTCATGCTGTGTGGA
GTAGAGGCCATACGGGAGGCCCTTGTGGACAAGGCTGAGGCCTTCTCTGGCCGGGGAAAA
ATCGCCATGGTCGACCCATTCTTCCGGGGATATGGTGTGATCTTTGCCAATGGAAACCGC
TGGAAGGTGCTTCGGCGATTCTCTGTGACCACTATGAGGGACTTCGGGATGGGAAAGCGG
AGTGTGGAGGAGCGGATTCAGGAGGAGGCTCAGTGTCTGATAGAGGAGCTTCGGAAATCC
AAGGGGGCCCTCATGGACCCCACCTTCCTCTTCCAGTCCATTACCGCCAACATCATCTGC
TCCATCGTCTTTGGAAAACGATTCCACTACCAAGATCAAGAGTTCCTGAAGATGCTGAAC
TTGTTCTACCAGACTTTTTCACTCATCAGCTCTGTATTCGGCCAGCTGTTTGAGCTCTTC
TCTGGCTTCTTGAAATACTTTCCTGGGGCACACAGGCAAGTTTACAAAAACCTGCAGGAA
ATCAATGCTTACATTGGCCACAGTGTGGAGAAGCACCGTGAAACCCTGGACCCCAGCGCC
CCCAAGGACCTCATCGACACCTACCTGCTCCACATGGAAAAAGAGAAATCCAACGCACAC
AGTGAATTCAGCCACCAGAACCTCAACCTCAACACGCTCTCGCTCTTCTTTGCTGGCACT
GAGACCACCAGCACCACTCTCCGCTACGGCTTCCTGCTCATGCTCAAATACCCTCATGTT
GCAGAGAGAGTCTACAGGGAGATTGAACAGGTGATTGGCCCACATCGCCCTCCAGAGCTT
CATGACCGAGCCAAAATGCCATACACAGAGGCAGTCATCTATGAGATTCAGAGATTTTCC
GACCTTCTCCCCATGGGTGTGCCCCACATTGTCACCCAACACACCAGCTTCCGAGGGTAC
ATCATCCCCAAGGACACAGAAGTATTTCTCATCCTGAGCACTGCTCTCCATGACCCACAC
TACTTTGAAAAACCAGACGCCTTCAATCCTGACCACTTTCTGGATGCCAATGGGGCACTG
AAAAAGACTGAAGCTTTTATCCCCTTCTCCTTAGGGAAGCGGATTTGTCTTGGTGAAGGC
ATCGCCCGTGCGGAATTGTTCCTCTTCTTCACCACCATCCTCCAGAACTTCTCCATGGCC
AGCCCCGTGGCCCCAGAAGACATCGATCTGACACCCCAGGAGTGTGGTGTGGGCAAAATA
CCCCCAACATACCAGATCCGCTTCCTGCCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular ketone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="13">
      <id>BE0003536</id>
      <name>Cytochrome P450 2C19</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33269</ref-id>
            <pubmed-id>12130704</pubmed-id>
            <citation>Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM: Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther. 2002 Aug;302(2):475-82. doi: 10.1124/jpet.102.033837.</citation>
          </article>
          <article>
            <ref-id>A38853</ref-id>
            <pubmed-id>22027650</pubmed-id>
            <citation>Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE: PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012 Feb;22(2):159-65. doi: 10.1097/FPC.0b013e32834d4962.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P33261" source="Swiss-Prot">
        <name>Cytochrome P450 2C19</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.</specific-function>
        <gene-name>CYP2C19</gene-name>
        <locus>10q24.1-q24.3</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.42</theoretical-pi>
        <molecular-weight>55930.545</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2621</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M61854</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1328</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P33261</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2CJ_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>CYPIIC17</synonym>
          <synonym>CYPIIC19</synonym>
          <synonym>Cytochrome P450-11A</synonym>
          <synonym>Cytochrome P450-254C</synonym>
          <synonym>Mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020694|Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19)
ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT
GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC
ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG
GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT
CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT
GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG
ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG
GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC
CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC
ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG
AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG
GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT
CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG
CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="14">
      <id>BE0002887</id>
      <name>Cytochrome P450 2C8</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38112</ref-id>
            <pubmed-id>26721703</pubmed-id>
            <citation>Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411.</citation>
          </article>
          <article>
            <ref-id>A184478</ref-id>
            <pubmed-id>11093784</pubmed-id>
            <citation>Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ: Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol. 2000 Dec;58(6):1441-50. doi: 10.1124/mol.58.6.1441.</citation>
          </article>
          <article>
            <ref-id>A33266</ref-id>
            <pubmed-id>11181490</pubmed-id>
            <citation>Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P: Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10632" source="Swiss-Prot">
        <name>Cytochrome P450 2C8</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).</specific-function>
        <gene-name>CYP2C8</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>55824.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1325</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIC8</synonym>
          <synonym>Cytochrome P450 form 1</synonym>
          <synonym>Cytochrome P450 IIC2</synonym>
          <synonym>Cytochrome P450 MP-12</synonym>
          <synonym>Cytochrome P450 MP-20</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="15">
      <id>BE0003533</id>
      <name>Cytochrome P450 2E1</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38991</ref-id>
            <pubmed-id>11286621</pubmed-id>
            <citation>Baron JM, Holler D, Schiffer R, Frankenberg S, Neis M, Merk HF, Jugert FK: Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol. 2001 Apr;116(4):541-8. doi: 10.1046/j.1523-1747.2001.01298.x.</citation>
          </article>
          <article>
            <ref-id>A184481</ref-id>
            <pubmed-id>9207195</pubmed-id>
            <citation>Sampol E, Mirrione A, Villard PH, Piccerelle P, Scoma H, Berbis P, Barra Y, Durand A, Lacarelle B: Evidence for a tissue-specific induction of cutaneous CYP2E1 by dexamethasone. Biochem Biophys Res Commun. 1997 Jun 27;235(3):557-61. doi: 10.1006/bbrc.1997.6829.</citation>
          </article>
          <article>
            <ref-id>A184484</ref-id>
            <pubmed-id>8249615</pubmed-id>
            <citation>Monostory K, Vereczkey L: Combined action of phenobarbital and dexamethasone on the activity of rat liver P450 system. Acta Pharm Hung. 1993 Sep;63(5):296-300.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05181" source="Swiss-Prot">
        <name>Cytochrome P450 2E1</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.</specific-function>
        <gene-name>CYP2E1</gene-name>
        <locus>10q24.3-qter</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.22</theoretical-pi>
        <molecular-weight>56848.42</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J02625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181360</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1330</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05181</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2E1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.13.-</synonym>
          <synonym>4-nitrophenol 2-hydroxylase</synonym>
          <synonym>CYP2E</synonym>
          <synonym>CYPIIE1</synonym>
          <synonym>Cytochrome P450-J</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012460|Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012461|Cytochrome P450 2E1 (CYP2E1)
ATGTCTGCCCTCGGAGTCACCGTGGCCCTGCTGGTGTGGGCGGCCTTCCTCCTGCTGGTG
TCCATGTGGAGGCAGGTGCACAGCAGCTGGAATCTGCCCCCAGGCCCTTTCCCGCTTCCC
ATCATCGGGAACCTCTTCCAGTTGGAATTGAAGAATATTCCCAAGTCCTTCACCCGGTTG
GCCCAGCGCTTCGGGCCGGTGTTCACGCTGTACGTGGGCTCGCAGCGCATGGTGGTGATG
CACGGCTACAAGGCGGTGAAGGAAGCGCTGCTGGACTACAAGGACGAGTTCTCGGGCAGA
GGCGACCTCCCCGCGTTCCATGCGCACAGGGACAGGGGAATCATTTTTAATAATGGACCT
ACCTGGAAGGACATCCGGCGGTTTTCCCTGACCACCCTCCGGAACTATGGGATGGGGAAA
CAGGGCAATGAGAGCCGGATCCAGAGGGAGGCCCACTTCCTGCTGGAAGCACTCAGGAAG
ACCCAAGGCCAGCCTTTCGACCCCACCTTCCTCATCGGCTGCGCGCCCTGCAACGTCATA
GCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTCTAAGGCTGATG
TATTTGTTTAATGAGAACTTCCACCTACTCAGCACTCCCTGGCTCCAGCTTTACAATAAT
TTTCCCAGCTTTCTACACTACTTGCCTGGAAGCCACAGAAAAGTCATAAAAAATGTGGCT
GAAGTAAAAGAGTATGTGTCTGAAAGGGTGAAGGAGCACCATCAATCTCTGGACCCCAAC
TGTCCCCGGGACCTCACCGACTGCCTGCTCGTGGAAATGGAGAAGGAAAAGCACAGTGCA
GAGCGCTTGTACACAATGGACGGTATCACCGTGACTGTGGCCGACCTGTTCTTTGCGGGG
ACAGAGACCACCAGCACAACTCTGAGATATGGGCTCCTGATTCTCATGAAATACCCTGAG
ATCGAAGAGAAGCTCCATGAAGAAATTGACAGGGTGATTGGGCCAAGCCGAATCCCTGCC
ATCAAGGATAGGCAAGAGATGCCCTACATGGATGCTGTGGTGCATGAGATTCAGCGGTTC
ATCACCCTCGTGCCCTCCAACCTGCCCCATGAAGCAACCCGAGACACCATTTTCAGAGGA
TACCTCATCCCCAAGGGCACAGTCGTAGTGCCAACTCTGGACTCTGTTTTGTATGACAAC
CAAGAATTTCCTGATCCAGAAAAGTTTAAGCCAGAACACTTCCTGAATGAAAATGGAAAG
TTCAAGTACAGTGACTATTTCAAGCCATTTTCCACAGGAAAACGAGTGTGTGCTGGAGAA
GGCCTGGCTCGCATGGAGTTGTTTCTTTTGTTGTGTGCCATTTTGCAGCATTTTAATTTG
AAGCCTCTCGTTGACCCAAAGGATATCGACCTCAGCCCTATACATATTGGGTTTGGCTGT
ATCCCACCACGTTACAAACTCTGTGTCATTCCCCGCTCATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organonitrogen compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ozone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>triglyceride metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="16">
      <id>BE0003550</id>
      <name>Cytochrome P450 3A43</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182732</ref-id>
            <pubmed-id>12679136</pubmed-id>
            <citation>Krusekopf S, Roots I, Kleeberg U: Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol. 2003 Apr 11;466(1-2):7-12. doi: 10.1016/s0014-2999(03)01481-x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9HB55" source="Swiss-Prot">
        <name>Cytochrome P450 3A43</name>
        <general-function>Monooxygenase activity</general-function>
        <specific-function>Exhibits low testosterone 6-beta-hydroxylase activity.</specific-function>
        <gene-name>CYP3A43</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57669.21</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:17450</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF319634</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>12642642</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9HB55</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP343_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006840|Cytochrome P450 3A43
MDLIPNFAMETWVLVATSLVLLYIYGTHSHKLFKKLGIPGPTPLPFLGTILFYLRGLWNF
DRECNEKYGEMWGLYEGQQPMLVIMDPDMIKTVLVKECYSVFTNQMPLGPMGFLKSALSF
AEDEEWKRIRTLLSPAFTSVKFKEMVPIISQCGDMLVRSLRQEAENSKSINLKDFFGAYT
MDVITGTLFGVNLDSLNNPQDPFLKNMKKLLKLDFLDPFLLLISLFPFLTPVFEALNIGL
FPKDVTHFLKNSIERMKESRLKDKQKHRVDFFQQMIDSQNSKETKSHKALSDLELVAQSI
IIIFAAYDTTSTTLPFIMYELATHPDVQQKLQEEIDAVLPNKAPVTYDALVQMEYLDMVV
NETLRLFPVVSRVTRVCKKDIEINGVFIPKGLAVMVPIYALHHDPKYWTEPEKFCPERFS
KKNKDSIDLYRYIPFGAGPRNCIGMRFALTNIKLAVIRALQNFSFKPCKETQIPLKLDNL
PILQPEKPIVLKVHLRDGITSGP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012469|Cytochrome P450 3A43 (CYP3A43)
ATGGATCTCATTCCAAACTTTGCCATGGAAACATGGGTTCTTGTGGCTACCAGCCTGGTA
CTCCTCTATATTTATGGGACCCATTCACATAAACTTTTTAAGAAGCTGGGAATTCCTGGG
CCAACCCCTCTGCCTTTTCTGGGAACTATTTTGTTCTACCTTAGGAGGTCTCTGAATAAG
ATTCCCAGCTGGGCGTGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAAGCA
GGAGGATCACCTAAGGTCAGGAGTTCGAGACCAGCTTTGCCAACATGGGTCTTTGGAATT
TTGACAGAGAATGTAATGAAAAATACGGAGAAATGTGGGGCACTCTTTCCATTTCTTACC
CCAGTTTTTGAAGCCCTAAATATCGGTTTGTTTCCAAAAGATGTTACCCATTTTTTAAAA
AATTCCATTGAAAGGATGAAAGAAAGTCGCCTCAAAGATAAACAAAAGCATCGAGTAGAT
TTCTTTCAACAGATGATCGACTCCCAGAATTCCAAAGAAACAAAGTCCCATAAAGCTCTG
TCTGATCTGGAGCTTGTGGCCCAGTCAATTATCATCATTTTTGCTGCCTATGACACAACT
AGCACCACTCTCCCCTTCATTATGTATGAACTGGCCACTCACCCTGATGTCCAGCAGAAA
CTGCAGGAGGAGATTGACGCAGTTTTACCCAATAAGGCACCTGTCACCTACGATGCCCTG
GTACAGATGGAGTACCTTGACATGGTGGTGAATGAAACGCTCAGATTATTCCCAGTTGTT
AGTAGAGTTACGAGAGTCTGCAAGAAAGATATTGAAATCAATGGAGTGTTCATTCCCAAA
GGGTTAGCAGTGATGGTTCCAATCTATGCTCTTCACCATGACCCAAAGTACTGGACAGAG
CCTGAGAAGTTCTGCCCTGAAAGGTTCAGTAAGAAGAACAAGGACAGCATAGATCTTTAC
AGATACATACCTTTTGGAGCTGGACCCCGAAACTGCATTGGCATGAGGTTTGCTCTCACA
AACATAAAACTTGCTGTCATTAGAGCACTGCAGAACTTCTCCTTCAAACCTTGTAAAGAG
ACTCAGATCCCACTGAAATTAGACAATCTACCAATTCTTCAACCAGAAAAACCTATTGTT
CTAAAAGTGCACTTAAGAGATGGGATTACAAGTGGACCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="17">
      <id>BE0000421</id>
      <name>Cytochrome P450 4A11</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37614</ref-id>
            <pubmed-id>10773044</pubmed-id>
            <citation>Cummings BS, Lasker JM, Lash LH: Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney. J Pharmacol Exp Ther. 2000 May;293(2):677-85.</citation>
          </article>
          <article>
            <ref-id>A182729</ref-id>
            <pubmed-id>12464261</pubmed-id>
            <citation>Savas U, Hsu MH, Johnson EF: Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch Biochem Biophys. 2003 Jan 1;409(1):212-20. doi: 10.1016/s0003-9861(02)00499-x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q02928" source="Swiss-Prot">
        <name>Cytochrome P450 4A11</name>
        <general-function>Leukotriene-b4 20-monooxygenase activity</general-function>
        <specific-function>Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).</specific-function>
        <gene-name>CYP4A11</gene-name>
        <locus>1p33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.99</theoretical-pi>
        <molecular-weight>59347.31</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2642</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP4A11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L04751</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q02928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP4AB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>20-HETE synthase</synonym>
          <synonym>20-hydroxyeicosatetraenoic acid synthase</synonym>
          <synonym>CYP4A2</synonym>
          <synonym>CYP4AII</synonym>
          <synonym>CYPIVA11</synonym>
          <synonym>Cytochrome P-450HK-omega</synonym>
          <synonym>Cytochrome P450HL-omega</synonym>
          <synonym>Fatty acid omega-hydroxylase</synonym>
          <synonym>Lauric acid omega-hydroxylase</synonym>
          <synonym>Long-chain fatty acid omega-monooxygenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000839|Cytochrome P450 4A11
MSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQFPCPPSHWLF
GHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSY
RFLAPWIGYGLLLLNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQD
SPLEVFQHVSLMTLDTIMKCAFSHQGSIQVDRNSQSYIQAISDLNNLVFSRVRNAFHQND
TIYSLTSAGRWTHRACQLAHQHTDQVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKM
ENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHSLLGDGAS
ITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFPDGRSLPKGIMVLLSIYGLHH
NPKVWPNPEVFDPFRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNELKVATALTLLRFEL
LPDPTRIPIPIARLVLKSKNGIHLRLRRLPNPCEDKDQL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020457|Cytochrome P450 4A11 (CYP4A11)
ATGAGTGTCTCTGTGCTGAGCCCCAGCAGACTCCTGGGTGATGTCTCTGGAATCCTCCAA
GCGGCCTCCCTGCTCATTCTGCTTCTGCTGCTGATCAAGGCAGTTCAGCTCTACCTGCAC
AGGCAGTGGCTGCTCAAAGCCCTCCAGCAGTTCCCGTGCCCTCCCTCCCACTGGCTCTTC
GGGCACATCCAGGAGCTCCAACAGGACCAGGAGCTACAACGGATTCAGAAATGGGTGGAG
ACATTCCCAAGTGCCTGTCCTCATTGGCTATGGGGAGGCAAAGTTCGTGTCCAGCTCTAT
GACCCTGACTATATGAAGGTGATTCTGGGGAGATCAGACCCGAAATCCCATGGTTCCTAC
AGATTCCTGGCTCCATGGATTGGGTACGGCTTGCTCCTGTTGAATGGGCAGACATGGTTC
CAGCATCGACGGATGCTGACCCCAGCCTTCCACTATGACATCCTGAAGCCCTATGTGGGG
CTCATGGCAGACTCTGTACGAGTGATGCTGGACAAATGGGAAGAGCTCCTTGGCCAGGAT
TCCCCTCTGGAGGTCTTTCAGCACGTCTCCTTGATGACCCTGGACACCATCATGAAGTGT
GCCTTCAGCCATCAGGGCAGCATCCAGGTGGACAGGAATTCTCAGTCCTACATACAGGCC
ATTAGTGACCTGAACAACCTGGTTTTTTCCCGTGTGAGGAATGCCTTTCACCAGAATGAC
ACCATCTACAGCCTGACCTCTGCTGGCCGCTGGACACACCGCGCCTGCCAGCTGGCCCAT
CAGCACACAGACCAAGTGATCCAACTGAGGAAGGCTCAACTACAGAAGGAGGGGGAGCTG
GAGAAGATCAAGAGGAAGAGGCATTTGGATTTTCTGGATATCCTCCTCTTGGCCAAAATG
GAGAATGGGAGCATCTTGTCAGACAAGGACCTCCGTGCTGAGGTGGACACGTTCATGTTT
GAGGGCCACGACACCACAGCCAGTGGGATCTCCTGGATCCTCTATGCTCTGGCCACACAC
CCCAAGCATCAGGAGAGGTGCCGGGAGGAGATCCACAGCCTCCTGGGTGATGGAGCCTCC
ATCACCTGGAACCACCTGGACCAGATGCCCTACACCACCATGTGCATTAAGGAGGCACTG
AGGCTCTACCCACCGGTGCCAGGCATTGGCAGAGAGCTCAGCACTCCCGTCACCTTCCCT
GATGGGCGCTCCTTGCCCAAAGGTATCATGGTCCTCCTCTCCATTTATGGCCTTCACCAC
AACCCAAAAGTGTGGCCCAACCCAGAGGTGTTTGACCCTTTCCGTTTTGCACCGGGTTCT
GCTCAACACAGCCACGCTTTCCTGCCCTTCTCAGGAGGATCAAGGAACTGCATCGGGAAA
CAATTTGCCATGAACGAGCTGAAGGTGGCCACGGCCCTGACCCTGCTCCGCTTTGAGCTG
CTGCCTGATCCCACCAGGATCCCCATCCCCATTGCACGACTTGTGTTGAAATCCAAAAAT
GGAATCCACCTGCGTCTCAGGAGGCTCCCTAACCCTTGTGAAGACAAGGACCAGCTTTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alkane 1-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>leukotriene-B4 20-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene B4 catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-chain fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of icosanoid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pressure natriuresis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal water homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="17">
      <id>BE0000731</id>
      <name>Cytochrome P450 11B1, mitochondrial</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182744</ref-id>
            <pubmed-id>11600544</pubmed-id>
            <citation>Fardella CE, Pinto M, Mosso L, Gomez-Sanchez C, Jalil J, Montero J: Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab. 2001 Oct;86(10):4805-7. doi: 10.1210/jcem.86.10.7920.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P15538" source="Swiss-Prot">
        <name>Cytochrome P450 11B1, mitochondrial</name>
        <general-function>Steroid 11-beta-monooxygenase activity</general-function>
        <specific-function>Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.</specific-function>
        <gene-name>CYP11B1</gene-name>
        <locus>8q21</locus>
        <cellular-location>Mitochondrion membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.42</theoretical-pi>
        <molecular-weight>57572.44</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2591</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP11B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M32879</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181333</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1359</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P15538</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>C11B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CYPXIB1</synonym>
          <synonym>Cytochrome P-450c11</synonym>
          <synonym>Cytochrome P450C11</synonym>
          <synonym>S11BH</synonym>
          <synonym>Steroid 11-beta-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037064|Cytochrome P450 11B1, mitochondrial
MALRAKAEVCMAVPWLSLQRAQALGTRAARVPRTVLPFEAMPRRPGNRWLRLLQIWREQG
YEDLHLEVHQTFQELGPIFRYDLGGAGMVCVMLPEDVEKLQQVDSLHPHRMSLEPWVAYR
QHRGHKCGVFLLNGPEWRFNRLRLNPEVLSPNAVQRFLPMVDAVARDFSQALKKKVLQNA
RGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFM
PRSLSRWTSPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFSRPQQYTSIVAELLLNAELS
PDAIKANSMELTAGSVDTTVFPLLMTLFELARNPNVQQALRQESLAAAASISEHPQKATT
ELPLLRAALKETLRLYPVGLFLERVASSDLVLQNYHIPAGTLVRVFLYSLGRNPALFPRP
ERYNPQRWLDIRGSGRNFYHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHLQVETLTQED
IKMVYSFILRPSMFPLLTFRAIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016190|Cytochrome P450 11B1, mitochondrial (CYP11B1)
ATGGCACTCAGGGCAAAGGCAGAGGTGTGCATGGCAGTGCCCTGGCTGTCCCTGCAAAGG
GCACAGGCACTGGGCACGAGAGCCGCCCGGGTCCCCAGGACAGTGCTGCCCTTTGAAGCC
ATGCCCCGGCGTCCAGGCAACAGGTGGCTGAGGCTGCTGCAGATCTGGAGGGAGCAGGGT
TATGAGGACCTGCACCTGGAAGTACACCAGACCTTCCAGGAACTAGGGCCCATTTTCAGG
TACGACTTGGGAGGAGCAGGCATGGTGTGTGTGATGCTGCCGGAGGACGTGGAGAAGCTG
CAACAGGTGGACAGCCTGCATCCCCACAGGATGAGCCTGGAGCCCTGGGTGGCCTACAGA
CAACATCGTGGGCACAAATGTGGCGTGTTCTTGCTGAATGGGCCTGAATGGCGCTTCAAC
CGATTGCGGCTGAATCCAGAAGTGCTGTCGCCCAACGCTGTGCAGAGGTTCCTCCCGATG
GTGGATGCAGTGGCCAGGGACTTCTCCCAGGCCCTGAAGAAGAAGGTGCTGCAGAACGCC
CGGGGGAGCCTGACCCTGGACGTCCAGCCCAGCATCTTCCACTACACCATAGAAGCCAGC
AACTTGGCTCTTTTTGGAGAGCGGCTGGGCCTGGTTGGCCACAGCCCCAGTTCTGCCAGC
CTGAACTTCCTCCATGCCCTGGAGGTCATGTTCAAATCCACCGTCCAGCTCATGTTCATG
CCCAGGAGCCTGTCTCGCTGGACCAGCCCCAAGGTGTGGAAGGAGCACTTTGAGGCCTGG
GACTGCATCTTCCAGTACGGCGACAACTGTATCCAGAAAATCTATCAGGAACTGGCCTTC
AGCCGCCCTCAACAGTACACCAGCATCGTGGCGGAGCTCCTGTTGAATGCGGAACTGTCG
CCAGATGCCATCAAGGCCAACTCTATGGAACTCACTGCAGGGAGCGTGGACACGACGGTG
TTTCCCTTGCTGATGACGCTCTTTGAGCTGGCTCGGAACCCCAACGTGCAGCAGGCCCTG
CGCCAGGAGAGCCTGGCCGCCGCAGCCAGCATCAGTGAACATCCCCAGAAGGCAACCACC
GAGCTGCCCTTGCTGCGTGCGGCCCTCAAGGAGACCTTGCGGCTCTACCCTGTGGGTCTG
TTTCTGGAGCGAGTGGCGAGCTCAGACTTGGTGCTTCAGAACTACCACATCCCAGCTGGG
ACATTGGTGCGCGTGTTCCTCTACTCTCTGGGTCGCAACCCCGCCTTGTTCCCGAGGCCT
GAGCGCTATAACCCCCAGCGCTGGCTAGACATCAGGGGCTCCGGCAGGAACTTCTACCAC
GTGCCCTTTGGCTTTGGCATGCGCCAGTGCCTTGGGCGGCGCCTGGCAGAGGCAGAGATG
CTGCTGCTGCTGCACCATGTGCTGAAACACCTCCAGGTGGAGACACTAACCCAAGAGGAC
ATAAAGATGGTCTACAGCTTCATATTGAGGCCCAGCATGTTCCCCCTCCTCACCTTCAGA
GCCATCAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>corticosterone 18-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid 11-beta-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aldosterone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>C21-steroid hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to peptide hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to potassium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cortisol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucocorticoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>secondary metabolite biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers>
    <carrier position="18">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A188559</ref-id>
            <pubmed-id>2316228</pubmed-id>
            <citation>Cummings DM, Larijani GE, Conner DP, Ferguson RK, Rocci ML Jr: Characterization of dexamethasone binding in normal and uremic human serum. DICP. 1990 Mar;24(3):229-31. doi: 10.1177/106002809002400301.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters>
    <transporter position="1">
      <id>BE0001032</id>
      <name>P-glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15860</ref-id>
            <pubmed-id>11297522</pubmed-id>
            <citation>Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31.</citation>
          </article>
          <article>
            <ref-id>A15808</ref-id>
            <pubmed-id>12387747</pubmed-id>
            <citation>Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91.</citation>
          </article>
          <article>
            <ref-id>A15875</ref-id>
            <pubmed-id>8845310</pubmed-id>
            <citation>Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG: Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ. 1995 Oct;6(10):1321-32.</citation>
          </article>
          <article>
            <ref-id>A15849</ref-id>
            <pubmed-id>11602674</pubmed-id>
            <citation>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</citation>
          </article>
          <article>
            <ref-id>A15818</ref-id>
            <pubmed-id>12699389</pubmed-id>
            <citation>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</citation>
          </article>
          <article>
            <ref-id>A15850</ref-id>
            <pubmed-id>11785684</pubmed-id>
            <citation>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</citation>
          </article>
          <article>
            <ref-id>A15876</ref-id>
            <pubmed-id>14661924</pubmed-id>
            <citation>Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.</citation>
          </article>
          <article>
            <ref-id>A15877</ref-id>
            <pubmed-id>7560060</pubmed-id>
            <citation>Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705.</citation>
          </article>
          <article>
            <ref-id>A187265</ref-id>
            <pubmed-id>24451000</pubmed-id>
            <citation>Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
        <name>Multidrug resistance protein 1</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
        <gene-name>ABCB1</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>141477.255</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:40</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MDR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.44</synonym>
          <synonym>ATP-binding cassette sub-family B member 1</synonym>
          <synonym>MDR1</synonym>
          <synonym>P-glycoprotein 1</synonym>
          <synonym>PGY1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G2/M transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stem cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0003645</id>
      <name>Solute carrier family 22 member 8</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33352</ref-id>
            <pubmed-id>19953504</pubmed-id>
            <citation>VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q8TCC7" source="Swiss-Prot">
        <name>Solute carrier family 22 member 8</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).</specific-function>
        <gene-name>SLC22A8</gene-name>
        <locus>11q11</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>10-30
124-144
155-175
177-197
213-233
237-257
328-348
355-375
387-407
412-432
472-492</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.05</theoretical-pi>
        <molecular-weight>59855.585</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10972</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF097491</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4378059</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1027</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8TCC7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT3</synonym>
          <synonym>OAT3</synonym>
          <synonym>Organic anion transporter 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007005|Solute carrier family 22 member 8
MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCRPPHNASTGPW
VLPMGPNGKPERCLRFVHPPNASLPNDTQRAMEPCLDGWVYNSTKDSIVTEWDLVCNSNK
LKEMAQSIFMAGILIGGLVLGDLSDRFGRRPILTCSYLLLAASGSGAAFSPTFPIYMVFR
FLCGFGISGITLSTVILNVEWVPTRMRAIMSTALGYCYTFGQFILPGLAYAIPQWRWLQL
TVSIPFFVFFLSSWWTPESIRWLVLSGKSSKALKILRRVAVFNGKKEEGERLSLEELKLN
LQKEISLAKAKYTASDLFRIPMLRRMTFCLSLAWFATGFAYYSLAMGVEEFGVNLYILQI
IFGGVDVPAKFITILSLSYLGRHTTQAAALLLAGGAILALTFVPLDLQTVRTVLAVFGKG
CLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRVGSMVSPLVKITGEVQPFIPNIIYGI
TALLGGSAALFLPETLNQPLPETIEDLENWSLRAKKPKQEPEVEKASQRIPLQPHGPGLG
SS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019450|Solute carrier family 22 member 8 (SLC22A8)
ATGACCTTCTCGGAGATCCTGGACCGTGTGGGAAGCATGGGCCATTTCCAGTTCCTGCAT
GTAGCCATACTGGGCCTCCCGATCCTCAACATGGCCAACCACAACCTGCTGCAGATCTTC
ACAGCCGCCACCCCTGTCCACCACTGTCGCCCGCCCCACAATGCCTCCACAGGGCCTTGG
GTGCTCCCCATGGGCCCAAATGGGAAGCCTGAGAGGTGCCTCCGTTTTGTACATCCGCCC
AATGCCAGCCTGCCCAATGACACCCAGAGGGCCATGGAGCCATGCCTGGATGGCTGGGTC
TACAACAGCACCAAGGACTCCATTGTGACAGAGTGGGACTTGGTGTGCAACTCCAACAAA
CTGAAGGAGATGGCCCAGTCTATCTTCATGGCAGGTATACTGATTGGAGGGCTCGTGCTT
GGAGACCTGTCTGACAGGTTTGGCCGCAGGCCCATCCTGACCTGCAGCTACCTGCTGCTG
GCAGCCAGCGGCTCCGGTGCAGCCTTCAGCCCCACCTTCCCCATCTACATGGTCTTCCGC
TTCCTGTGTGGCTTTGGCATCTCAGGCATTACCCTGAGCACCGTCATCTTGAATGTGGAA
TGGGTGCCTACCCGGATGCGGGCCATCATGTCGACAGCACTCGGGTACTGCTACACCTTT
GGCCAGTTCATTCTGCCCGGCCTGGCCTACGCCATCCCCCAGTGGCGTTGGCTGCAGTTA
ACTGTGTCCATTCCCTTCTTCGTCTTCTTCCTATCATCCTGGTGGACACCAGAGTCCATA
CGCTGGTTGGTCTTGTCTGGAAAGTCCTCGAAGGCCCTGAAGATACTCCGGCGGGTGGCT
GTCTTCAATGGCAAGAAGGAAGAGGGAGAAAGGCTCAGCTTGGAGGAGCTCAAACTCAAC
CTGCAGAAGGAGATCTCCTTGGCCAAGGCCAAGTACACCGCAAGTGACCTGTTCCGGATA
CCCATGCTGCGCCGCATGACCTTCTGTCTTTCCCTGGCCTGGTTTGCTACCGGTTTTGCC
TACTATAGTTTGGCTATGGGTGTGGAAGAATTTGGAGTCAACCTCTACATCCTCCAGATC
ATCTTTGGTGGGGTCGATGTCCCAGCCAAGTTCATCACCATCCTCTCCTTAAGCTACCTG
GGCCGGCATACCACTCAGGCCGCTGCCCTGCTCCTGGCAGGAGGGGCCATCTTGGCTCTC
ACCTTTGTGCCCTTGGACTTGCAGACCGTGAGGACAGTATTGGCTGTGTTTGGGAAGGGA
TGCCTATCCAGCTCCTTCAGCTGCCTCTTCCTCTACACAAGTGAATTATACCCCACAGTC
ATCAGGCAAACAGGTATGGGCGTAAGTAACCTGTGGACCCGCGTGGGAAGCATGGTGTCC
CCGCTGGTGAAAATCACGGGTGAGGTACAGCCCTTCATCCCCAATATCATCTACGGGATC
ACCGCCCTCCTCGGGGGCAGTGCTGCCCTCTTCCTGCCTGAGACCCTGAATCAGCCCTTG
CCAGAGACTATCGAAGACCTGGAAAACTGGTCCCTGCGGGCAAAGAAGCCAAAGCAGGAG
CCAGAGGTGGAAAAGGCCTCCCAGAGGATCCCTCTACAGCCTCACGGACCAGGCCTGGGC
TCCAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0000703</id>
      <name>Bile salt export pump</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15803</ref-id>
            <pubmed-id>11557128</pubmed-id>
            <citation>Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V: Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 2001 Oct 5;167(1):37-46.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O95342" source="Swiss-Prot">
        <name>Bile salt export pump</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.</specific-function>
        <gene-name>ABCB11</gene-name>
        <locus>2q24</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>63-83
148-168
216-236
241-261
320-340
354-374
756-776
795-815
870-890
891-911
980-1000
1012-1032</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.52</theoretical-pi>
        <molecular-weight>146405.83</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:42</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF091582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3873243</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCBB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family B member 11</synonym>
          <synonym>BSEP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010492|Bile salt export pump
MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW
LMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN
QNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR
RIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK
LTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE
VERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLV
QIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI
EFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT
VDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF
IMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV
LSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG
NQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST
YEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL
GTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML
GQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL
SLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI
EALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV
ISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF
VDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID
GHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF
VMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA
LDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI
S</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010493|Bile salt export pump (ABCB11)
ATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT
GAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT
GATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG
CTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA
CTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC
CAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC
CAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA
TTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA
TGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG
AGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA
AGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC
ATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA
CTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT
CTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG
GCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG
GTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA
GTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCACTGGCC
TTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC
CAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG
GAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA
CCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT
GAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC
CTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA
AAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC
GTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA
GTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA
GAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC
ATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT
GGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG
CTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG
CTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC
AGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT
GAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA
AATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG
ACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG
TCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC
TATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA
GTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG
GGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT
GGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA
CTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT
GCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG
GGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA
CTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC
AATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG
AGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG
ATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA
AATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT
GAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT
TACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC
AGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG
ATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT
TATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA
ATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT
GTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA
GTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC
ACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT
GGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC
CAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC
AAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT
GTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT
AGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG
CTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT
CTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC
CAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT
GAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC
AGTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercellular canaliculus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid-exporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>canalicular bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-exporting ATPase activity, phosphorylative mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>canalicular bile acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="6">
      <id>BE0001069</id>
      <name>Canalicular multispecific organic anion transporter 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16010</ref-id>
            <pubmed-id>9929003</pubmed-id>
            <citation>Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R: Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999 Jan 15;442(2-3):208-14.</citation>
          </article>
          <article>
            <ref-id>A15785</ref-id>
            <pubmed-id>11323161</pubmed-id>
            <citation>Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q92887" source="Swiss-Prot">
        <name>Canalicular multispecific organic anion transporter 1</name>
        <general-function>Organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.</specific-function>
        <gene-name>ABCC2</gene-name>
        <locus>10q24</locus>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions>28-48
69-89
94-114
127-147
166-186
314-334
361-381
438-458
462-482
545-565
588-608
972-992
1034-1054
1098-1118
1120-1140
1212-1232
1235-1255</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.46</theoretical-pi>
        <molecular-weight>174205.64</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:53</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCC2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U63970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1764162</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>780</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92887</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 2</synonym>
          <synonym>Canalicular multidrug resistance protein</synonym>
          <synonym>CMOAT</synonym>
          <synonym>CMOAT1</synonym>
          <synonym>CMRP</synonym>
          <synonym>MRP2</synonym>
          <synonym>Multidrug resistance-associated protein 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010748|Canalicular multispecific organic anion transporter 1
MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSS
TTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYS
RQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILI
FSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS
KFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSG
TKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIG
YLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGET
VNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAIL
STKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFS
QLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMI
SSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLD
IMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNIL
FGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLD
IYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIV
EKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAAS
ITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETG
KVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQR
DMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRI
VNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMF
YVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSW
ITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTS
EIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGI
TCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTII
PQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIG
QRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMD
SDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010749|Canalicular multispecific organic anion transporter 1 (ABCC2)
ATGCTGGAGAAGTTCTGCAACTCTACTTTTTGGAATTCCTCATTCCTGGACAGTCCGGAG
GCAGACCTGCCACTTTGTTTTGAGCAAACTGTTCTGGTGTGGATTCCCTTGGGCTTCCTA
TGGCTCCTGGCCCCCTGGCAGCTTCTCCACGTGTATAAATCCAGGACCAAGAGATCCTCT
ACCACCAAACTCTATCTTGCTAAGCAGGTATTCGTTGGTTTTCTTCTTATTCTAGCAGCC
ATAGAGCTGGCCCTTGTACTCACAGAAGACTCTGGACAAGCCACAGTCCCTGCTGTTCGA
TATACCAATCCAAGCCTCTACCTAGGCACATGGCTCCTGGTTTTGCTGATCCAATACAGC
AGACAATGGTGTGTACAGAAAAACTCCTGGTTCCTGTCCCTATTCTGGATTCTCTCGATA
CTCTGTGGCACTTTCCAATTTCAGACTCTGATCCGGACACTCTTACAGGGTGACAATTCT
AATCTAGCCTACTCCTGCCTGTTCTTCATCTCCTACGGATTCCAGATCCTGATCCTGATC
TTTTCAGCATTTTCAGAAAATAATGAGTCATCAAATAATCCATCATCCATAGCTTCATTC
CTGAGTAGCATTACCTACAGCTGGTATGACAGCATCATTCTGAAAGGCTACAAGCGTCCT
CTGACACTCGAGGATGTCTGGGAAGTTGATGAAGAGATGAAAACCAAGACATTAGTGAGC
AAGTTTGAAACGCACATGAAGAGAGAGCTGCAGAAAGCCAGGCGGGCACTCCAGAGACGG
CAGGAGAAGAGCTCCCAGCAGAACTCTGGAGCCAGGCTGCCTGGCTTGAACAAGAATCAG
AGTCAAAGCCAAGATGCCCTTGTCCTGGAAGATGTTGAAAAGAAAAAAAAGAAGTCTGGG
ACCAAAAAAGATGTTCCAAAATCCTGGTTGATGAAGGCTCTGTTCAAAACTTTCTACATG
GTGCTCCTGAAATCATTCCTACTGAAGCTAGTGAATGACATCTTCACGTTTGTGAGTCCT
CAGCTGCTGAAATTGCTGATCTCCTTTGCAAGTGACCGTGACACATATTTGTGGATTGGA
TATCTCTGTGCAATCCTCTTATTCACTGCGGCTCTCATTCAGTCTTTCTGCCTTCAGTGT
TATTTCCAACTGTGCTTCAAGCTGGGTGTAAAAGTACGGACAGCTATCATGGCTTCTGTA
TATAAGAAGGCATTGACCCTATCCAACTTGGCCAGGAAGGAGTACACCGTTGGAGAAACA
GTGAACCTGATGTCTGTGGATGCCCAGAAGCTCATGGATGTGACCAACTTCATGCACATG
CTGTGGTCAAGTGTTCTACAGATTGTCTTATCTATCTTCTTCCTATGGAGAGAGTTGGGA
CCCTCAGTCTTAGCAGGTGTTGGGGTGATGGTGCTTGTAATCCCAATTAATGCGATACTG
TCCACCAAGAGTAAGACCATTCAGGTCAAAAATATGAAGAATAAAGACAAACGTTTAAAG
ATCATGAATGAGATTCTTAGTGGAATCAAGATCCTGAAATATTTTGCCTGGGAACCTTCA
TTCAGAGACCAAGTACAAAACCTCCGGAAGAAAGAGCTCAAGAACCTGCTGGCCTTTAGT
CAACTACAGTGTGTAGTAATATTCGTCTTCCAGTTAACTCCAGTCCTGGTATCTGTGGTC
ACATTTTCTGTTTATGTCCTGGTGGATAGCAACAATATTTTGGATGCACAAAAGGCCTTC
ACCTCCATTACCCTCTTCAATATCCTGCGCTTTCCCCTGAGCATGCTTCCCATGATGATC
TCCTCCATGCTCCAGGCCAGTGTTTCCACAGAGCGGCTAGAGAAGTACTTGGGAGGGGAT
GACTTGGACACATCTGCCATTCGACATGACTGCAATTTTGACAAAGCCATGCAGTTTTCT
GAGGCCTCCTTTACCTGGGAACATGATTCGGAAGCCACAGTCCGAGATGTGAACCTGGAC
ATTATGGCAGGCCAACTTGTGGCTGTGATAGGCCCTGTCGGCTCTGGGAAATCCTCCTTG
ATATCAGCCATGCTGGGAGAAATGGAAAATGTCCACGGGCACATCACCATCAAGGGCACC
ACTGCCTATGTCCCACAGCAGTCCTGGATTCAGAATGGCACCATAAAGGACAACATCCTT
TTTGGAACAGAGTTTAATGAAAAGAGGTACCAGCAAGTACTGGAGGCCTGTGCTCTCCTC
CCAGACTTGGAAATGCTGCCTGGAGGAGATTTGGCTGAGATTGGAGAGAAGGGTATAAAT
CTTAGTGGGGGTCAGAAGCAGCGGATCAGCCTGGCCAGAGCTACCTACCAAAATTTAGAC
ATCTATCTTCTAGATGACCCCCTGTCTGCAGTGGATGCTCATGTAGGAAAACATATTTTT
AATAAGGTCTTGGGCCCCAATGGCCTGTTGAAAGGCAAGACTCGACTCTTGGTTACACAT
AGCATGCACTTTCTTCCTCAAGTGGATGAGATTGTAGTTCTGGGGAATGGAACAATTGTA
GAGAAAGGATCCTACAGTGCTCTCCTGGCCAAAAAAGGAGAGTTTGCTAAGAATCTGAAG
ACATTTCTAAGACATACAGGCCCTGAAGAGGAAGCCACAGTCCATGATGGCAGTGAAGAA
GAAGACGATGACTATGGGCTGATATCCAGTGTGGAAGAGATCCCCGAAGATGCAGCCTCC
ATAACCATGAGAAGAGAGAACAGCTTTCGTCGAACACTTAGCCGCAGTTCTAGGTCCAAT
GGCAGGCATCTGAAGTCCCTGAGAAACTCCTTGAAAACTCGGAATGTGAATAGCCTGAAG
GAAGACGAAGAACTAGTGAAAGGACAAAAACTAATTAAGAAGGAATTCATAGAAACTGGA
AAGGTGAAGTTCTCCATCTACCTGGAGTACCTACAAGCAATAGGATTGTTTTCGATATTC
TTCATCATCCTTGCGTTTGTGATGAATTCTGTGGCTTTTATTGGATCCAACCTCTGGCTC
AGTGCTTGGACCAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGG
GACATGAGAGTTGGAGTCTACGGAGCTCTGGGATTAGCCCAAGGTATATTTGTGTTCATA
GCACATTTCTGGAGTGCCTTTGGTTTCGTCCATGCATCAAATATCTTGCACAAGCAACTG
CTGAACAATATCCTTCGAGCACCTATGAGATTTTTTGACACAACACCCACAGGCCGGATT
GTGAACAGGTTTGCCGGCGATATTTCCACAGTGGATGACACCCTGCCTCAGTCCTTGCGC
AGCTGGATTACATGCTTCCTGGGGATAATCAGCACCCTTGTCATGATCTGCATGGCCACT
CCTGTCTTCACCATCATCGTCATTCCTCTTGGCATTATTTATGTATCTGTTCAGATGTTT
TATGTGTCTACCTCCCGCCAGCTGAGGCGTCTGGACTCTGTCACCAGGTCCCCAATCTAC
TCTCACTTCAGCGAGACCGTATCAGGTTTGCCAGTTATCCGTGCCTTTGAGCACCAGCAG
CGATTTCTGAAACACAATGAGGTGAGGATTGACACCAACCAGAAATGTGTCTTTTCCTGG
ATCACCTCCAACAGGTGGCTTGCAATTCGCCTGGAGCTGGTTGGGAACCTGACTGTCTTC
TTTTCAGCCTTGATGATGGTTATTTATAGAGATACCCTAAGTGGGGACACTGTTGGCTTT
GTTCTGTCCAATGCACTCAATATCACACAAACCCTGAACTGGCTGGTGAGGATGACATCA
GAAATAGAGACCAACATTGTGGCTGTTGAGCGAATAACTGAGTACACAAAAGTGGAAAAT
GAGGCACCCTGGGTGACTGATAAGAGGCCTCCGCCAGATTGGCCCAGCAAAGGCAAGATC
CAGTTTAACAACTACCAAGTGCGGTACCGACCTGAGCTGGATCTGGTCCTCAGAGGGATC
ACTTGTGACATCGGTAGCATGGAGAAGATTGGTGTGGTGGGCAGGACAGGAGCTGGAAAG
TCATCCCTCACAAACTGCCTCTTCAGAATCTTAGAGGCTGCCGGTGGTCAGATTATCATT
GATGGAGTAGATATTGCTTCCATTGGGCTCCACGACCTCCGAGAGAAGCTGACCATCATC
CCCCAGGACCCCATCCTGTTCTCTGGAAGCCTGAGGATGAATCTCGACCCTTTCAACAAC
TACTCAGATGAGGAGATTTGGAAGGCCTTGGAGCTGGCTCACCTCAAGTCTTTTGTGGCC
AGCCTGCAACTTGGGTTATCCCACGAAGTGACAGAGGCTGGTGGCAACCTGAGCATAGGC
CAGAGGCAGCTGCTGTGCCTGGGCAGGGCTCTGCTTCGGAAATCCAAGATCCTGGTCCTG
GATGAGGCCACTGCTGCGGTGGATCTAGAGACAGACAACCTCATTCAGACGACCATCCAA
AACGAGTTCGCCCACTGCACAGTGATCACCATCGCCCACAGGCTGCACACCATCATGGAC
AGTGACAAGGTAATGGTCCTAGACAACGGGAAGATTATAGAGTGCGGCAGCCCTGAAGAA
CTGCTACAAATCCCTGGACCCTTTTACTTTATGGCTAAGGAAGCTGGCATTGAGAATGTG
AACAGCACAAAATTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular chloride ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to arsenic-containing substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="7">
      <id>BE0001067</id>
      <name>ATP-binding cassette sub-family G member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16373</ref-id>
            <pubmed-id>20307139</pubmed-id>
            <citation>Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UNQ0" source="Swiss-Prot">
        <name>ATP-binding cassette sub-family G member 2</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.</specific-function>
        <gene-name>ABCG2</gene-name>
        <locus>4q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>396-416
429-449
478-498
507-527
536-556
631-651</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.9</theoretical-pi>
        <molecular-weight>72313.47</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:74</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF103796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4185796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UNQ0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABCP</synonym>
          <synonym>BCRP</synonym>
          <synonym>BCRP1</synonym>
          <synonym>Breast cancer resistance protein</synonym>
          <synonym>CDw338</synonym>
          <synonym>Mitoxantrone resistance-associated protein</synonym>
          <synonym>MXR</synonym>
          <synonym>Placenta-specific ATP-binding cassette transporter</synonym>
          <synonym>Urate exporter</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002125|ATP-binding cassette sub-family G member 2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT
GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA
ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA
ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF01061</identifier>
            <name>ABC2_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="7">
      <id>BE0003642</id>
      <name>Solute carrier organic anion transporter family member 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16262</ref-id>
            <pubmed-id>9539145</pubmed-id>
            <citation>Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G: Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998 Mar 13;424(3):173-6.</citation>
          </article>
          <article>
            <ref-id>A15971</ref-id>
            <pubmed-id>8786566</pubmed-id>
            <citation>Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P46721" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 1A2</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.</specific-function>
        <gene-name>SLCO1A2</gene-name>
        <locus>12p12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>21-40
60-80
87-111
156-184
204-224
243-267
312-333
354-377
382-405
514-536
546-571
606-623</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.75</theoretical-pi>
        <molecular-weight>74144.105</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10956</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U21943</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>885978</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P46721</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OATP</synonym>
          <synonym>OATP-1</synonym>
          <synonym>OATP-A</synonym>
          <synonym>OATP1</synonym>
          <synonym>OATP1A2</synonym>
          <synonym>Organic anion-transporting polypeptide 1</synonym>
          <synonym>SLC21A3</synonym>
          <synonym>Sodium-independent organic anion transporter</synonym>
          <synonym>Solute carrier family 21 member 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007000|Solute carrier organic anion transporter family member 1A2
MGETEKRIETHRIRCLSKLKMFLLAITCAFVSKTLSGSYMNSMLTQIERQFNIPTSLVGF
INGSFEIGNLLLIIFVSYFGTKLHRPIMIGIGCVVMGLGCFLKSLPHFLMNQYEYESTVS
VSGNLSSNSFLCMENGTQILRPTQDPSECTKEVKSLMWVYVLVGNIVRGMGETPILPLGI
SYIEDFAKFENSPLYIGLVETGAIIGPLIGLLLASFCANVYVDTGFVNTDDLIITPTDTR
WVGAWWFGFLICAGVNVLTAIPFFFLPNTLPKEGLETNADIIKNENEDKQKEEVKKEKYG
ITKDFLPFMKSLSCNPIYMLFILVSVIQFNAFVNMISFMPKYLEQQYGISSSDAIFLMGI
YNLPPICIGYIIGGLIMKKFKITVKQAAHIGCWLSLLEYLLYFLSFLMTCENSSVVGINT
SYEGIPQDLYVENDIFADCNVDCNCPSKIWDPVCGNNGLSYLSACLAGCETSIGTGINMV
FQNCSCIQTSGNSSAVLGLCDKGPDCSLMLQYFLILSAMSSFIYSLAAIPGYMVLLRCMK
SEEKSLGVGLHTFCTRVFAGIPAPIYFGALMDSTCLHWGTLKCGESGACRIYDSTTFRYI
YLGLPAALRGSSFVPALIILILLRKCHLPGENASSGTELIETKVKGKENECKDIYQKSTV
LKDDELKTKL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012532|Solute carrier organic anion transporter family member 1A2 (SLCO1A2)
ATGGGAGAAACTGAGAAAAGAATTGAAACCCATAGAATAAGATGTCTTTCCAAGTTGAAG
ATGTTTCTGTTGGCAATAACATGTGCATTTGTATCCAAAACACTGTCTGGATCTTATATG
AATTCCATGCTCACACAAATAGAGAGACAATTCAACATCCCAACATCTCTAGTTGGATTC
ATTAATGGAAGCTTTGAGATTGGAAATCTTTTGTTGATTATATTTGTGAGTTATTTTGGA
ACCAAACTGCATAGACCTATAATGATTGGCATTGGATGTGTGGTTATGGGCTTAGGCTGT
TTCTTAAAATCACTACCTCATTTCCTCATGAACCAATATGAATATGAATCTACAGTTTCA
GTTTCAGGCAACTTGTCCTCAAACAGTTTCTTGTGTATGGAAAATGGAACCCAGATTTTA
AGACCAACGCAGGATCCATCAGAGTGTACAAAGGAAGTTAAATCATTAATGTGGGTGTAC
GTCCTAGTAGGCAATATTGTACGTGGAATGGGTGAAACTCCCATCCTGCCTTTGGGTATT
TCCTATATAGAAGATTTTGCCAAATTTGAAAATTCTCCTTTATATATTGGGCTTGTAGAA
ACAGGAGCTATTATTGGTCCTTTGATTGGACTTTTGTTGGCATCATTCTGTGCAAATGTT
TATGTTGACACTGGATTTGTGAACACAGATGATCTGATCATAACTCCCACTGACACTCGT
TGGGTCGGTGCATGGTGGTTTGGCTTTCTGATTTGTGCAGGAGTTAACGTGCTCACTGCC
ATTCCTTTTTTCTTTTTGCCCAACACACTTCCAAAGGAAGGACTAGAGACTAATGCTGAC
ATCATTAAAAATGAAAATGAAGACAAACAAAAAGAAGAGGTCAAGAAGGAAAAATATGGA
ATCACTAAAGATTTTCTACCTTTCATGAAAAGTCTTTCCTGCAATCCAATTTATATGCTT
TTCATACTTGTAAGTGTGATACAGTTCAATGCATTCGTTAACATGATCTCCTTCATGCCT
AAATACCTAGAACAGCAATATGGAATATCATCTTCAGATGCAATCTTTCTAATGGGTATT
TATAACTTACCTCCAATATGTATTGGATATATAATTGGTGGTTTAATTATGAAGAAGTTC
AAGATTACTGTCAAACAAGCTGCCCACATAGGATGTTGGTTATCCTTACTTGAGTATCTT
CTCTATTTTTTATCTTTTCTCATGACTTGTGAAAATTCTTCAGTTGTTGGAATAAATACC
TCTTATGAAGGAATTCCACAAGATTTATATGTGGAAAATGACATCTTTGCTGATTGCAAT
GTGGATTGCAACTGTCCATCTAAAATATGGGATCCTGTGTGTGGAAACAATGGCTTGTCA
TATCTGTCAGCTTGTCTTGCTGGTTGTGAGACATCCATTGGAACGGGAATAAACATGGTG
TTCCAAAATTGCAGCTGTATTCAAACATCAGGAAATTCATCTGCAGTTCTTGGGCTGTGC
GACAAAGGACCTGACTGTTCCTTGATGCTCCAGTACTTCCTAATCTTGTCAGCGATGAGC
AGTTTCATTTATTCTTTGGCTGCCATACCTGGATATATGGTTCTCTTGAGGTGTATGAAA
TCTGAAGAGAAGTCCCTTGGTGTGGGATTACATACATTTTGCACAAGAGTATTTGCTGGC
ATTCCTGCACCTATATATTTTGGCGCTTTAATGGATTCCACATGTTTACACTGGGGAACT
TTGAAATGTGGTGAGTCAGGGGCATGCAGGATATATGATTCCACCACCTTCAGATACATC
TACCTCGGATTGCCGGCAGCACTAAGAGGATCAAGCTTTGTTCCAGCCTTAATCATCTTA
ATTCTTTTGAGGAAGTGTCATCTACCTGGTGAAAATGCCTCTTCAGGAACAGAGCTTATA
GAGACAAAAGTCAAAGGGAAGGAAAATGAGTGCAAAGATATATACCAAAAGTCCACGGTT
TTGAAAGATGATGAATTGAAAACTAAATTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>